[
  {
    "filename": "homeopathic_1e5c425c-1387-49c4-8200-b36cb8925f9c.xml",
    "document_id": "1e5c425c-1387-49c4-8200-b36cb8925f9c",
    "document_type": "OTC ANIMAL DRUG LABEL",
    "title": "REBALANCER",
    "effective_date": "20251027",
    "version": "2",
    "author": {
      "name": "The Adored Beast Apothecary, Ltd",
      "id": "203463179"
    },
    "product": {
      "ndc": "86083-0009",
      "name": "REBALANCER",
      "form": "LIQUID",
      "generic_name": "Silicea, Thuja occidentalis",
      "active_ingredients": [
        {
          "name": "SILICON DIOXIDE",
          "code": "ETJ7Z6XBU4",
          "strength": "30 [hp_C]",
          "per": "30 mL"
        },
        {
          "name": "THUJA OCCIDENTALIS LEAFY TWIG",
          "code": "1NT28V9397",
          "strength": "12 [hp_C]",
          "per": "30 mL"
        }
      ],
      "inactive_ingredients": [
        "ALCOHOL",
        "WATER",
        "glycerin"
      ],
      "packaging": [
        {
          "quantity": "30 mL",
          "ndc": "86083-0009-1",
          "container": "BOTTLE"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20201207",
      "approval_status": "unapproved homeopathic"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section",
        "title": "",
        "content": ""
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "title": "",
        "content": "DRUG FACTS HPUS Active Ingredients: Silicea 30C, Thuja Occidentalis 12C. The letters HPUS indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States. Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "",
        "content": "Indications: Supports the body in coming back to balance after inoculation without removing any benefits."
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "",
        "content": "WARNINGS FOR ANIMAL USE ONLY. KEEP OUT OF REACH OF CHILDREN. DO NOT USE IF TAMPER EVIDENT NECK SEAL IS BROKEN OR MISSING. Safe use in pregnant animals or animals intended for breeding has not been proven. If animal\u2019s condition worsens or does not improve, discontinue use and consult your veterinarian"
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "title": "",
        "content": "KEEP OUT OF REACH OF CHILDREN"
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "",
        "content": "Directions: Add 4 pumps to a small amount of food twice per day. Not to be used for more than 10 consecutive days. For more information or options to administer refer to our website."
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "title": "",
        "content": "Inactive Ingredients: Organic Ethanol 15%, Purified Water, Vegetable Non-GMO Glycerin."
      },
      {
        "code": "53413-1",
        "type": "OTC - QUESTIONS SECTION",
        "title": "",
        "content": "Questions or Comments? 1-833-933-7839 \ufeffDistributed by Adored Beast Apothecary 189 Business Park Rd, Eureka, Montana 59917"
      },
      {
        "code": "60561-8",
        "type": "OTHER SAFETY INFORMATION",
        "title": "",
        "content": "Safe use in pregnant animals or animals intended for breeding has not been proven. If animal\u2019s condition worsens or does not improve, discontinue use and consult your veterinarian"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "",
        "content": "NDC#: 86083-0009-1 ADORED BEAST APOTHECARY REBALANCER \ufeffHomeopathic REBALANCE AND SUPPORT THE BODY AFTER INOCULATION \ufeffFor Cats & Dogs 1 fl oz (30mL)"
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "title": "",
        "content": "Supports the body in coming back to balance after inoculation without removing any benefits."
      }
    ],
    "category": "Homeopathic"
  },
  {
    "filename": "homeopathic_40e5e7b1-80c7-b406-e063-6394a90ac7e2.xml",
    "document_id": "40e5e7b1-80c7-b406-e063-6394a90ac7e2",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "QUENT 4X",
    "effective_date": "20251011",
    "version": "3",
    "author": {
      "name": "Symbiopathic",
      "id": "202697595"
    },
    "product": {
      "ndc": "69710-175",
      "name": "SYMBIO QUENT DROPS",
      "form": "LIQUID",
      "generic_name": "Penicillium frequentans",
      "active_ingredients": [
        {
          "name": "PENICILLIUM GLABRUM",
          "code": "2IN23YUE0I",
          "strength": "4 [hp_X]",
          "per": "1 mL"
        }
      ],
      "inactive_ingredients": [
        "SODIUM CHLORIDE",
        "WATER"
      ],
      "packaging": [
        {
          "quantity": "10 mL",
          "ndc": "",
          "container": "BOTTLE"
        },
        {
          "quantity": "1 1",
          "ndc": "69710-175-11",
          "container": "CARTON"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20231008",
      "approval_status": "unapproved homeopathic"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "title": "ACTIVE INGREDIENTS:",
        "content": "Penicillium frequentans 4X"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "WARNINGS:",
        "content": "Do not use if the tamper evident strip is broken or removed from the base of the cap."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "DIRECTIONS:",
        "content": "Take 5 \u2013 10 drops orally, three times per day."
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "title": "INACTIVE INGREDIENTS:",
        "content": "Purified water USP, sodium chloride"
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "title": "KEEP OUT OF REACH OF CHILDREN:",
        "content": "KEEP OUT OF REACH OF CHILDREN: In case of overdose, get medical help or call a Poison Control Center right away."
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "INDICATIONS:",
        "content": "This remedy is indicated for symptoms associated with colds; flu, inflamed nasal passages, pre- and post- influenza neuralgia, laryngitis, sinusitis and myalgias according to traditional homeopathic practice.*"
      },
      {
        "code": "53413-1",
        "type": "OTC - QUESTIONS SECTION",
        "title": "QUESTIONS:",
        "content": "Call toll-free from US & CA +1-844-880-4881 or visit our website www.biological-health.com"
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "title": "PURPOSE:",
        "content": "For internal indications according to traditional homeopathic practice."
      },
      {
        "code": "53414-9",
        "type": "OTC - PREGNANCY OR BREAST FEEDING SECTION",
        "title": "If pregnant or breast feeding...",
        "content": "If pregnant or breast feeding, ask a health professional before use."
      },
      {
        "code": "50569-3",
        "type": "OTC - ASK DOCTOR SECTION",
        "title": "ASK DOCTOR:",
        "content": "Consult a physician if symptoms worsen or last for more than 7 days."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "OTHER INFORMATION:",
        "content": "Protect from light and heat. For professional distribution only. *These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration."
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PACKAGE LABEL DISPLAY:",
        "content": ""
      }
    ],
    "category": "Homeopathic"
  },
  {
    "filename": "homeopathic_4278ca93-86f2-71de-e063-6394a90a137b.xml",
    "document_id": "4278ca93-86f2-71de-e063-6394a90a137b",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "Hepar (Liver) 30X",
    "effective_date": "20251119",
    "version": "1",
    "author": {
      "name": "True Botanica, LLC",
      "id": "182071519"
    },
    "product": {
      "ndc": "53645-2470",
      "name": "Hepar (Liver) 30X",
      "form": "LIQUID",
      "generic_name": "Hepar (Liver) 30X",
      "active_ingredients": [
        {
          "name": "BEEF LIVER",
          "code": "W8N8R55022",
          "strength": "30 [hp_X]",
          "per": "30 mL"
        }
      ],
      "inactive_ingredients": [
        "POTASSIUM SORBATE",
        "CITRIC ACID MONOHYDRATE",
        "WATER"
      ],
      "packaging": [
        {
          "quantity": "30 mL",
          "ndc": "53645-2470-6",
          "container": "BOTTLE"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20251119",
      "approval_status": "unapproved homeopathic"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "content": "Bovine Liver 30X"
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "content": "For constitutional treatments based on homeopathic and anthroposophic indications or as directed by your physician."
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "Use:",
        "content": "For constitutional treatments based on homeopathic and anthroposophic indications or as directed by your physician."
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "Warnings:",
        "content": "Consult your health care provider if symptoms persist more than 5 days or worsen."
      },
      {
        "code": "53414-9",
        "type": "OTC - PREGNANCY OR BREAST FEEDING SECTION",
        "content": "If pregnant or breastfeeding ask a health professional before use."
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "content": "Keep out of the reach of children."
      },
      {
        "code": "50570-1",
        "type": "OTC - DO NOT USE SECTION",
        "content": "TAMPER EVIDENT: Do not use if safety seal is broken before first use."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "Directions for Use:",
        "content": "Place drops under tongue for 30 seconds. Adults 7 drops 3 times a day. Children 2-12 years, 7 drops 3 times a day. Under 2 years, consult your doctor. Use until symptoms are relieved or as directed by your health care provider."
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "title": "Other Ingredients:",
        "content": "Citric Acid, Potassium Sorbate, Water"
      },
      {
        "code": "53413-1",
        "type": "OTC - QUESTIONS SECTION",
        "content": "Developed and Made by True Botanica, LLC 1005 Richards Rd., Suite D Hartland, WI 53029 800-315-8783 www.truebotanica.com"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Principal Display Panel",
        "content": ""
      }
    ],
    "category": "Homeopathic"
  },
  {
    "filename": "homeopathic_42e02de9-d1e2-0388-e063-6394a90aa127.xml",
    "document_id": "42e02de9-d1e2-0388-e063-6394a90aa127",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "Coffea cruda 6C",
    "effective_date": "20251105",
    "version": "3",
    "author": {
      "name": "Boiron",
      "id": "282560473"
    },
    "product": {
      "ndc": "0220-1427",
      "name": "Coffea cruda",
      "form": "PELLET",
      "generic_name": "ARABICA COFFEE BEAN\t",
      "active_ingredients": [
        {
          "name": "ARABICA COFFEE BEAN",
          "code": "3SW678MX72",
          "strength": "6 [hp_C]",
          "per": "6 [hp_C]"
        }
      ],
      "inactive_ingredients": [
        "SUCROSE",
        "LACTOSE, UNSPECIFIED FORM"
      ],
      "packaging": [
        {
          "quantity": "6 [hp_C]",
          "ndc": "0220-1427-41",
          "container": "TUBE"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "19830303",
      "approval_status": "unapproved homeopathic",
      "shape": "ROUND",
      "color": "white",
      "size": "4 mm"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "content": "Coffea cruda 6C HPUS Active ingredient**: See product name on front panel (contains 0.443 mg of the active ingredient per pellet)."
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "content": "Relieves sleeplessness with mental hyperactivity *"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION"
      },
      {
        "code": "50566-9",
        "type": "OTC - STOP USE SECTION",
        "content": "Stop use and ask a doctor if symptoms persist for more than 3 days or worsen."
      },
      {
        "code": "53414-9",
        "type": "OTC - PREGNANCY OR BREAST FEEDING SECTION",
        "content": "If pregnant or breast-feeding, ask a health professional before use."
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "content": "Keep out of reach of children."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "content": "Adults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor."
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "content": "lactose, sucrose"
      },
      {
        "code": "53413-1",
        "type": "OTC - QUESTIONS SECTION",
        "content": "BoironUSA.com Info@boiron.com 1-800-BOIRON-1 (1-800-264-7661) Distributed by Boiron, Inc. Newtown Square, PA 19073"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "content": "Do not use if pellet dispenser seal is broken. Contains approx 80 pellets. How to dispense pellets? Turn tube upside down. Twist until 5 pellets are dispensed into cap. Carefully remove the cap and use it to pour pellets under the tongue. *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE NOT ACCEPTED MEDICAL EVIDENCE. NOT FDA EVALUATED. *C,K,CK, and X are homeopathic dilutions: see BoironUSA.com/info for details."
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "content": ""
      }
    ],
    "category": "Homeopathic"
  },
  {
    "filename": "homeopathic_43e18608-e21a-0110-e063-6394a90a287d.xml",
    "document_id": "43e18608-e21a-0110-e063-6394a90a287d",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "Astragalus Formica",
    "effective_date": "20251118",
    "version": "4",
    "author": {
      "name": "Uriel Pharmacy Inc.",
      "id": "043471163"
    },
    "product": {
      "ndc": "48951-1407",
      "name": "Astragalus Formica",
      "form": "PELLET",
      "generic_name": "Astragalus Formica",
      "active_ingredients": [
        {
          "name": "ARNICA MONTANA",
          "code": "O80TY208ZW",
          "strength": "3 [hp_X]",
          "per": "1 1"
        },
        {
          "name": "ASTRAGALUS PROPINQUUS ROOT",
          "code": "922OP8YUPF",
          "strength": "3 [hp_X]",
          "per": "1 1"
        },
        {
          "name": "FORMICA RUFA",
          "code": "55H0W83JO5",
          "strength": "6 [hp_X]",
          "per": "1 1"
        },
        {
          "name": "SILVER",
          "code": "3M4G523W1G",
          "strength": "30 [hp_X]",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [
        "SUCROSE"
      ],
      "packaging": [
        {
          "quantity": "1350 1",
          "ndc": "48951-1407-2",
          "container": "BOTTLE, GLASS"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20090901",
      "approval_status": "unapproved homeopathic",
      "color": "white",
      "shape": "ROUND",
      "size": "3 mm"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "content": "Directions: FOR ORAL USE ONLY."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "content": "Dissolve pellets under the tongue 3-4 times daily. Ages 12 and older: 10 pellets. Ages 2-11: 5 pellets. Under age 2: Consult a doctor."
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "content": "Active Ingredients: Arnica 3X, Astragalus (Milk vetch) 3X, Formica (Red wood ant) 6X, Argentum (Silver) 30X"
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "content": "Inactive Ingredient: Organic sucrose Prepared using rhythmical processes."
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "content": "Use: Temporary relief of headache."
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "content": "KEEP OUT OF REACH OF CHILDREN."
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "content": "Warnings: Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Contains sugar. Diabetics and persons intolerant of sucrose (sugar): Consult a doctor before use. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions or if conditions worsen or persist. If pregnant or nursing, consult a doctor before use. Do not use if safety seal is broken or missing."
      },
      {
        "code": "53413-1",
        "type": "OTC - QUESTIONS SECTION",
        "content": "Questions? Call 866.642.2858 Uriel,  East Troy, WI 53120 shopuriel.com"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "content": ""
      }
    ],
    "category": "Homeopathic"
  },
  {
    "filename": "otc_2f8bbda5-0100-4d14-84b7-e5712f6dad6f.xml",
    "document_id": "2f8bbda5-0100-4d14-84b7-e5712f6dad6f",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "Dolgencorp, LLC Pain Relief Drug Facts",
    "effective_date": "20251024",
    "version": "7",
    "author": {
      "name": "Dolgencorp Inc",
      "id": "068331990"
    },
    "product": {
      "ndc": "55910-506",
      "name": "DG Health Pain Relief",
      "form": "TABLET, FILM COATED",
      "generic_name": "Acetaminophen",
      "active_ingredients": [
        {
          "name": "ACETAMINOPHEN",
          "code": "362O9ITL9D",
          "strength": "500 mg",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [
        "CROSCARMELLOSE SODIUM",
        "CROSPOVIDONE, UNSPECIFIED",
        "FD&C RED NO. 40 ALUMINUM LAKE",
        "FD&C YELLOW NO. 6 ALUMINUM LAKE",
        "HYPROMELLOSE, UNSPECIFIED",
        "POLYETHYLENE GLYCOL, UNSPECIFIED",
        "POLYSORBATE 80",
        "POVIDONE, UNSPECIFIED",
        "STEARIC ACID"
      ],
      "packaging": [
        {
          "quantity": "24 1",
          "ndc": "",
          "container": "BOTTLE"
        },
        {
          "quantity": "1 1",
          "ndc": "55910-506-62",
          "container": "CARTON"
        },
        {
          "quantity": "50 1",
          "ndc": "55910-506-00",
          "container": "BOTTLE"
        },
        {
          "quantity": "1 1",
          "ndc": "55910-506-71",
          "container": "CARTON"
        },
        {
          "quantity": "100 1",
          "ndc": "",
          "container": "BOTTLE"
        },
        {
          "quantity": "1 1",
          "ndc": "55910-506-78",
          "container": "CARTON"
        },
        {
          "quantity": "120 1",
          "ndc": "",
          "container": "BOTTLE"
        },
        {
          "quantity": "1 1",
          "ndc": "55910-506-76",
          "container": "CARTON"
        },
        {
          "quantity": "225 1",
          "ndc": "55910-506-83",
          "container": "BOTTLE"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20170414",
      "approval_status": "OTC Monograph Drug",
      "color": "RED",
      "size": "18 mm",
      "shape": "OVAL",
      "imprint": "3S0"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "title": "Active ingredient (in each caplet)",
        "content": "Acetaminophen 500 mg"
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "title": "Purpose",
        "content": "Pain reliever/fever reducer"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "Uses",
        "content": "\u2022 temporarily relieves minor aches and pains due to: \u2022 the common cold \u2022 headache \u2022 minor pain of arthritis \u2022 backache \u2022 muscular aches \u2022 toothache \u2022 premenstrual and menstrual cramps \u2022 temporarily reduces fever"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "Warnings",
        "content": "Liver warning: This product contains acetaminophen. Severe liver damage may occur if you take \u2022 more than 4,000 mg of acetaminophen in 24 hours \u2022 with other drugs containing acetaminophen \u2022 3 or more alcoholic drinks every day while using this product Allergy alert: Acetaminophen may cause severe skin reactions. Symptoms may include: \u2022 skin reddening \u2022 blisters \u2022 rash If a skin reaction occurs, stop use and seek medical help right away."
      },
      {
        "code": "50570-1",
        "type": "OTC - DO NOT USE SECTION",
        "title": "Do not use",
        "content": "\u2022 with any other drug containing acetaminophen (prescription or nonprescription). If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist. \u2022 if you have ever had an allergic reaction to this product or any of its ingredients"
      },
      {
        "code": "50569-3",
        "type": "OTC - ASK DOCTOR SECTION",
        "title": "Ask a doctor before use if you have",
        "content": "liver disease"
      },
      {
        "code": "50568-5",
        "type": "OTC - ASK DOCTOR/PHARMACIST SECTION",
        "title": "Ask a doctor or pharmacist before use if you are",
        "content": "taking the blood thinning drug warfarin"
      },
      {
        "code": "50566-9",
        "type": "OTC - STOP USE SECTION",
        "title": "Stop use and ask a doctor if",
        "content": "\u2022 pain gets worse or lasts more than 10 days \u2022 fever gets worse or lasts more than 3 days \u2022 new symptoms occur \u2022 redness or swelling is present These could be signs of a serious condition."
      },
      {
        "code": "53414-9",
        "type": "OTC - PREGNANCY OR BREAST FEEDING SECTION",
        "title": "If pregnant or breast-feeding,",
        "content": "ask a health professional before use."
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "title": "Keep out of reach of children.",
        "content": "Overdose warning: In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222). Quick medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "Directions",
        "content": "\u2022 do not take more than directed (see overdose warning) adults and children 12 years and over \u2022 take 2 caplets every 6 hours while symptoms last \u2022 do not take more than 6 caplets in 24 hours, unless directed by a doctor \u2022 do not use for more than 10 days unless directed by a doctor children under 12 years ask a doctor"
      },
      {
        "code": "60561-8",
        "type": "OTHER SAFETY INFORMATION",
        "title": "Other information ",
        "content": "\u2022 store at 20-25\u00b0C (68-77\u00b0F)"
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "title": "Inactive ingredients",
        "content": "croscarmellose sodium, crospovidone, FD&C red #40 aluminum lake, FD&C yellow #6 aluminum lake, hypromellose, mica-based pearlescent pigment, polyethylene glycol, polysorbate 80, povidone, pregelatinized starch, stearic acid"
      },
      {
        "code": "53413-1",
        "type": "OTC - QUESTIONS SECTION",
        "title": "Questions or comments?",
        "content": "1-888-309-9030"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Package/Label Principal Display Panel",
        "content": "DG \u00ae | health Compare to the active ingredient of Tylenol \u00ae Extra Strength Rapid Release Gels Rapid Release Pain Relief Acetaminophen 500 mg Fast Relief Pain Reliever/Fever Reducer 100 Caplets 500 mg \u2022 Extra strength \u2022 For adults Actual Caplet Size"
      }
    ],
    "category": "OTC (Over-the-Counter)"
  },
  {
    "filename": "otc_409989d2-3458-6fab-e063-6294a90a57ab.xml",
    "document_id": "409989d2-3458-6fab-e063-6294a90a57ab",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "",
    "effective_date": "20251007",
    "version": "2",
    "author": {
      "name": "Sinsin Pharmaceutical Co., Ltd.",
      "id": "823149161"
    },
    "product": {
      "ndc": "55264-116",
      "name": "Sinsinpas Arex Flex Gel Pain Relieving Patch",
      "form": "PATCH",
      "generic_name": "L-Menthol",
      "active_ingredients": [
        {
          "name": "METHYL SALICYLATE",
          "code": "LAV5U5022Y",
          "strength": "57.6 mg",
          "per": "1 1"
        },
        {
          "name": "CAMPHOR (SYNTHETIC)",
          "code": "5TJD82A1ET",
          "strength": "96 mg",
          "per": "1 1"
        },
        {
          "name": "LEVOMENTHOL",
          "code": "BZ1R15MTK7",
          "strength": "76.8 mg",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [
        "METHYLPARABEN",
        "EDETATE DISODIUM",
        "TARTARIC ACID",
        "CARBOXYMETHYLCELLULOSE SODIUM",
        "SORBITOL",
        "GELATIN",
        "CASTOR OIL",
        "SODIUM POLYACRYLATE (8000 MW)",
        "NONIVAMIDE",
        "GLYCERYL MONOSTEARATE",
        "ALOE VERA LEAF",
        "BUTYLATED HYDROXYTOLUENE",
        "WATER",
        "POLYSORBATE 80",
        "TITANIUM DIOXIDE",
        "ALUMINUM HYDROXIDE",
        "KAOLIN"
      ],
      "packaging": [
        {
          "quantity": "6 1",
          "ndc": "55264-116-01",
          "container": "PATCH"
        },
        {
          "quantity": "1 1",
          "ndc": "55264-116-02",
          "container": "POUCH"
        }
      ],
      "route": "TOPICAL",
      "marketing_status": "active",
      "marketing_start_date": "20240501",
      "approval_status": "OTC Monograph Drug"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "title": "Active Ingredients",
        "content": "L-Menthol 76.8mg Methyl Salicylate 57.6mg DL-Camphor 96.0mg"
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "title": "Purpose",
        "content": "Topical Analgesic"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "content": "For the temporary relief of minor aches and pains of muscles and joints associated with: Arthritis Simple backache Strains Bruises Sprains"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "content": "For external use only Allergy alert: If prone to allergic reaction from aspirin or salicylates, consult a doctor before use. Do not use on wounds or damaged skin if you are allergic to any ingredients of this product with a heating pad When using this product use only as directed avoid contact with eyes, mucous membranes, and rashes Stop use and ask a doctor if skin reactions such as redness, itching, rash, excessive irritation, burning sensation, swelling or blistering occur condition worsens symptoms persist for longer than 7 days symptoms clear up and reoccur within a few days If pregnant or breast-feeding , ask a health professional before use."
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "title": "Keep out or reach of children",
        "content": "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "Directions",
        "content": "Adults and children 12 years of age and over: \u25a0 clean and dry affected area \u25a0 remove patch from film \u25a0 apply to affected area not more than 3 times daily \u25a0 remove patch from skin after at most 8 hours of application children under 12 years of age: Consult a doctor"
      },
      {
        "code": "60561-8",
        "type": "OTHER SAFETY INFORMATION",
        "title": "Other Information",
        "content": "\u25a0 avoid storing product in direct sunlight \u25a0 protect product from excessive moisture"
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "title": "Inactive Ingredients",
        "content": "Butylated hydroxytoluene, Methylparaben, Polysorbate 80, Castor Oil, D-Sorbitol Solution, Concentrated Glycerin, Dihydroxyaluminum, Aminoacetate, Disodium Edetate Hydrate, Carboxymethylcellulose sodium, Kaolin, Titanium Dioxide, Sodium Polyacrylate, Aloe Vera Gel, Gelatin, Nikasol TS-620, Tartaric Acid, Nonylic acid vanillyamide, Purified Water"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "content": ""
      }
    ],
    "category": "OTC (Over-the-Counter)"
  },
  {
    "filename": "otc_4276a9af-4bc4-0e6b-e063-6294a90a774f.xml",
    "document_id": "4276a9af-4bc4-0e6b-e063-6294a90a774f",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "Allergy Relief",
    "effective_date": "20251031",
    "version": "8",
    "author": {
      "name": "Shield Pharmaceuticals Corp",
      "id": "118724924"
    },
    "product": {
      "ndc": "83059-0021",
      "name": "Allergy Relief",
      "form": "TABLET, COATED",
      "generic_name": "Diphenhydramine Hydrochloride",
      "active_ingredients": [
        {
          "name": "DIPHENHYDRAMINE HYDROCHLORIDE",
          "code": "TC2D6JAD40",
          "strength": "25 mg",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [
        "CROSCARMELLOSE SODIUM",
        "FD&C RED NO. 3",
        "HYPROMELLOSES",
        "MAGNESIUM STEARATE",
        "MICROCRYSTALLINE CELLULOSE",
        "POLYETHYLENE GLYCOL, UNSPECIFIED",
        "TALC",
        "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
        "TITANIUM DIOXIDE",
        "SILICON DIOXIDE"
      ],
      "packaging": [
        {
          "quantity": "36 1",
          "ndc": "",
          "container": "BOTTLE"
        },
        {
          "quantity": "1 1",
          "ndc": "83059-0021-3",
          "container": "CARTON"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20240123",
      "approval_status": "OTC Monograph Drug",
      "size": "11 mm",
      "imprint": "13",
      "color": "pink",
      "shape": "CAPSULE"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "content": "Drug Facts"
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "title": "\n                  ",
        "content": "Diphenhydramine HCl 25 mg"
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "title": "\n                  ",
        "content": "Antihistamine"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "\n                  ",
        "content": "temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching\u00a0of the nose or throat temporarily relieves these\u00a0symptoms due to the common cold: runny nose sneezing"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "\n                  ",
        "content": ""
      },
      {
        "code": "50570-1",
        "type": "OTC - DO NOT USE SECTION",
        "content": "Do not use to make a child sleepy with any other product containing diphenhydramine, even one used on skin"
      },
      {
        "code": "50569-3",
        "type": "OTC - ASK DOCTOR SECTION",
        "content": "Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis trouble urinating due to an enlarged prostate gland glaucoma"
      },
      {
        "code": "50568-5",
        "type": "OTC - ASK DOCTOR/PHARMACIST SECTION",
        "content": "Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers"
      },
      {
        "code": "50567-7",
        "type": "OTC - WHEN USING SECTION",
        "content": "When using this product marked drowsiness may occur avoid alcoholic drinks alcohol, sedatives and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery excitability may occur, especially in children"
      },
      {
        "code": "53414-9",
        "type": "OTC - PREGNANCY OR BREAST FEEDING SECTION",
        "content": "If pregnant or breast-feeding, ask a health professional before use."
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "content": "Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "\n                  ",
        "content": "take every 4 to 6 hours, or as directed by a doctor do not take more than 6 times in 24 hours adults and children 12 years and over 1 to 2 tablets children 6 to under 12 years 1 tablet children under 6 years do not use"
      },
      {
        "code": "60561-8",
        "type": "OTHER SAFETY INFORMATION",
        "title": "\n                  ",
        "content": "each tablet contains: calcium 25 mg store between 20-25\u00b0 C (68-77\u00b0 F) protect from moisture and light"
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "title": "\n                  ",
        "content": "dibasic calcium phosphate, colloidal silicon dioxide, croscarmellose sodium, FD&C red #3, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, titanium dioxide"
      },
      {
        "code": "53413-1",
        "type": "OTC - QUESTIONS SECTION",
        "title": "\n                  ",
        "content": "1-800-373-6981"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "content": "Distributed by: Shield Pharmaceuticals Corp. Hauppauge, NY 11788"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PRINCIPAL DISPLAY PANEL",
        "content": "Allergy Relief Diphenhydramine HCl 25 mg Carton Label"
      }
    ],
    "category": "OTC (Over-the-Counter)"
  },
  {
    "filename": "otc_43f770ab-1ea6-c06a-e063-6294a90aebd2.xml",
    "document_id": "43f770ab-1ea6-c06a-e063-6294a90aebd2",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "geri-mox chry",
    "effective_date": "20251119",
    "version": "5",
    "author": {
      "name": "Geri-Care Pharmaceuticals, Corp",
      "id": "611196254"
    },
    "product": {
      "ndc": "57896-638",
      "name": "GERI-MOX MAX CHERRY",
      "form": "SUSPENSION",
      "generic_name": "aluminum hydroxide, magnesium hydroxide, dimethicone",
      "active_ingredients": [
        {
          "name": "ALUMINUM HYDROXIDE",
          "code": "5QB0T2IUN0",
          "strength": "400 mg",
          "per": "5 mL"
        },
        {
          "name": "MAGNESIUM HYDROXIDE",
          "code": "NBZ3QY004S",
          "strength": "400 mg",
          "per": "5 mL"
        },
        {
          "name": "DIMETHICONE",
          "code": "92RU3N3Y1O",
          "strength": "40 mg",
          "per": "5 mL"
        }
      ],
      "inactive_ingredients": [
        "BENZYL ALCOHOL",
        "BUTYLPARABEN",
        "CARBOXYMETHYLCELLULOSE SODIUM",
        "HYPROMELLOSES",
        "CELLULOSE, MICROCRYSTALLINE",
        "PROPYLPARABEN",
        "WATER",
        "SACCHARIN SODIUM",
        "SORBITOL"
      ],
      "packaging": [
        {
          "quantity": "355 mL",
          "ndc": "57896-638-12",
          "container": "BOTTLE"
        },
        {
          "quantity": "30 mL",
          "ndc": "",
          "container": "CUP, UNIT-DOSE"
        },
        {
          "quantity": "100 1",
          "ndc": "57896-638-10",
          "container": "CASE"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20110301",
      "approval_status": "OTC Monograph Drug"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "title": "Active ingredients (in each 5 mL teaspoonful)",
        "content": "Aluminum hydroxide 400 mg (equivalent to dried gel, USP) Magnesium hydroxide 400 mg Simethicone 40mg"
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "title": "Purposes",
        "content": "Antacid Antigas"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "Uses",
        "content": "relieves heartburn sour stomach acid indigestion the symptoms referred to as gas"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "Warnings",
        "content": "Ask a doctor before use if you have \u2022 kidney disease \u2022 a magnesium-restricted diet Ask a doctor or pharmacist before use if you are taking a prescription drug. Antacids may interact with certain prescription drugs. Stop use and ask a doctor if symptoms last more than 2 weeks If pregnant or breast-feeding, ask a health professional before use."
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "content": "Keep out of reach of children."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "Directions",
        "content": "\u2022 shake well before use \u2022 adults and children 12 years and older: take 2 to 4 teaspoonfuls two times a day, or as directed by a doctor \u2022 do not take more than 8 teaspoonfuls in 24 hours or use the maximum dosage for more than 2 weeks \u2022 children under 12 years: ask a doctor"
      },
      {
        "code": "44425-7",
        "type": "STORAGE AND HANDLING SECTION",
        "title": "Other information",
        "content": "\u2022 each 5 mL teaspoonful contains: magnesium 165 mg, sodium 1 mg \u2022 store at room temperature \u2022 protect from freezing \u2022 keep tightly closed \u2022 TAMPER-EVIDENT: Do not use if breakaway band on bottle cap is missing or broken."
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "title": "Inactive ingredients",
        "content": "benzyl alcohol, butylparaben, carboxymethylcellulose sodium, flavor, hypromellose, microcrystalline cellulose, propylparaben, purified water, saccharin sodium, sorbitol solution"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "package Label",
        "content": "NDC 57896-638-12 GERICARE GERI-MOX MAXIMUM STRENGTH antacid and antigas Alumina, Magnesia and Simethicone Oral Suspension For Fast Relief of: HEARTBURN ACID INDIGESTION PRESSURE AND BLOATING cherry flavor pleasant tasting 12 FL OZ (355 mL) compare to the active ingredients of Maximum Strength MAALOX ADVANCED"
      }
    ],
    "category": "OTC (Over-the-Counter)"
  },
  {
    "filename": "otc_ba65223d-080f-40e2-807a-eaf4d3611cd4.xml",
    "document_id": "ba65223d-080f-40e2-807a-eaf4d3611cd4",
    "document_type": "HUMAN OTC DRUG LABEL",
    "title": "Marcs",
    "effective_date": "20241111",
    "version": "12",
    "author": {
      "name": "Mark Glassman, Inc.",
      "id": "094487477"
    },
    "product": {
      "ndc": "68998-134",
      "name": "Marcs Everyday Care Dandruff",
      "form": "SHAMPOO",
      "generic_name": "Pyrithione Zinc",
      "active_ingredients": [
        {
          "name": "Pyrithione Zinc",
          "code": "R953O2RHZ5",
          "strength": "10 mg",
          "per": "1 mL"
        }
      ],
      "inactive_ingredients": [
        "Water",
        "SODIUM LAURETH-3 SULFATE",
        "Sodium Lauryl Sulfate",
        "COCO MONOETHANOLAMIDE",
        "GLYCOL DISTEARATE",
        "Dimethicone",
        "Cetyl Alcohol",
        "GUAR HYDROXYPROPYLTRIMONIUM CHLORIDE",
        "MAGNESIUM SULFATE, UNSPECIFIED FORM",
        "Sodium Benzoate",
        "Magnesium Carbonate Hydroxide",
        "AMMONIUM LAURETH-5 SULFATE",
        "Benzyl Alcohol",
        "Sodium Chloride",
        "Methylchloroisothiazolinone",
        "Methylisothiazolinone",
        "Sodium Xylenesulfonate",
        "FD&C BLUE NO. 1",
        "FD&C RED NO. 4"
      ],
      "packaging": [
        {
          "quantity": "399 mL",
          "ndc": "68998-134-01",
          "container": "BOTTLE, PLASTIC"
        }
      ],
      "route": "TOPICAL",
      "marketing_status": "active",
      "marketing_start_date": "20111130",
      "approval_status": "OTC Monograph Drug",
      "color": "blue"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL listing data elements section"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "",
        "content": "Drug Facts"
      },
      {
        "code": "55106-9",
        "type": "OTC - ACTIVE INGREDIENT SECTION",
        "title": "Active ingredient",
        "content": "Pyrithione Zinc 1%"
      },
      {
        "code": "55105-1",
        "type": "OTC - PURPOSE SECTION",
        "title": "Purpose",
        "content": "Anti-dandruff"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "Use",
        "content": "helps prevent recurrence of flaking and itching associated with dandruff."
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "Warnings",
        "content": "For external use only"
      },
      {
        "code": "50567-7",
        "type": "OTC - WHEN USING SECTION",
        "title": "When using this product",
        "content": "do not get into eyes. If contact occurs, rinse eyes thoroughly with water"
      },
      {
        "code": "50566-9",
        "type": "OTC - STOP USE SECTION",
        "title": "Stop use and ask a doctor if",
        "content": "condition worsens or does not improve after regular use of this product as directed"
      },
      {
        "code": "50565-1",
        "type": "OTC - KEEP OUT OF REACH OF CHILDREN SECTION",
        "title": "",
        "content": "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away"
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "Directions",
        "content": "shake well wet hair massage onto scalp rinse repeat if desired for best results use at least twice a week or as directed by a doctor for maximum dandruff control, use every time you shampoo"
      },
      {
        "code": "51727-6",
        "type": "INACTIVE INGREDIENT SECTION",
        "title": "Inactive ingredients",
        "content": "water, sodium laureth sulfate, sodium lauryl sulfate, cocamide MEA, glycol distearate, dimethicone, fragrance, cetyl alcohol, guar hydroxytrimonium chloride,  magnesium sulfate, sodium benzoate, magnesium carbonate hydroxide, ammonium laureth sulfate, benzyl alcohol, sodium chloride, methylchloroisothiazolinone, methylisothiazolinone, sodium xylenesulfonate, blue 1, red 4"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "",
        "content": "Distributed by: Marc Glassman, Inc. West 130th Street Cleveland, OH 44130"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PRINCIPAL DISPLAY PANEL - 399 mL Bottle Label",
        "content": "*Compare to the active ingredient in Head & Shoulders\u00ae Marcs \u00ae pyrithione zinc Dandruff Shampoo Everyday Care Basic everyday cleaning for normal hair pyrithione zinc 1 % 13.5 FL OZ (399 mL)"
      }
    ],
    "category": "OTC (Over-the-Counter)"
  },
  {
    "filename": "other_14ed4ac8-b9ab-495c-9bef-bf3dd441ac78.xml",
    "document_id": "14ed4ac8-b9ab-495c-9bef-bf3dd441ac78",
    "document_type": "STANDARDIZED ALLERGENIC",
    "title": "ALLERGENIC EXTRACTS STANDARDIZED GRASS POLLEN (glycerinated)",
    "effective_date": "20251119",
    "version": "11",
    "author": {
      "name": "Jubilant HollisterStier LLC",
      "id": "069263643"
    },
    "product": {
      "ndc": "65044-0611",
      "name": "Standardized Grass Pollen, Fescue, Meadow",
      "form": "INJECTION, SOLUTION",
      "generic_name": "Standardized Grass Pollen, Fescue, Meadow",
      "active_ingredients": [
        {
          "name": "LOLIUM PRATENSE POLLEN",
          "code": "A0WFQ8P6N1",
          "strength": "10000 [BAU]",
          "per": "1 mL"
        }
      ],
      "inactive_ingredients": [
        "GLYCERIN",
        "SODIUM CHLORIDE",
        "SODIUM BICARBONATE"
      ],
      "packaging": [
        {
          "quantity": "5 mL",
          "ndc": "65044-0611-1",
          "container": "VIAL"
        },
        {
          "quantity": "10 mL",
          "ndc": "65044-0611-2",
          "container": "VIAL"
        },
        {
          "quantity": "30 mL",
          "ndc": "65044-0611-3",
          "container": "VIAL"
        },
        {
          "quantity": "50 mL",
          "ndc": "65044-0611-4",
          "container": "VIAL"
        }
      ],
      "route": "PERCUTANEOUS",
      "marketing_status": "active",
      "marketing_start_date": "19980115",
      "approval_status": "BLA"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL listing data elements section"
      },
      {
        "code": "34066-1",
        "type": "BOXED WARNING SECTION",
        "title": "WARNINGS",
        "content": "This product is intended for use only by licensed medical personnel experienced in administering allergenic extracts and trained to provide immediate emergency treatment in the event of a life-threatening reaction. Allergenic extracts may potentially elicit a severe life-threatening systemic reaction, rarely resulting in death 1 . Therefore, emergency measures and personnel trained in their use must be available immediately in the event of such a reaction. Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician's office if symptoms occur. See ADVERSE REACTION , Section 3, of this insert for information regarding adverse event reporting. Standardized glycerinated extracts may differ in potency from regular extracts and therefore, are not directly interchangeable with non-standardized extracts, or other manufacturers' products. Note: BAU/mL Standardized grass pollens are not interchangeable with any other grass pollen products. This product should never be injected intravenously. Patients with cardiovascular diseases or pulmonary diseases such as symptomatic unstable, steroid-dependent asthma, and/or those who are receiving cardiovascular drugs such as beta blockers, may be at higher risk for severe adverse reactions. These patients may also be more refractory to the normal allergy treatment regimen. Patients should be treated only if the benefit of treatment outweighs the risks. 1 Refer also to the CONTRAINDICATIONS , WARNINGS , PRECAUTIONS , ADVERSE REACTIONS and OVERDOSE Sections for further discussion."
      },
      {
        "code": "34089-3",
        "type": "DESCRIPTION SECTION",
        "title": "DESCRIPTION",
        "content": "The grass pollens available in standardized form are: Bermuda Grass ( Cynodon dactylon ), Orchard Grass ( Dactylis glomerata ), Perennial Ryegrass ( Lolium perenne ), Timothy Grass ( Phleum pratense ), Redtop Grass ( Agrostis alba ), Kentucky Bluegrass ( Poa pratensis ), Meadow Fescue ( Festuca elatior ), and Sweet Vernalgrass ( Anthoxanthum odoratum ). The pollen extracts are intended for subcutaneous injection for immunotherapy; and intradermal and prick or puncture for diagnosis. Pollen extracts are sterile solutions containing the extractables of pollens, 0.5% Sodium Chloride, 0.275% Sodium Bicarbonate, and 50% Glycerin by volume as a preservative. Sterile, diluted Standardized Grass Pollen Extracts available for intradermal testing contain 0.9% sodium chloride, not more than 0.5% glycerin by volume, 0.03% sodium bicarbonate, and 0.4% phenol as a preservative. Source material for the extracts is collected using techniques such as water set or vacuuming. Source material for allergenic extracts contains no more than a total of 1% of detectable foreign materials (99% pollen purity). Note: BAU/mL Standardized grass pollens are not interchangeable with any other grass pollen products. Product Concentration: 1. Bioequivalent Allergy Units . These allergenic extracts are labeled in Bioequivalent Allergy Units/mL (BAU/mL) based on their comparison (by ELISA Competition) to Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) Reference Preparations. 2 The FDA reference extracts have been assigned Bioequivalent Allergy Units based on the CBER ID 50 EAL method. 5 Briefly, highly sensitive patients are skin tested to the reference preparation using an intradermal technique employing 3-fold extract dilutions. Depending on the dilution which elicits a summation of erythema diameter of 50mm (D 50 ), Bioequivalent Allergy Units are assigned as follows: BAU/mL Intradermal Mean Dilution D 50 1000,000 1:5,000,000 13-14.9 10,000 1:500,000 11-12.9 1,000 1:50,000 9-10.9 The vial potency of Mixtures of Standardized Grasses is calculated by summation of the BAU/mL values of the components of the ingredient list which expresses the potency of each component per mL of the mixture. 2. Concentrate. a. Concentrate label terminology applies to allergenic extract Custom Mixtures where the individual allergens being combined vary in strength or the designation of strength. e.g. Concentrate 50% Short Ragweed 1:20 w/v 25% Kentucky Bluegrass 100,000 BAU/mL 25% Std. Mite D. farinae 10,000 AU/mL Should the physician choose to calculate the actual strength of each component in the \"Concentrate\" mixture, the following formulation may be used: Actual Allergen Strength in Concentrate Mixture = Allergen Manufacturing Strength x Allergen in Formulation (by volume or parts) b . In the list of components portion of the product label for Stock Mixtures Containing Standardized Grasses ,  the potency of each component is calculated to express the potency of each component per 1 mL of the mixture. Vial potency is expressed as concentrate, or as a volume/volume dilution of concentrate."
      },
      {
        "code": "34090-1",
        "type": "CLINICAL PHARMACOLOGY SECTION",
        "title": "CLINICAL PHARMACOLOGY",
        "content": "20 The mechanisms by which hyposensitization is achieved are not completely understood. It has been shown that repeated injections of appropriate allergenic extracts will ameliorate the intensity of allergic symptoms upon contact with the allergen.6, 7, 8, 9   Clinical studies which address the efficacy of immunotherapy are available. The allergens which have been studied are cat, mite, and some pollen extracts.10, 11, 12, 13, 14, 15 IgE antibodies bound to receptors on mast cell membranes are required for the allergic reaction, and their level is probably related to serum IgE concentrations. Immunotherapy has been associated with decreased levels of IgE, and also with increases in allergen specific IgG \"blocking\" antibody. The histamine release response of circulating basophils to a specific allergen is reduced in some patients by immunotherapy, but the mechanism of this change is not yet clear. The relationships among changes in blocking antibody, reaginic antibody, and mediator-releasing cells, and successful immunotherapy need study and clarification. The CBER has evaluated the potency of eight grass pollen extract reference preparations and assigned potency units (BAU/mL) to each.5  The CBER clinical results follow in Table 1. Puncture data were obtained using a bifurcated needle. Table 1 PUNCTURE AND INTRADERMAL DATA WITH CBER GRASS REFERENCES 3 A. Puncture Data with 10,000 BAU/mL Grass Extracts Sum of Erythema (mm) Sum of Wheal (mm) Reference Pollen N Mean Range Mean Range Bermuda Grass - Cynodon dactylon 15 90.3 43-123 15.7 7-31 Kentucky Bluegrass (June) - Poa pratensis 15 77.3 47-107 15.9 6-28 Meadow Fescue - Festuca elatior 15 81.1 57-115 11.9 7-22 Orchard Grass - Dactylis glomerata 15 84.3 57-111 14.1 9-19 Perennial Ryegrass - Lolium perenne 15 92.3 73-135 17.5 6-36 Redtop - Agrostis gigantea (alba) 15 77.1 42-98 14.1 8-19 Sweet Vernalgrass - Anthoxanthum odoratum 15 81.2 28-123 15.7 8-30 Timothy - Phleum pratense 15 88.3 51-109 16.9 8-40 B. Intradermal Dose of CBER Grass References for 50mm Sum of Erythema (BAU 50 ) Reference Pollen Mean BAU 50 /mL Range Bermuda Grass - Cynodon dactylon 0.02 0.4-0.0003 Kentucky Bluegrass (June) - Poa pratensis 0.02 0.1-0.004 Meadow Fescue - Festuca elatior 0.02 0.9-0.002 Orchard Grass - Dactylis glomerata 0.02 1.9-0.002 Perennial Ryegrass - Lolium Perenne 0.02 0.7-0.002 Redtop - Agrostis gigantea (alba) 0.02 0.8-0.004 Sweet Vernalgrass - Anthoxanthum odoratum 0.02 1.0-0.002 Timothy - Phleum pratense 0.02 0.6-0.002 TABLE 2 RELATIVE POTENCY OF PREVIOUSLY MANUFACTURED AND DISTRIBUTED NON-STANDARDIZED GRASSES TO CBER REFERENCE STANDARDS Glycerinated (1:20 w/v) and Non-Glycerinated Pollen Extracts (1:10 w/v) # of Jubilant HollisterStier LLC Lots Relative to the CBER Reference* Pollen # of Lots Tested Less than Equal to Greater Than Calculated BAU/mL Range** (Rounded to the nearest 000) Orchard Grass 20 2 13 5 66,000 - 242,000 Perennial Ryegrass 17 5 12 0 25,000 - 127,000 Sweet Vernalgrass 13 1 12 0 73,000 - 110,000 Kentucky Bluegrass 21 8 12 1 32,000 - 145,000 Redtop 20 5 6 9 13,000 - 402,000 Meadow Fescue 21 0 1 20 128,000 - 948,000 Bermuda Grass 22 3 13 6 6,000 - 28,000 Timothy 19 11 6 2 43,000 - 176,000 *All CBER reference extracts contain 100,000 BAU/mL except Bermuda Grass which contains 10,000 BAU/mL. **BAU/mL ranges between 69,990 and 143,100 are considered equivalent to the CBER 100,000 BAU/mL Standard, and between 6,990 and 14,310 for the CBER 10,000 BAU/mL Standard when assays are done in triplicate."
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "INDICATIONS AND USAGE",
        "content": "16, 17, 18, 20 Standardized glycerinated allergenic extracts in potencies of 10,000 BAU/mL and 100,000 BAU/mL are indicated for use in diagnosis and immunotherapy of patients presenting symptoms of allergy (hay fever, rhinitis, etc.) to specific grass pollens. Concentrated extracts must be diluted prior to use in intradermal testing and immunotherapy. The selection of allergenic extracts to be used should be based on a thorough and carefully taken history of hypersensitivity, and confirmed by skin testing. 27, 28 10,000 BAU/mL dose form should be used initially for percutaneous testing. If negative, the 100,000 BAU/mL dose can be used. The use of mixed or unrelated antigens for skin testing is not recommended since, in the case of a positive reaction, it does not indicate which component of the mix is responsible for the reaction, while, in the case of a negative reaction, it fails to indicate whether the individual antigens at full concentration would give a positive reaction. Utilization of such mixes for compounding a treatment may result, in the former case, in administering unnecessary antigens and, in the latter case, in the omission of a needed allergen. Allergens to which a patient is extremely sensitive should not be included in treatment mixes with allergens to which there is much less sensitivity, but should be administered separately. This allows individualized and better control of dosage increases, including adjustments in dosage becoming necessary after severe reactions which may occur to the highly reactive allergen. Note: BAU/mL Standardized grass pollens are not interchangeable with any other grass pollen products."
      },
      {
        "code": "34070-3",
        "type": "CONTRAINDICATIONS SECTION",
        "title": "CONTRAINDICATIONS",
        "content": "There are no known absolute contraindications to immunotherapy. See PRECAUTIONS for pregnancy risks. Patients with cardiovascular diseases or pulmonary diseases such as symptomatic unstable, steroid-dependent asthma, and/or those who are receiving cardiovascular drugs such as beta blockers, may be at higher risk for severe adverse reactions. These patients may also be more refractory to the normal allergy treatment regimen. Patients should be treated only if the benefit of treatment outweighs the risks. 1 Any injections, including immunotherapy, should be avoided in patients with a bleeding tendency. Since there are differences of opinion concerning the possibility of routine immunizations exacerbating autoimmune diseases, immunotherapy should be given cautiously to patients with autoimmune diseases, and only if the risk from exposure to the allergen is greater than the risk of exacerbating the autoimmune process."
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "WARNINGS",
        "content": "See WARNINGS at the beginning of this instruction sheet. Allergenic extract should be temporarily withheld from patients or the dose adjusted downward if any of the following conditions exist: (1) severe symptoms of rhinitis and/or asthma; (2) infection or flu accompanied by fever; or (3) exposure to excessive amounts of clinically relevant allergen prior to a scheduled injection. Do not start immunotherapy during a period of symptoms due to exposure. Since the individual components of the extract are those to which the patient is allergic, and to which he or she will be exposed, typical allergic symptoms may follow shortly after the injection, particularly when the antigen load from exposure plus the injected antigen exceeds the patient's antigen tolerance. (4) Any evidence of a local or generalized reaction requires a reduction in dosage during the initial stages of immunotherapy, as well as during maintenance therapy. THE CONCENTRATE SHOULD NOT BE INJECTED AT ANY TIME UNLESS TOLERANCE HAS BEEN ESTABLISHED. DILUTE CONCENTRATED EXTRACTS WITH STERILE ALBUMIN SALINE WITH PHENOL (0.4%) FOR INTRADERMAL TESTING. INJECTIONS SHOULD NEVER BE GIVEN INTRAVENOUSLY. Subcutaneous injection is recommended. Intracutaneous or intramuscular injections may produce large local reactions or be excessively painful. AFTER INSERTING NEEDLE SUBCUTANEOUSLY, BUT BEFORE INJECTING, ALWAYS WITHDRAW THE PLUNGER SLIGHTLY. IF BLOOD APPEARS IN THE SYRINGE, CHANGE NEEDLE AND GIVE THE INJECTION IN ANOTHER SITE."
      },
      {
        "code": "34066-1",
        "type": "BOXED WARNING SECTION",
        "title": "",
        "content": "IF CHANGING TO A DIFFERENT LOT OF STANDARDIZED EXTRACT: Even though it is the same formula and concentration, the first dose of the new extract should not exceed 25% to 50% of the last administered dose from the previous extract. IF THE STANDARDIZED EXTRACT PREVIOUSLY USED WAS FROM ANOTHER MANUFACTURER: Since manufacturing processes and sources of raw materials differ among manufacturers, the interchangeability of extracts from different manufacturers cannot be insured. The starting dose of the standardized glycerinated extract therefore should be greatly decreased even though the extract is the same formula and dilution. Initiate therapy as though patient had not been receiving immunotherapy, or determine initial dose by skin test using serial dilutions of the extract. In highly sensitive individuals, the skin test method may be preferable. See  DOSAGE AND ADMINISTRATION and  ADVERSE REACTIONS Sections. IF A PROLONGED PERIOD OF TIME HAS ELAPSED SINCE THE LAST INJECTION: Patients may lose tolerance for allergen injections during prolonged periods between doses. The duration of tolerance is an individual characteristic and varies from patient to patient. In general, the longer the lapse in the injection schedule, the greater dose reduction required. If the interval since last dose is over four weeks, perform skin tests to determine starting dose. IF THE PREVIOUS EXTRACT WAS OUTDATED: The dating period for allergenic extracts indicates the time that they can be expected to remain potent under refrigerated storage conditions (2\u00b0- 8\u00b0C).  During the storage of extracts, even under ideal conditions, some loss of potency occurs. For this reason, extracts should not be used beyond their expiration date. If a patient has been receiving injections of an outdated extract, he may experience excessive local or systemic reactions when changed to a new, and possibly more potent extract. In general, the longer the material has been outdated, the greater the dose reduction necessary for the fresh extract. IF THE PREVIOUS EXTRACT WAS NON-STANDARDIZED: Standardized extracts differ in potency from non-standardized extracts. Use Table 2 for guidance in selecting dose for switching. To confirm dose selected, side-by-side skin testing of new and old extracts can be carried out. (See  CLINICAL PHARMACOLOGY, Table 2.)  Initiate therapy as though the patient had not been receiving immunotherapy, or determine initial dose by skin test using serial dilutions of the extract. See PRECAUTIONS and  DOSAGE AND ADMINISTRATION Sections below. IF ANY OTHER CHANGES HAVE BEEN MADE IN THE EXTRACT CONCENTRATE FORMULA: Changes other than those listed above may include situations such as a redistribution of component parts or percentages, a difference in extracting fluid (i.e., change from non-glycerin extracts to 50% glycerin extracts), combining two or more stock concentrates, or any other change. It should be recognized that any change in formula can affect a patient's tolerance of the treatment. The usual 1/2 of the previous dose for a new extract may produce an adverse reaction; extra dilutions are recommended whenever starting a revised formula. The greater the change, the greater the number of dilutions required."
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "",
        "content": "Proper selection of the dose and careful injection should prevent most systemic reactions. It must be remembered, however, that allergenic extracts are highly potent in sensitive individuals, and that systemic reactions of varying degrees of severity may occur, including urticaria, rhinitis, conjunctivitis, wheezing, coughing, angioedema, hypotension, bradycardia, pallor, laryngeal edema, fainting, or even anaphylactic shock and death. Patients should be informed of this, and the precautions should be discussed prior to immunotherapy.  (See  PRECAUTIONS below.) Severe systemic reactions should be treated as indicated in the  ADVERSE REACTIONS Section below."
      },
      {
        "code": "42232-9",
        "type": "PRECAUTIONS SECTION",
        "title": "PRECAUTIONS"
      },
      {
        "code": "34072-9",
        "type": "GENERAL PRECAUTIONS SECTION",
        "title": "1. GENERAL",
        "content": "The presence of asthmatic signs and symptoms appear to be an indicator for severe reactions following allergy injections. An assessment of airway obstruction either by measurement of peak flow or an alternate procedure may provide a useful indicator as to the advisability of administering an allergy injection. 1, 30, 31, 32, 33 Concentrated extracts must be diluted prior to use: See DOSAGE AND ADMINISTRATION Section for detailed instructions on the dilution of standardized glycerinated allergenic extracts. Allergenic extracts diluted with Albumin Saline with Phenol (0.4%) may be more potent than extracts diluted with diluents which do not contain stabilizers. When switching from non-stabilized to stabilized diluent, consider weaker initial dilutions for both intradermal testing and immunotherapy. Sterile solutions, vials, syringes, etc. should be used and aseptic precautions observed in making dilutions. To avoid cross-contamination, do not use the same needle to withdraw materials from vials of more than one extract, or extract followed by diluent. A sterile tuberculin syringe graduated in 0.01 mL units should be used to measure each dose from the appropriate dilution. Aseptic techniques should always be employed when injections of allergenic extracts are being administered. A separate sterile syringe should be used for each patient to prevent transmission of hepatitis and other infectious agents from one person to another. Patient reactions to previous injections should be reviewed before each new injection. A conservative dosage schedule should be followed by the physician until a pattern of local responses is established which can be used to monitor increases in dosage. Rarely, a patient is encountered who develops systemic reactions to minute doses of allergen and does not demonstrate increasing tolerance to injections after several months of treatment. If systemic reactions or excessive local responses occur persistently at very small doses, efforts at immunotherapy should be stopped. PATIENTS SHOULD BE OBSERVED IN THE OFFICE FOR AT LEAST 30 MINUTES AFTER EACH TREATMENT INJECTION. Most severe reactions will occur within this time period, and rapid treatment measures should be instituted. See ADVERSE REACTIONS Section for such treatment measures."
      },
      {
        "code": "34076-0",
        "type": "INFORMATION FOR PATIENTS SECTION",
        "title": "2. INFORMATION FOR PATIENTS",
        "content": "Patients should be instructed in the recognition of adverse reactions to immunotherapy, and in particular, to the symptoms of shock. Patients should be made to understand the importance of a 30 minute observation period, and be warned to return to the office promptly if symptoms occur after leaving."
      },
      {
        "code": "34083-6",
        "type": "CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION",
        "title": "3. CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY",
        "content": "Long-term studies in animals have not been conducted with allergenic extracts to determine their potential for carcinogenicity, mutagenicity or impairment of fertility."
      },
      {
        "code": "42228-7",
        "type": "PREGNANCY SECTION",
        "title": "4. PREGNANCY",
        "content": "29 Allergenic Extracts. Animal reproduction studies have not been conducted with allergenic extracts. It is also not known whether allergenic extracts can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Allergenic extracts should be given to a pregnant woman only if clearly needed. For women who have been getting maintenance doses of allergen without side effect, the occurrence of pregnancy is not an indication to stop immunotherapy."
      },
      {
        "code": "34080-2",
        "type": "NURSING MOTHERS SECTION",
        "title": "5. NURSING MOTHERS",
        "content": "There are no current studies on secretion of the allergenic extract components in human milk, or of their effect on the nursing infant. Because many drugs are excreted in human milk, caution should be exercised when allergenic extracts are administered to a nursing woman."
      },
      {
        "code": "34081-0",
        "type": "PEDIATRIC USE SECTION",
        "title": "6. PEDIATRIC USE",
        "content": "Since dosage for the pediatric population is the same as for adults, 21 the larger volumes of solution may produce excessive discomfort. Therefore, in order to achieve the total dose required, the volume of the dose may need to be divided into more than one injection per visit."
      },
      {
        "code": "34082-8",
        "type": "GERIATRIC USE SECTION",
        "title": "7. GERIATRIC USE",
        "content": "The reactions from immunotherapy can be expected to be the same in elderly patients as in younger ones. Elderly patients may be more likely to be on medication that could block the effect of epinephrine which could be used to treat serious reactions, or they could be more sensitive to the cardiovascular side effect of epinephrine because of pre-existing cardiovascular disease. 4"
      },
      {
        "code": "34073-7",
        "type": "DRUG INTERACTIONS SECTION",
        "title": "8. DRUG INTERACTIONS",
        "content": "Patients on non-selective beta blockers may be more reactive to allergens given for diagnosis or treatment, and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. 19 Certain medications may lessen the skin test wheal and erythema responses elicited by allergens and histamine for varying time periods. Conventional antihistamines should be discontinued at least 5 days before skin testing. Long acting antihistamines should be discontinued for at least 3 weeks prior to skin testing. 23 Topical steroids should be discontinued at the skin test site for at least 2-3 weeks before skin testing. 23, 24 Tricyclic antidepressants such as Doxepin should be withheld for at least 7 days before skin testing. 25 Topical local anesthetics may suppress the flare responses and should be avoided in skin test sites. 26"
      },
      {
        "code": "34084-4",
        "type": "ADVERSE REACTIONS SECTION",
        "title": "ADVERSE REACTIONS",
        "content": "1. Local Reactions Some erythema, swelling or pruritus at the site of injection are common, the extent varying with the patient. Such reactions should not be considered significant unless they persist for at least 24 hours. Local reactions (erythema or swelling) which exceed 4-5 cm in diameter are not only uncomfortable, but also indicate the possibility of a systemic reaction if dosage is increased. In such cases the dosage should be reduced to the last level not causing the reaction and maintained at this level for two or three treatments before cautiously increasing again. Large persistent local reactions may be treated by local cold, wet dressings and/or the use of oral antihistamines. They should be considered a warning of possible severe systemic reactions and an indication of the need for temporarily reduced dosages. A mild burning immediately after the injection is to be expected. This usually leaves in 10 to 20 seconds. 2. Systemic Reactions With careful attention to dosage and administration, systemic reactions occur infrequently, but it cannot be overemphasized that in sensitive individuals, any injection could result in anaphylactic shock. Therefore, it is imperative that physicians administering allergenic extracts understand and be prepared for the treatment of severe reactions. Other possible systemic reactions which may occur in varying degrees of severity are laryngeal edema, fainting, pallor, bradycardia, hypotension, angioedema, cough, wheezing, conjunctivitis, rhinitis, and urticaria. Adverse reaction frequency data for allergenic extract administration for testing and treatment show that risk is low.1, 22 If a systemic or anaphylactic reaction does occur, apply a tourniquet above the site of injection and inject 1:1,000 epinephrine-hydrochloride intramuscularly or subcutaneously into the opposite arm. Loosen the tourniquet at least every 10 minutes. Do not obstruct arterial blood flow with the tourniquet. EPINEPHRINE DOSAGE ADULT DOSAGE: 0.3 to 0.5 mL should be injected. Repeat in 5 to 10 minutes if necessary. PEDIATRIC DOSAGE: The usual initial dose is 0.01 mg (mL) per kg body weight or 0.3 mg (mL) per square meter of body surface area. Suggested dosage for infants to 2 years of age is 0.05 to 0.1 mL; for children 2 to 6 years, 0.15 mL; and children 6 to 12 years, 0.2 mL. Single pediatric doses should not exceed 0.3 mg (mL). Doses may be repeated as frequently as every 20 minutes, depending on the severity of the condition and the response of the patient. After administration of epinephrine, profound shock or vasomotor collapse should be treated with intravenous fluids, and possibly vasoactive drugs. Airway patency should be insured. Oxygen should be given by mask. Intravenous antihistamines, inhaled bronchodilators, theophylline and/or corticosteroids may be used if necessary after adequate epinephrine and circulatory support have been given. Emergency resuscitation measures and personnel trained in their use must be available immediately in the event of a serious systemic or anaphylactic reaction not responsive to the above measures [ Ref. J.Allergy and Clinical Immunology , 77(2): p. 271-273, 1986]. Rarely are all of the above measures necessary; the tourniquet and epinephrine usually produce prompt responses. However, the physician should be prepared in advance for all contingencies. Promptness in beginning emergency treatment measures is of utmost importance. Severe systemic reactions mandate a decrease of at least 50% in the next dose, followed by cautious increases. Repeated systemic reactions, even of a mild nature, are sufficient reason for the cessation of  further attempts to increase the reaction-causing dose. 3. Adverse Event Reporting Report all adverse events to Jubilant HollisterStier LLC Customer Technical Services Department at 1 (800) 992-1120. A voluntary adverse event reporting system for health professionals is available through the FDA MEDWATCH program. Preprinted forms (FDA Form 3500) are available from the FDA by calling 1 (800) FDA-1088. Completed forms should be mailed to MEDWATCH, 5600 Fisher Lane, Rockville, MD 20852-9787 or Fax to: 1 (800) FDA-0178."
      },
      {
        "code": "34088-5",
        "type": "OVERDOSAGE SECTION",
        "title": "OVERDOSAGE",
        "content": "See ADVERSE REACTIONS Section."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "DOSAGE AND ADMINISTRATION",
        "content": "1. General Sterile aqueous diluent containing albumin (human) [Albumin Saline with Phenol (0.4%)] or diluent of 50% glycerin may be used when preparing dilutions of the concentrate for immunotherapy. For intradermal testing dilutions, Albumin Saline with Phenol (0.4%) is recommended. Dilutions should be made accurately and aseptically, using sterile diluent, vials, syringes, etc. Mix thoroughly and gently by rocking or swirling. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. 2. Diagnosis Prick or Puncture Test: To identify highly sensitive individuals and as a safety precaution, it is recommended that a prick or puncture test using a drop of 10,000 BAU/mL extract be performed prior to initiating intradermal testing. If this test is negative, a second prick/puncture test may be performed using a 100,000 BAU/mL extract. Prick tests are performed by placing a drop of extract on the skin and piercing through the drop into the skin with a slight lifting motion. Puncture tests are performed by placing a drop of extract concentrate on the skin and piercing the skin through the drop with a small needle such as a Prick Lancetter. Fifteen minutes after puncture is made the diameter of wheal and erythema reactions are measured, and the sensitivity class of the patient determined by Table 3. Less sensitive individuals (Class 0 to 1+) can be tested intradermally with the recommended dilutions of the extract concentrate (See intradermal testing instructions). Intradermal Test: Patients with a negative prick or puncture test should be tested intradermally with 100 BAU/mL. If this test is negative, a second intradermal test may be performed using a 1,000 BAU/mL extract. The negative control should have glycerin concentration equivalent to the glycerin concentration of the intradermal test solution, not to exceed 5% glycerin. It is recommended that patients be tested using the intradermal technique only after screening by prick or puncture test. Extract for intradermal testing should be prepared by diluting the stock concentrate, provided in multiple-dose vials, with Sterile Albumin Saline with Phenol (0.4%) (refer to Table 4 in the Immunotherapy section below). To administer the intradermal strength dilutions, a 1 mL tuberculin syringe with a short 27-gauge needle should be used. The needle is inserted intradermally at a 30\u00b0 angle, bevel down, and 0.02 to 0.05 mL of the extract is injected. Fifteen minutes following injection, the diameter of wheal and erythema reactions are measured, and the patient's sensitivity class is determined by the table below. Skin tests are graded in terms of the wheal and erythema response noted at 10 to 20 minutes. Wheal and erythema size may be recorded by actual measurement of the extent of both responses. Refer to Table 3 to determine the skin test sensitivity class. The corresponding \u2211E (sum of the longest diameter and the mid-point orthogonal diameters of erythema) is also presented. TABLE 3 Classification of Skin Test Sensitivity for Intradermal and Pick or Puncture Class Wheal Diameter Erythema Diameter Corresponding \u2211E 0 < 5 mm <5 mm <10 mm \u00b1 5-10 mm 5-10 mm 10-20 mm 1+ 5-10 mm 11-20 mm 20-40 mm 2+ 5-10 mm 21-30 mm 40-60 mm 3+ 10-15 mm a 31-40 mm 60-80 mm 4+ >15 mm b >40 mm >80 mm a. or with pseudopods b. or with many pseudopods 3. Immunotherapy Allergenic extracts should be administered using a sterile syringe with 0.01 mL gradations and a 25-27 gauge X 1/2\" to 5/8\" needle. The injections are given subcutaneously. The most common sites of injection are the lateral aspect of the upper arm or thigh. Intracutaneous or intramuscular injections may produce large local reactions which may be very painful. Dosage of allergenic extracts is a highly individualized matter and varies according to the degree of sensitivity of the patient, his clinical response, and tolerance to the extract administered during the early phases of an injection regimen. The starting dose should be based on skin tests of the extract to be used for immunotherapy. To prepare dilutions for intradermal and therapeutic use, make a 1:10 dilution by adding 1.0 mL of the concentrate to 9.0 mL of Sterile Albumin Saline with Phenol (0.4%). Subsequent serial dilutions are made in a similar manner. (See Table 4.) To determine the starting dose, begin intradermal testing with the most dilute extract preparation. Inject 0.02 mL and read the reaction after 15 minutes. Intradermal testing is continued with increasing concentrations of the extract until a reaction of 11-20 mm erythema \u2211E 20-40 mm) and/or a 5 mm wheal occurs. This concentration at a dose of 0.03 mL then can serve as a starting dose for immunotherapy and be increased by 0.03 mL to as high as 0.12 mL increments each time until 0.3 mL is reached, at which time a dilution 10 times as strong can be used, starting with 0.03 mL. Proceed in this way until a tolerance dose is reached or symptoms are controlled. Suggested maintenance dose is 0.2 mL of the concentrate. Occasionally, higher doses are necessary to relieve symptoms. Special caution is required in administering doses greater than 0.2 mL. The interval between doses normally is 3 to 7 days. Potencies of 10,000 BAU/mL and 100,000 BAU/mL are available for treatment. The two selections are available to facilitate safe switching by providing flexibility in dosing. For previously untreated patients, initiate treatment using dilutions made from the 10,000 BAU/mL concentrate. If tolerated and symptoms justify a higher dosage, then use of dilutions made from the 100,000 BAU/mL concentrate is warranted. Proceed with caution when using 100,000 BAU/mL in higher doses. When converting a patient who is currently receiving non-standardized grass pollen extracts, it is recommended that skin testing be performed to compare the potency of the new and old extracts. If you choose not to skin test as recommended, but to continue therapy, the maximum first dose of the new allergenic product should not exceed 10% (1/10) of the previous dose. This is offered as a suggested schedule for average patients and will be satisfactory in most cases. However, the degree of sensitivity varies in many patients. The size of the dose should be adjusted and should be regulated by the patient's tolerance and reaction. The size of the dose should be decreased if the previous injection resulted in marked local or the slightest general reaction. Another dose should never be given until all local reactions resulting from the previous dose have disappeared. In some patients, the dosage may be increased more rapidly than called for in the schedule. In seasonal allergies, treatment should be started and the interval between doses regulated so that at least the first twenty doses will have been administered by the time symptoms are expected. Thus, the shorter the interval between the start of immunotherapy and the expected onset of symptoms, the shorter the interval between each dose. Some patients may even tolerate daily doses. A maintenance dose, the largest dose tolerated by the patient that relieves symptoms without producing undesirable local or general reactions, is recommended for most patients. The upper limits of dosage have not been established; however, doses larger than 0.2 mL of the glycerin concentrate may be painful due to the glycerin content. The dosage of allergenic extract does not vary significantly with the respiratory allergic disease under treatment. The size of this dose and the interval between doses will vary and can be adjusted as necessary. Should symptoms develop before the next injection is scheduled, the interval between doses should be decreased. Should allergic symptoms or local reactions develop shortly after the dose is administered, the size of the dose should be decreased. In seasonal allergies, it is often advisable to decrease the dose to one-half or one-quarter of the maximum dose previously attained if the patient has any seasonal symptoms. The interval between maintenance doses can be increased gradually from one week to 10 days, to two weeks, to three weeks, or even to four weeks if tolerated. Repeat the doses at a given interval three or four times to check for untoward reactions before further increasing the interval. Protection is lost rapidly if the interval between doses is more than four weeks. (See WARNINGS Section.) The usual duration of treatment has not been established. A period of two or three years of injection therapy constitutes an average minimum course of treatment. TABLE 4 TEN-FOLD DILUTION SERIES Standardized Extracts Labeled 100,000 BAU/mL Dilution Extract + Diluent = BAU/mL Concentration 0 Concentrate +0 mL = 100,000 1 1 mL Concentrate +9 mL = 10,000 2 1 mL dilution #1 +9 mL = 1,000 3 1 mL dilution #2 +9 mL = 100 4 1 mL dilution #3 +9 mL = 10 5 1 mL dilution #4 +9 mL = 1.0 6 1 mL dilution #5 +9 mL = 0.10 7 1 mL dilution #6 +9 mL = 0.010"
      },
      {
        "code": "34081-0",
        "type": "PEDIATRIC USE SECTION",
        "title": "(4) PEDIATRIC USE",
        "content": "The dose for the pediatric population is the same as for adults. (See PRECAUTIONS .)"
      },
      {
        "code": "34082-8",
        "type": "GERIATRIC USE SECTION",
        "title": "(5) GERIATRIC USE",
        "content": "The dose for elderly patients is the same as for adult patients under 65. 4"
      },
      {
        "code": "34069-5",
        "type": "HOW SUPPLIED SECTION",
        "title": "HOW SUPPLIED",
        "content": "Standardized allergenic extracts of grass pollens are supplied for diagnostic and therapeutic use: Diagnostics: Extracts: Pollens* Prick/puncture tests, 10,000 BAU/mL and 100,000 BAU/mL [50% glycerin (v/v)] in 5 mL dropper vial. Intradermal Tests [Aqueous] of 100 BAU/mL in 5 mL vial, and 1,000 BAU/mL in 5 mL vial. (Intradermal test solutions may contain up to 5% glycerin.) *Bermuda grass, 10,000 BAU/mL is highest concentration. Bulk Therapeutics [50% glycerin (v/v)] in multiple dose vials: Extracts: Pollens* 10 mL vial, in strengths of 100,000 BAU/mL and 10,000 BAU/mL 30 mL vial, in strengths of 100,000 BAU/mL and 10,000 BAU/mL 50 mL vial, in strengths of 100,000 BAU/mL and 10,000 BAU/mL *Bermuda grass, 10,000 BAU/mL only."
      },
      {
        "code": "44425-7",
        "type": "STORAGE AND HANDLING SECTION",
        "title": "STORAGE",
        "content": "The\nexpiration date of pollen extract in 50% glycerin is listed on the\ncontainer label. The extract should be stored at 2\u00b0- 8\u00b0C. Dilutions\ncontaining less than 50% glycerin are less stable and, if loss of\npotency is suspected, should be checked by skin testing with equal\nunits of a freshly prepared dilution on known pollen allergic\nindividuals. The expiration date of the intradermal tests is listed on\ncontainer labels. Store at 2\u00b0- 8\u00b0C."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "LIMITED WARRANTY",
        "content": "A number of factors beyond our control could reduce the efficacy of this product or even result in an ill effect following its use. These include storage and handling of the product after it leaves our hands, diagnosis, dosage, method of administration and biological differences in individual patients. Because of these factors, it is important that this product be stored properly and that the directions be followed carefully during use. No warranty, express or implied, including any warranty of merchantability or fitness, is made. Representatives of the Company are not authorized to vary the terms or the contents of any printed labeling, including the package insert, for this product except by printed notice from the Company's headquarters. The prescriber and user of this product must accept the terms hereof."
      },
      {
        "code": "34093-5",
        "type": "REFERENCES SECTION",
        "title": "REFERENCES",
        "content": "1. Lockey, Richard F., Linda M. Benedict, Paul C. Turkeltaub, Samuel C. Bukantz. Fatalities from immunotherapy (IT) and skin testing (ST). J. Allergy Clin. Immunol., 79 (4): 660-677, 1987. 2. U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER). ELISA competition assay (Enzyme-linked Immunosorbent Assay). Methods of Allergenic Products Testing Laboratory. October 1993. CBER Docket No. 94N.0012. 3. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Data on file. 4. Peebles, Ray Stokes, Jr., B. Bochner, Howard J. Zeitz, ed. Anaphylaxis in the elderly. Immunology and Allergy Clinics of North America. 13 (3): 627-646, August 1993. 5. Turkeltaub, P., S. Rastogi. Quantitative intradermal test procedure for evaluation of subject sensitivity to standardized allergenic extracts and for assignment of bioequivalent allergy units to reference preparations using the ID 50 EAL method, Allergenic Products Testing Laboratory, Center for Biologics Evaluation and Research (CBER), FDA. Revised November 1994. 6. Lowell, F. C., W. Franklin. A \"double-blind\" study of treatment with aqueous allergenic extracts in cases of allergic rhinitis. J. Allergy, 34 (2): 165-182, 1983. 7. Lowell, F. C., W. Franklin. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N. Eng. J. Med., 273 (13): 675-679, 1965. 8. Zavazal, V., A. Stajner. Immunologic changes during specific treatment of the atopic state. II. Acta. Allergol., 25 (1): 11-17, 1970. 9. Reisman, R.E., J.I. Wypych, E.E. Arbesman. Relationship of immunotherapy, seasonal pollen exposure and clinical response to serum concentrations of total IgE and ragweed-specific IgE. Int. Arch. Allergy Appl. Immunol., 48 (6): 721-730, 1975. 10. Taylor, W.W., J.L. Ohman, F. C. Lowell. Immunotherapy in cat-induced asthma; double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J. Allergy and Clin. Immunol., 61 (5): 283-287, 1978. 11. Smith, A. P. Hyposensitization with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust. Br. Med. J., 4: 204-206, 1971. 12. Chapman, M.D., T.A.E. Platts-Mills, M. Gabriel, H.K. Ng, W. G. L. Allen, L. E. Hill, A. J. Nunn. Antibody response following prolonged hyposensitization with Dermatophagoides pteronyssinus extract. Int. Arch. Allergy Appl. Immunol., 61: 431-440, 1980. 13. Norman, P.S. Postgraduate Course Presentation. An overview of immunotherapy, implications for the future. J. Allergy Clin. Immunol., 65 (2): 87-96, 1980. 14. Norman, P.S., W. L. Winkenwerder. Maintenance immunotherapy in ragweed hay fever. J. Allergy, 74: 273-282, 1971. 15. Norman, P.S., W. L. Winkenwerder, L. M. Lichtenstein. Immunotherapy of hay fever with ragweed antigen E; comparisons with whole pollen extract and placebos. J. Allergy, 42: 93-108, 1968. 16. Sheldon, J. M., R. G. Lovell, K. P. Matthews. A Manual of Clinical Allergy. Second Edition. W.B. Saunders, Philadelphia, 1967, pp. 107-112. 17. Sherman, W. B. Hypersensitivity mechanism and management. W. B. Sanders, Philadelphia, 1968, pp. 169-172. 18. Swineford, O. Asthma and Hay Fever. Charles C. Thomas, Springfield, IL, 1971, pp. 148-155. 19. Jacobs, R. L., G. W. Rake, Jr., et al. Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. J. Allergy and Clin. Immunol., 68 (2): 125-127, August 1981. 20. Patterson, Roy, et al. Allergy Principles and Practice, 2nd ed. E. Middleton, Jr., C.E. Reed, E.F. Ellis, Ed., C.V. Mosby Co., 1983, St. Louis, MO, 1983, Chapter 52. 21. Levy, D.A., L.M. Lichtenstein, E.O. Goldstein, and K. Ishizaka. Immunologic and cellular changes accompanying the therapy of pollen allergy. J. Clinical Investigation, 50:360, 1971. 22. Turkeltaub, Paul C., MD, and Peter J. Gergen, MD. The risk of adverse reactions from percutaneous prick-puncture allergen skin testing, venipuncture, and body measurements: data from the Second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). J. Allergy Clin. Immunol. 84(6): 886-890, Dec. 1989. 23. Pipkorn, Ulf. Pharmacological influence of anti-allergic medication on In Vivo allergen testing. Allergy.  43: 81-86, 1988. 24. Andersson, M. and U. Pipkorn. Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids. J. Allergy Clin. Immunol. 79 (2): 345-349, Feb. 1987. 25. Rao, Kamineni S., et al. Duration of suppressive effect of tricyclic anti-depressants on histamine induced wheal and flare reactions on human skin. J. Allergy Clin. Immunol. 82: 752-757, November 1988. 26. Pipkorn, Ulf, and M. Andersson. Topical dermal anesthesia inhibits the flare but not the wheal response to allergen and histamine in the skin prick test. Clinical Allergy. 17: 307-311, 1987. 27. Pauli, G., J.C. Bessot, R. Thierry and A. Lamensons. Correlation between skin, inhalation tests and specific IgE in a study of 120 subjects to house dust and D. pteronyssinus. Clin. Allergy. 7:337, 1977. 28. Murray, A.B., A.C. Ferguson and B.J. Morrison. Diagnosis of house dust mite allergy in asthamatic children. What constitutes positive history? J. Allergy Clin. Immunol. 71: 21, 1983. 29. Metzger, W.J., E. Turner and R. Patterson. The safety of immunotherapy during pregnancy. J. Allergy Clin. Immunol. 61 (4): 268-272, 1978. 30. Reid, M.J., R.F. Lockey, P.C. Turkletaub, T.A.E. Platts-Mills. Survey of fatalities from skin testing and immunotherapy. J. Allergy Clin. Immunol. 92 (1): 6-15, July 1993. 31. Reid, M.J., G. Gurka. Deaths associated with skin testing and immunotherapy. J. Allergy Clin. Immunol. 97(1) Part 3:231, Abstract 195, January 1996. 32. Thompson, R.A. et al, report of a WHO/IUIS working group. The current status of allergen immunotherapy (hyposensitization). Allergy. 44: 369-379, 1989. 33. Malling, H.-J., B. Weeke, et al, The European Academy of Allergology and Clinical Immunology. Position Papers. Allergy. 48 (Supplement 14): 9-82, 1993."
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Bermuda Grass 10 mL, 10,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Bermuda Grass 10 mL, 10,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Bermuda Grass 50 mL, 10,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Bermuda Grass 50 mL, 10,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Kentucky Bluegrass 5 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Kentucky Bluegrass 5 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Kentucky Bluegrass 10 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Kentucky Bluegrass 10 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Kentucky Bluegrass 50 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Kentucky Bluegrass 50 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Meadow Fescue 5 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Meadow Fescue 5 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Meadow Fescue 10 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Meadow Fescue 10 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Meadow Fescue 50 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Meadow Fescue 50 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Orchard Grass 5 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Orchard Grass 5 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Orchard Grass 10 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Orchard Grass 10 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Orchard Grass 50 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Orchard Grass 50 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Perennial Ryegrass 5 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Perennial Ryegrass 5 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Perennial Ryegrass 10 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Perennial Ryegrass 10 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Perennial Ryegrass 50 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Perennial Ryegrass 50 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Redtop 5 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Redtop 5 mL, 100,000\u00a0BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Redtop 10 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Redtop 10 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Redtop 50 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Redtop 50 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Sweet Vernal Grass 5 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Sweet Vernal Grass 5 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Sweet Vernal Grass 10 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Sweet Vernal Grass 10 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Sweet Vernal Grass 50 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Sweet Vernal Grass 50 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Timothy 5 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Timothy 5 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Timothy 10 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Timothy 10 mL, 100,000 BAU/mL Vial Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Timothy 50 mL, 100,000 BAU/mL\u00a0Carton Label",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Standardized Grass Pollen, Timothy 50 mL, 100,000 BAU/mL\u00a0Vial Label",
        "content": ""
      }
    ],
    "category": "Other/Bulk Ingredient"
  },
  {
    "filename": "other_26395c33-a90d-483a-96e9-f9f446cf5b53.xml",
    "document_id": "26395c33-a90d-483a-96e9-f9f446cf5b53",
    "document_type": "BULK INGREDIENT - ANIMAL DRUG",
    "title": "Pimobendan",
    "effective_date": "20251117",
    "version": "3",
    "author": {
      "name": "Liaoning Pharmaceutical Innovation Co., Ltd.",
      "id": "614439236"
    },
    "product": {
      "ndc": "86212-002",
      "name": "pimobendan",
      "form": "POWDER",
      "generic_name": "pimobendan",
      "active_ingredients": [
        {
          "name": "PIMOBENDAN",
          "code": "34AP3BBP9T",
          "strength": "1 kg",
          "per": "1 kg"
        }
      ],
      "inactive_ingredients": [],
      "packaging": [
        {
          "quantity": "1 kg",
          "ndc": "86212-002-05",
          "container": "BAG"
        },
        {
          "quantity": "0.05 kg",
          "ndc": "86212-002-01",
          "container": "BAG"
        },
        {
          "quantity": "0.1 kg",
          "ndc": "86212-002-02",
          "container": "BAG"
        },
        {
          "quantity": "0.5 kg",
          "ndc": "86212-002-03",
          "container": "PACKAGE"
        },
        {
          "quantity": "5 kg",
          "ndc": "86212-002-06",
          "container": "BAG"
        },
        {
          "quantity": "10 kg",
          "ndc": "86212-002-07",
          "container": "BAG"
        },
        {
          "quantity": "0.01 kg",
          "ndc": "86212-002-08",
          "container": "BAG"
        },
        {
          "quantity": "0.025 kg",
          "ndc": "86212-002-09",
          "container": "BAG"
        }
      ],
      "route": "NOT APPLICABLE",
      "marketing_status": "active",
      "marketing_start_date": "20241113",
      "approval_status": "bulk ingredient for animal drug compounding",
      "color": "white"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section",
        "title": "",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "Pimobendan_label_20241115.jpg",
        "content": "Pimobendan_label_20241115.jpg"
      }
    ],
    "category": "Other/Bulk Ingredient"
  },
  {
    "filename": "other_375fc53c-643d-4137-b034-ac11b783022c.xml",
    "document_id": "375fc53c-643d-4137-b034-ac11b783022c",
    "document_type": "BULK INGREDIENT - ANIMAL DRUG",
    "title": "",
    "effective_date": "20251029",
    "version": "2",
    "author": {
      "name": "LIVZON NEW NORTH RIVER PHARMACEUTICAL CO., LTD.",
      "id": "420097636"
    },
    "product": {
      "ndc": "20076-0406",
      "name": "Doramectin",
      "form": "POWDER",
      "generic_name": "Doramectin",
      "active_ingredients": [
        {
          "name": "DORAMECTIN",
          "code": "KGD7A54H5P",
          "strength": "1 kg",
          "per": "1 kg"
        }
      ],
      "inactive_ingredients": [],
      "packaging": [
        {
          "quantity": "5 kg",
          "container": "BAG"
        },
        {
          "quantity": "1 1",
          "container": "BAG"
        },
        {
          "quantity": "1 1",
          "ndc": "20076-0406-1",
          "container": "DRUM"
        }
      ],
      "route": "NOT APPLICABLE",
      "marketing_status": "active",
      "marketing_start_date": "20250924",
      "approval_status": "bulk ingredient",
      "color": "white"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section",
        "title": "",
        "content": ""
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "",
        "content": ""
      }
    ],
    "category": "Other/Bulk Ingredient"
  },
  {
    "filename": "other_8b6fce68-cae9-4b85-8e14-6944f403c0c1.xml",
    "document_id": "8b6fce68-cae9-4b85-8e14-6944f403c0c1",
    "document_type": "DIETARY SUPPLEMENT",
    "title": "Gutstor",
    "effective_date": "20251014",
    "version": "1",
    "author": {
      "name": "Blue Heron Pharmaceuticals, LLC",
      "id": "137019051"
    },
    "product": {
      "ndc": "85622-104",
      "name": "Gutstor",
      "form": "CAPSULE",
      "generic_name": "LACTOBACILLUS ACIDOPHILUS",
      "active_ingredients": [
        {
          "name": "LACTOBACILLUS ACIDOPHILUS",
          "code": "1PRR1V42V5",
          "strength": "20000000000 [CFU]",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [
        "MALTODEXTRIN"
      ],
      "packaging": [
        {
          "quantity": "30 1",
          "ndc": "85622-104-30",
          "container": "BOTTLE"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20251014",
      "approval_status": "dietary supplement",
      "color": "white",
      "shape": "capsule",
      "size": "25 mm"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section",
        "title": "",
        "content": ""
      },
      {
        "code": "69719-3",
        "type": "HEALTH CLAIM SECTION",
        "title": "\n                  ",
        "content": "Gutstor Probiotic Capsules Dispensed by Prescription"
      },
      {
        "code": "69718-5",
        "type": "STATEMENT OF IDENTITY SECTION",
        "title": "\n                  ",
        "content": "Gutstor is an orally adminstered prescription probiotic dietary supplement. Gutstor Probiotic Capsules are clear capsules dispensed in plastic bottles of 30 ct. 85622-0103-30 Reserved for Professional Recommendation This listed product is not a National Drug Code, but instead has merely been formatted to comply with standard industry practice for pharmacy and insurance computer systems. These statements have not been evaluated by the Food and Drug Administration.\u00a0 This product is not intended to diagnose, treat, cure or prevent any disease. All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician\u2019s supervision. There are no implied or explicit claims on therapeutic equivalence. Manufactured for: Blue Heron Pharmaceuticals Lutz, FL 33559"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "\n                  ",
        "content": "This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. As with any supplement, if you are pregnant, nursing, taking medication, or have a medical condition, ask a health professional before taking this product. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "\n                  ",
        "content": "Usual adult dose is 2 capsules by mouth daily once daily, or as prescribed by a licensed medical practitioner. Gutstor is an orally administered prescription probiotic formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed."
      },
      {
        "code": "42232-9",
        "type": "PRECAUTIONS SECTION",
        "title": "\n                  ",
        "content": "CONTRAINDICATIONS This product is contraindicated in patients with known hypersensitivity to any of the ingredients. PRECAUTIONS This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. ADVERSE REACTIONS Allergic sensitizations have been reported following oral administration of folic acid. Consult your physician immediately if adverse side effects occur. KEEP OUT OF THE REACH OF CHILDREN."
      },
      {
        "code": "50741-8",
        "type": "SAFE HANDLING WARNING SECTION",
        "title": "\n                  ",
        "content": "STORAGE: Handling (before opening): Product is sensitive to moisture and heat. Keep bottle tightly closed in a dry, cool place. Store at 20 \ufeff0 \ufeffC to 25 \ufeff0 \ufeffC (68 \ufeff0 \ufeffF to 77\ufeff \ufeff0 \ufeffF). Handling (after opening): Store in the refrigerator after opening, DO NOT FREEZE. Store at 2\ufeff 0 \ufeffC to 8 \ufeff0 \ufeffC (35 \ufeff0 \ufeffF to 46 \ufeff0 \ufeffF)."
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "\n                  ",
        "content": ""
      }
    ],
    "category": "Other/Bulk Ingredient"
  },
  {
    "filename": "other_cfe5fb33-3f93-4fb1-a754-bf65bf291c1a.xml",
    "document_id": "cfe5fb33-3f93-4fb1-a754-bf65bf291c1a",
    "document_type": "DIETARY SUPPLEMENT",
    "title": "Probistor Capsules",
    "effective_date": "20251030",
    "version": "2",
    "author": {
      "name": "Trivia Pharmaceuticals, LLC",
      "id": "119353862"
    },
    "product": {
      "ndc": "84781-107",
      "name": "Probistor",
      "form": "Capsule",
      "generic_name": "Acidophilus/Pectin",
      "active_ingredients": [
        {
          "name": "LACTOBACILLUS ACIDOPHILUS",
          "code": "1PRR1V42V5",
          "strength": "200000000 [CFU]",
          "per": "1 1"
        },
        {
          "name": "DICALCIUM PHOSPHATE",
          "code": "L11K75P92J",
          "strength": "304 mg",
          "per": "1 1"
        },
        {
          "name": "PECTIN, CITRUS",
          "code": "47EQO8LE7H",
          "strength": "20 mg",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [],
      "packaging": [
        {
          "quantity": "30 1",
          "ndc": "84781-107-30",
          "container": "BOTTLE"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20250922",
      "approval_status": "DIETARY SUPPLEMENT",
      "color": "WHITE",
      "shape": "CAPSULE",
      "size": "25 mm"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL LISTING DATA ELEMENTS SECTION"
      },
      {
        "code": "69719-3",
        "type": "HEALTH CLAIM SECTION",
        "title": "\n                  ",
        "content": "Probistor Probiotic Capsules"
      },
      {
        "code": "69718-5",
        "type": "STATEMENT OF IDENTITY SECTION",
        "title": "\n                  ",
        "content": "Probistor is an orally adminstered probiotic dietary supplement. Probistor Probiotic Capsules are clear capsules dispensed in plastic bottles of 30 ct. 84781-0107-30 Reserved for Professional Recommendation This listed product is not a National Drug Code, but instead has merely been formatted to comply with standard industry practice for pharmacy and insurance computer systems. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician\u2019s supervision. There are no implied or explicit claims on therapeutic equivalence. Manufactured for: Trivia Pharmacueticals, LLC Gilbert, AZ"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "\n                  ",
        "content": "This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. As with any supplement, if you are pregnant, nursing, taking medication, or have a medical condition, ask a health professional before taking this product. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "\n                  ",
        "content": "Usual adult dose is 2 capsules by mouth daily once daily, preferably with food, as a dietary supplement or as prescribed by a licensed medical practitioner. Probistor is an orally administered prescription probiotic formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed."
      },
      {
        "code": "42232-9",
        "type": "PRECAUTIONS SECTION",
        "title": "\n                  ",
        "content": "CONTRAINDICATIONS This product is contraindicated in patients with known hypersensitivity to any of the ingredients. PRECAUTIONS This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. ADVERSE REACTIONS Allergic sensitizations have been reported following oral administration of folic acid. Consult your physician immediately if adverse side effects occur. KEEP OUT OF THE REACH OF CHILDREN."
      },
      {
        "code": "50741-8",
        "type": "SAFE HANDLING WARNING SECTION",
        "title": "\n                  ",
        "content": "Store at 20\u00b0 - 25\u00b0 C (68\u00b0 - 77\u00b0 F); excursions permitted to 15\u00b0-30\u00b0C (59\u00b0-86\u00b0F) [See USP Controlled Room Temperature]"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "\n                  ",
        "content": ""
      }
    ],
    "category": "Other/Bulk Ingredient"
  },
  {
    "filename": "prescription_1a0301ba-9f66-ac39-e063-6394a90a34bb.xml",
    "document_id": "1a0301ba-9f66-ac39-e063-6394a90a34bb",
    "document_type": "HUMAN PRESCRIPTION DRUG LABEL",
    "title": "Ibuprofen 400 mg Tablets",
    "effective_date": "20240603",
    "version": "1",
    "author": {
      "name": "Boswell Pharmacy Services LLC d/b/a BPS Wholesale",
      "id": "129218355"
    },
    "product": {
      "ndc": "83209-464",
      "name": "Ibuprofen",
      "form": "TABLET",
      "generic_name": "Ibuprofen",
      "active_ingredients": [
        {
          "name": "IBUPROFEN",
          "code": "WK2XYI10QM",
          "strength": "400 mg",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [],
      "packaging": [
        {
          "quantity": "9 1",
          "ndc": "83209-464-09",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "12 1",
          "ndc": "83209-464-12",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "14 1",
          "ndc": "83209-464-14",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "10 1",
          "ndc": "83209-464-10",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "15 1",
          "ndc": "83209-464-15",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "18 1",
          "ndc": "83209-464-18",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "20 1",
          "ndc": "83209-464-20",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "21 1",
          "ndc": "83209-464-21",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "24 1",
          "ndc": "83209-464-24",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "28 1",
          "ndc": "83209-464-28",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "30 1",
          "ndc": "83209-464-30",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "60 1",
          "ndc": "83209-464-60",
          "container": "BLISTER PACK"
        },
        {
          "quantity": "40 1",
          "ndc": "83209-464-40",
          "container": "BLISTER PACK"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20240603",
      "approval_status": "ANDA",
      "color": "white",
      "imprint": "IP;464",
      "shape": "ROUND",
      "size": "13 mm"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "34066-1",
        "type": "BOXED WARNING SECTION",
        "title": "",
        "content": "Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see WARNINGS and PRECAUTIONS ]. Ibuprofen Tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see CONTRAINDICATIONS and WARNINGS ]. Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events [see WARNINGS ]."
      },
      {
        "code": "34089-3",
        "type": "DESCRIPTION SECTION",
        "title": "DESCRIPTION",
        "content": "Ibuprofen Tablets, USP contain the active ingredient ibuprofen, which is (\u00b1)-2-( p -isobutylphenyl) propionic acid. Ibuprofen is a white powder with a melting point of 74\u00b0 to 77\u00b0C and is very slightly soluble in water (<1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. The structural formula is represented below: Ibuprofen Tablets, USP, a nonsteroidal anti-inflammatory drug (NSAID), is available in 400 mg, 600 mg and 800 mg tablets for oral administration. Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, talc, stearic acid, and titanium dioxide."
      },
      {
        "code": "34090-1",
        "type": "CLINICAL PHARMACOLOGY SECTION",
        "title": "CLINICAL PHARMACOLOGY",
        "content": "Ibuprofen tablets contain ibuprofen which possesses analgesic and antipyretic activities. Its mode of action, like that of other NSAIDs, is not completely understood, but may be related to prostaglandin synthetase inhibition. In clinical studies in patients with rheumatoid arthritis and osteoarthritis, ibuprofen tablets have been shown to be comparable to aspirin in controlling pain and inflammation and to be associated with a statistically significant reduction in the milder gastrointestinal side effects [see ADVERSE REACTIONS ]. Ibuprofen tablets may be well tolerated in some patients who have had gastrointestinal side effects with aspirin, but these patients when treated with ibuprofen tablets should be carefully followed for signs and symptoms of gastrointestinal ulceration and bleeding. Although it is not definitely known whether ibuprofen tablets causes less peptic ulceration than aspirin, in one study involving 885 patients with rheumatoid arthritis treated for up to one year, there were no reports of gastric ulceration with ibuprofen tablets whereas frank ulceration was reported in 13 patients in the aspirin group (statistically significant p<0.001). Gastroscopic studies at varying doses show an increased tendency toward gastric irritation at higher doses. However, at comparable doses, gastric irritation is approximately half that seen with aspirin. Studies using 51 Cr-tagged red cells indicate that fecal blood loss associated with ibuprofen tablets in doses up to 2400 mg daily did not exceed the normal range, and was significantly less than that seen in aspirin-treated patients. In clinical studies in patients with rheumatoid arthritis, ibuprofen tablets have been shown to be comparable to indomethacin in controlling the signs and symptoms of disease activity and to be associated with a statistically significant reduction of the milder gastrointestinal [see ADVERSE REACTIONS ] and CNS side effects. Ibuprofen tablets may be used in combination with gold salts and/or corticosteroids. Controlled studies have demonstrated that ibuprofen tablets are a more effective analgesic than propoxyphene for the relief of episiotomy pain, pain following dental extraction procedures, and for the relief of the symptoms of primary dysmenorrhea. In patients with primary dysmenorrhea, ibuprofen tablets have been shown to reduce elevated levels of prostaglandin activity in the menstrual fluid and to reduce resting and active intrauterine pressure, as well as the frequency of uterine contractions. The probable mechanism of action is to inhibit prostaglandin synthesis rather than simply to provide analgesia. Pharmacodynamics In a healthy volunteer study, ibuprofen 400 mg given once daily, administered 2 hours prior to immediate-release aspirin (81 mg) for 6 days, showed an interaction with the antiplatelet activity of aspirin as measured by % serum thromboxane B2 (TxB2) inhibition at 24 hours following the day-6 aspirin dose [53%]. An interaction was still observed, but minimized, when ibuprofen 400 mg given once-daily was administered as early as 8 hours prior to the immediate-release aspirin dose [90.7%]. However, there was no interaction with the antiplatelet activity of aspirin when ibuprofen 400 mg, given once daily, was administered 2 hours after (but not concomitantly, 15 min, or 30 min after) the immediate-release aspirin dose [99.2%]. In another study, where immediate-release aspirin 81 mg was administered once daily with ibuprofen 400 mg given three times daily (1, 7, and 13 hours post-aspirin dose) for 10 consecutive days, the mean % serum thromboxane B2 (TxB2) inhibition suggested no interaction with the antiplatelet activity of aspirin [98.3%]. However, there were individual subjects with serum TxB2 inhibition below 95%, with the lowest being 90.2%. When a similarly designed study was conducted with enteric-coated aspirin, where healthy subjects were administered enteric-coated aspirin 81 mg once daily for 6 days and ibuprofen 400 mg three times daily (2, 7 and 12 h post-aspirin dose) for 6 days, there was an interaction with the antiplatelet activity at 24 hours following the day-6 aspirin dose [67%] [see PRECAUTIONS, Drug Interactions ]. Pharmacokinetics The ibuprofen in ibuprofen tablets is rapidly absorbed. Peak serum ibuprofen levels are generally attained one to two hours after administration. With single doses up to 800 mg, a linear relationship exists between amount of drug administered and the integrated area under the serum drug concentration vs time curve. Above 800 mg, however, the area under the curve increases less than proportional to increases in dose. There is no evidence of drug accumulation or enzyme induction. The administration of ibuprofen tablets either under fasting conditions or immediately before meals yields quite similar serum ibuprofen concentration-time profiles. When ibuprofen tablets are administered immediately after a meal, there is a reduction in the rate of absorption but no appreciable decrease in the extent of absorption. The bioavailability of the drug is minimally altered by the presence of food. A bioavailability study has shown that there was no interference with the absorption of ibuprofen when ibuprofen tablets were given in conjunction with an antacid containing both aluminum hydroxide and magnesium hydroxide. Ibuprofen is rapidly metabolized and eliminated in the urine. The excretion of ibuprofen is virtually complete 24 hours after the last dose. The serum half-life is 1.8 to 2.0 hours. Studies have shown that following ingestion of the drug, 45% to 79% of the dose was recovered in the urine within 24 hours as metabolite A (25%), (+)-2-[ p -(2hydroxymethyl-propyl) phenyl] propionic acid and metabolite B (37%), (+)-2-[ p -(2carboxypropyl)phenyl] propionic acid; the percentages of free and conjugated ibuprofen were approximately 1% and 14%, respectively."
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "INDICATIONS AND USAGE",
        "content": "Carefully consider the potential benefits and risks of Ibuprofen Tablets and other treatment options before deciding to use Ibuprofen Tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see WARNINGS ]. Ibuprofen Tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen Tablets are indicated for relief of mild to moderate pain. Ibuprofen Tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of Ibuprofen Tablets in children have not been conducted."
      },
      {
        "code": "34070-3",
        "type": "CONTRAINDICATIONS SECTION",
        "title": "CONTRAINDICATIONS",
        "content": "Ibuprofen tablets are contraindicated in patients with known hypersensitivity to ibuprofen. Ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients [see WARNINGS, Anaphylactoid Reactions , and PRECAUTIONS, Preexisting Asthma ]. In the setting of coronary artery bypass graft (CABG) surgery [see WARNINGS ]."
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "WARNINGS",
        "content": "CARDIOVASCULAR EFFECTS Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as ibuprofen, increases the risk of serious gastrointestinal (GI) events [see WARNINGS ]. Status Post Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [see CONTRAINDICATIONS ]. Post-MI Patients Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up. Avoid the use of ibuprofen tablets in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ibuprofen tablets are used in patients with a recent MI, monitor patients for signs of cardiac ischemia. Hypertension NSAIDs including ibuprofen tablets can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including ibuprofen tablets should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy. Heart Failure and Edema The Coxib and traditional NSAID Trialists\u2019 Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death. Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of Ibuprofen may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] [see DRUG INTERACTIONS ]. Avoid the use of ibuprofen tablets in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ibuprofen tablets are used in patients with severe heart failure, monitor patients for signs of worsening heart failure. Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation NSAIDs, including ibuprofen tablets can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk. NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients treated with neither of these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population. To minimize the potential risk for an adverse GI event in patients treated with a NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulcerations and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered. Renal Effects Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Advanced Renal Disease No information is available from controlled clinical studies regarding the use of ibuprofen tablets in patients with advanced renal disease. Therefore, treatment with ibuprofen tablets is not recommended in these patients with advanced renal disease. If ibuprofen tablets therapy must be initiated, close monitoring of the patients renal function is advisable. Anaphylactoid Reactions As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ibuprofen tablets. Ibuprofen tablets should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs [see CONTRAINDICATIONS and PRECAUTIONS, Preexisting Asthma ]. Emergency help should be sought in cases where an anaphylactoid reaction occurs. Skin Reactions NSAIDs, including ibuprofen tablets can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ibuprofen tablets. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ibuprofen tablets and evaluate the patient immediately. Fetal Toxicity Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs, including ibuprofen tablets, in pregnant women at about 30 weeks gestation and later. NSAIDs including ibuprofen tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment: Use of NSAIDs, including ibuprofen tablets, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit ibuprofen tablets use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if ibuprofen tablets treatment extends beyond 48 hours. Discontinue ibuprofen tablets if oligohydramnios occurs and follow up according to clinical practice [see PRECAUTIONS, Pregnancy ]."
      },
      {
        "code": "42232-9",
        "type": "PRECAUTIONS SECTION",
        "title": "PRECAUTIONS"
      },
      {
        "code": "34072-9",
        "type": "GENERAL PRECAUTIONS SECTION",
        "title": "General",
        "content": "Ibuprofen tablets cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. The pharmacological activity of ibuprofen tablets in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions. Hepatic effects Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including ibuprofen tablets. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice, fulminant hepatitis, liver necrosis, and hepatic failure, some of them with fatal outcomes have been reported. A patient with symptoms and/or signs suggesting liver dysfunction, or with abnormal liver test values, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with ibuprofen tablets. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), ibuprofen tablets should be discontinued. Hematological effects Anemia is sometimes seen in patients receiving NSAIDs, including ibuprofen tablets. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ibuprofen tablets should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. In two postmarketing clinical studies the incidence of a decreased hemoglobin level was greater than previously reported. Decrease in hemoglobin of 1 gram or more was observed in 17.1% of 193 patients on 1600 mg ibuprofen daily (osteoarthritis), and in 22.8% of 189 patients taking 2400 mg of ibuprofen daily (rheumatoid arthritis). Positive stool occult blood tests and elevated serum creatinine levels were also observed in these studies. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving ibuprofen tablets who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants should be carefully monitored. Preexisting asthma Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal. Since cross reactivity, including bronchospasm, between aspirin and NSAIDs has been reported in such aspirin-sensitive patients, ibuprofen tablets should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma. Ophthalmological effects Blurred and/or diminished vision, scotomata, and/or changes in color vision have been reported. If a patient develops such complaints while receiving ibuprofen tablets, the drug should be discontinued, and the patient should have an ophthalmologic examination which includes central visual fields and color vision testing. Aseptic Meningitis Aseptic meningitis with fever and coma has been observed on rare occasions in patients on ibuprofen therapy. Although it is probably more likely to occur in patients with systemic lupus erythematosus and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease. If signs or symptoms of meningitis develop in a patient on ibuprofen tablets, the possibility of its being related to ibuprofen tablets should be considered. Information for Patients Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed. Cardiovascular Thrombotic Events Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their health care provider immediately [see WARNINGS ]. Ibuprofen tablets, like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative signs or symptoms including epigastric pain, dyspepsia, melena, and hematemesis. Patients should be apprised of the importance of this follow-up [see WARNINGS , Gastrointestinal Effects-Risk of Ulceration, Bleeding and Perforation ]. Serious Skin Reactions, including DRESS Advise patients to stop taking ibuprofen tablets immediately if they develop any type of rash or fever and to contact their healthcare provider as soon as possible [see WARNINGS ]. Patients should be advised to stop the drug immediately if they develop any type of rash and contact their physicians as soon as possible. Heart Failure And Edema Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [see WARNINGS ]. Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness and \"flu-like\" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy. Patients should be informed of the signs of an anaphylactoid reaction (e.g., difficulty breathing, swelling of the face or throat). If these occur, patients should be instructed to seek immediate emergency help [see WARNINGS ]. Fetal Toxicity Inform pregnant women to avoid use of ibuprofen tablets and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus. If treatment with ibuprofen tablets is needed for a pregnant woman between about 20 to 30 weeks gestation, advise her that she may need to be monitored for oligohydramnios, if treatment continues for longer than 48 hours [see WARNINGS, Fetal Toxicity and PRECAUTIONS, Pregnancy ]. Laboratory Tests Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs should have their CBC and chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash etc.), or abnormal liver tests persist or worsen, ibuprofen tablets should be discontinued."
      },
      {
        "code": "34073-7",
        "type": "DRUG INTERACTIONS SECTION",
        "title": "Drug Interactions",
        "content": "ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin Pharmacodynamic studies have demonstrated interference with the antiplatelet activity of aspirin when ibuprofen 400 mg, given three times daily, is administered with enteric-coated low-dose aspirin. The interaction exists even following a once-daily regimen of ibuprofen 400 mg, particularly when ibuprofen is dosed prior to aspirin. The interaction is alleviated if immediate-release low-dose aspirin is dosed at least 2 hours prior to a once-daily regimen of ibuprofen; however, this finding cannot be extended to enteric-coated low-dose aspirin [see CLINICAL PHARMACOLOGY, Pharmacodynamics ]. Because there may be an increased risk of cardiovascular events due to the interference of ibuprofen with the antiplatelet effect of aspirin, for patients taking low-dose aspirin for cardioprotection who require analgesics, consider use of an NSAID that does not interfere with the antiplatelet effect of aspirin, or non-NSAID analgesics, where appropriate. When ibuprofen tablets are administered with aspirin, its protein binding is reduced, although the clearance of free ibuprofen tablets is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of ibuprofen and aspirin is not generally recommended because of the potential for increased adverse effects. Diuretics Clinical studies, as well as post marketing observations, have shown that ibuprofen tablets can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure [see WARNINGS, Renal Effects ], as well as to assure diuretic efficacy. Lithium Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers. The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration. This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen. Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. (Read circulars for lithium preparation before use of such concurrent therapy.) Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate. Warfarin-type anticoagulants Several short-term controlled studies failed to show that ibuprofen tablets significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants. However, because bleeding has been reported when ibuprofen tablets and other NSAIDs have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen tablets to patients on anticoagulants. The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that the users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone. H-2 Antagonists In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations."
      },
      {
        "code": "42228-7",
        "type": "PREGNANCY SECTION",
        "title": "Pregnancy",
        "content": "Risk Summary Use of NSAIDs, including ibuprofen tablets, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, limit dose and duration of ibuprofen tablets use between about 20 and 30 weeks of gestation, and avoid ibuprofen tablets use at about 30 weeks of gestation and later in pregnancy [see WARNINGS, Fetal Toxicity ]. Premature Closure of Fetal Ductus Arteriosus Use of NSAIDs, including ibuprofen tablets, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. Data from observational studies regarding other potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. Reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities. However, animal reproduction studies are not always predictive of human response. Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors such as ibuprofen, resulted in increased pre- and post-implantation loss. Prostaglandins also have been shown to have an important role in fetal kidney development. In published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses. Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors such as ibuprofen, resulted in increased pre- and post-implantation loss. Prostaglandins also have been shown to have an important role in fetal kidney development. In published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses. The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy, because NSAIDs, including ibuprofen tablets, can cause premature closure of the fetal ductus arteriosus [see WARNINGS, Fetal Toxicity ]. Oligohydramnios/Neonatal Renal Impairment If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit the use to the lowest effective dose and shortest duration possible. If ibuprofen tablets treatment extends beyond 48 hours, consider monitoring with ultrasound for oligohydramnios. If oligohydramnios occurs, discontinue ibuprofen tablets and follow up according to clinical practice [see WARNINGS, Fetal Toxicity ]. Data Human Data There are no adequate, well-controlled studies in pregnant women. Ibuprofen tablets should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Premature Closure of Fetal Ductus Arteriosus: Published literature reports that the use of NSAIDs at about 30 weeks of gestation and later in pregnancy may cause premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment: Published studies and postmarketing reports describe maternal NSAID use at about 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. In many cases, but not all, the decrease in amniotic fluid was transient and reversible with cessation of the drug. There have been a limited number of case reports of maternal NSAID use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible. Some cases of neonatal renal dysfunction required treatment with invasive procedures, such as exchange transfusion or dialysis. Methodological limitations of these postmarketing studies and reports include lack of a control group; limited information regarding dose, duration, and timing of drug exposure; and concomitant use of other medications. These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal NSAID use. Because the published safety data on neonatal outcomes involved mostly preterm infants, the generalizability of certain reported risks to the full-term infant exposed to NSAIDs through maternal use is uncertain. Labor and Delivery In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of ibuprofen tablets on labor and delivery in pregnant women are unknown."
      },
      {
        "code": "34080-2",
        "type": "NURSING MOTHERS SECTION",
        "title": "Nursing Mothers",
        "content": "It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ibuprofen tablets, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother."
      },
      {
        "code": "34081-0",
        "type": "PEDIATRIC USE SECTION",
        "title": "Pediatric Use",
        "content": "Safety and effectiveness of ibuprofen tablets in pediatric patients have not been established."
      },
      {
        "code": "34082-8",
        "type": "GERIATRIC USE SECTION",
        "title": "Geriatric Use",
        "content": "As with any NSAIDs, caution should be exercised in treating the elderly (65 years and older)."
      },
      {
        "code": "34084-4",
        "type": "ADVERSE REACTIONS SECTION",
        "title": "ADVERSE REACTIONS",
        "content": "The most frequent type of adverse reaction occurring with ibuprofen tablets is gastrointestinal. In controlled clinical trials the percentage of patients reporting one or more gastrointestinal complaints ranged from 4% to 16%. In controlled studies when ibuprofen tablets were compared to aspirin and indomethacin in equally effective doses, the overall incidence of gastrointestinal complaints was about half that seen in either the aspirin- or indomethacin-treated patients. Adverse reactions observed during controlled clinical trials at an incidence greater than 1% are listed in the table. Those reactions listed in Column one encompass observations in approximately 3,000 patients. More than 500 of these patients were treated for periods of at least 54 weeks. Still other reactions occurring less frequently than 1 in 100 were reported in controlled clinical trials and from marketing experience. These reactions have been divided into two categories: Column two of the table lists reactions with therapy with ibuprofen tablets where the probability of a causal relationship exists: for the reactions in Column three, a causal relationship with ibuprofen tablets has not been established. Reported side effects were higher at doses of 3200 mg/day than at doses of 2400 mg or less per day in clinical trials of patients with rheumatoid arthritis. The increases in incidence were slight and still within the ranges reported in the table. Incidence Greater Than 1% (but less than 3%) Probable Causal Relationship Precise Incidence Unknown (but less than 1%) Probable Causal Relationship** Precise Incidence Unknown (but less than 1%) Causal Relationship Unknown** GASTROINTESTINAL Nausea*, epigastric pain*, heartburn*, diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of Gl tract (bloating and flatulence) Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena, gastritis, hepatitis, jaundice, abnormal liver function tests; pancreatitis CENTRAL NERVOUS SYSTEM Dizziness*, headache, nervousness Depression, insomnia, confusion, emotional liability, somnolence, aseptic meningitis with fever and coma [see PRECAUTIONS ] Paresthesias, hallucinations, dream abnormalities, pseudotumor cerebri DERMATOLOGIC Rash* (including maculopapular type), pruritus Vesiculobullous eruptions, urticaria, erythema multiforme, Stevens-Johnson syndrome, alopecia Toxic epidermal necrolysis, photoallergic skin reactions SPECIAL SENSES Tinnitus Hearing loss, amblyopia (blurred and/or diminished vision, scotomata and/or changes in color vision) [see PRECAUTIONS ] Conjunctivitis, diplopia, optic neuritis, cataracts HEMATOLOGIC Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs positive), thrombocytopenia with or without purpura, eosinophilia, decreases in hemoglobin and hematocrit [see PRECAUTIONS ] Bleeding episodes (e.g., epistaxis, menorrhagia) METABOLIC/ENDOCRINE Decreased appetite Gynecomastia, hypoglycemic reaction, acidosis CARDIOVASCULAR Edema, fluid retention (generally responds promptly to drug discontinuation) [see PRECAUTIONS ] Congestive heart failure in patients with marginal cardiac function, elevated blood pressure, palpitations Arrhythmias (sinus tachycardia, sinus bradycardia) ALLERGIC Syndrome of abdominal pain, fever, chills, nausea and vomiting; anaphylaxis; bronchospasm [see CONTRAINDICATIONS ] Serum sickness, lupus erythematosus syndrome, Henoch-Schonlein vasculitis, angioedema RENAL Acute renal failure [see PRECAUTIONS ], decreased creatinine clearance, polyuria, azotemia, cystitis, hematuria Renal papillary necrosis MISCELLANEOUS Dry eyes and mouth, gingival ulcer, rhinitis tests * Reactions occurring in 3% to 9% of patients treated with ibuprofen tablets. (Those reactions occurring in less than 3% of the patients are unmarked.) ** Reactions are classified under \u201cProbable Causal Relationship (PCR)\u201d if there has been one positive rechallenge or if three or more cases occur which might be causally related. Reactions are classified under \u201cCausal Relationship Unknown\u201d if seven or more events have been reported but the criteria for PCR have not been met. To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
      },
      {
        "code": "34088-5",
        "type": "OVERDOSAGE SECTION",
        "title": "OVERDOSAGE",
        "content": "Approximately 1\u00bd hours after the reported ingestion of from 7 to 10 ibuprofen tablets (400 mg), a 19-month old child weighing 12 kg was seen in the hospital emergency room, apneic and cyanotic, responding only to painful stimuli. This type of stimulus, however, was sufficient to induce respiration. Oxygen and parenteral fluids were given; a greenish-yellow fluid was aspirated from the stomach with no evidence to indicate the presence of ibuprofen. Two hours after ingestion the child's condition seemed stable; she still responded only to painful stimuli and continued to have periods of apnea lasting from 5 to 10 seconds. She was admitted to intensive care and sodium bicarbonate was administered as well as infusions of dextrose and normal saline. By four hours post-ingestion she could be aroused easily, sit by herself and respond to spoken commands. Blood level of ibuprofen was 102.9 mcg/mL approximately 8\u00bd hours after accidental ingestion. At 12 hours she appeared to be completely recovered. In two other reported cases where children (each weighing approximately 10 kg) accidentally, acutely ingested approximately 120 mg/kg, there were no signs of acute intoxication or late sequelae. Blood level in one child 90 minutes after ingestion was 700 mcg/mL - about 10 times the peak levels seen in absorption-excretion studies. A 19-year old male who had taken 8,000 mg of ibuprofen over a period of a few hours complained of dizziness, and nystagmus was noted. After hospitalization, parenteral hydration and three days bed rest, he recovered with no reported sequelae. In cases of acute overdosage, the stomach should be emptied by vomiting or lavage, though little drug will likely be recovered if more than an hour has elapsed since ingestion. Because the drug is acidic and is excreted in the urine, it is theoretically beneficial to administer alkali and induce diuresis. In addition to supportive measures, the use of oral activated charcoal may help to reduce the absorption and reabsorption of ibuprofen tablets."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "DOSAGE AND ADMINISTRATION",
        "content": "Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see WARNINGS ]. After observing the response to initial therapy with ibuprofen tablets, the dose and frequency should be adjusted to suit an individual patient's needs. Do not exceed 3200 mg total daily dose. If gastrointestinal complaints occur, administer ibuprofen tablets with meals or milk. Rheumatoid arthritis and osteoarthritis, including flare-ups of chronic disease: Suggested Dosage: 1200 mg to 3200 mg daily (400 mg, 600 mg or 800 mg tid or qid). Individual patients may show a better response to 3200 mg daily, as compared with 2400 mg, although in well-controlled clinical trials patients on 3200 mg did not show a better mean response in terms of efficacy. Therefore, when treating patients with 3200 mg/day, the physician should observe sufficient increased clinical benefits to offset potential increased risk. The dose should be tailored to each patient, and may be lowered or raised depending on the severity of symptoms either at time of initiating drug therapy or as the patient responds or fails to respond. In general, patients with rheumatoid arthritis seem to require higher doses of ibuprofen tablets than do patients with osteoarthritis. The smallest dose of ibuprofen tablets that yields acceptable control should be employed. A linear blood level dose-response relationship exists with single doses up to 800 mg [See CLINICAL PHARMACOLOGY for effects of food on rate of absorption]. The availability of three tablet strengths facilitates dosage adjustment. In chronic conditions, a therapeutic response to therapy with ibuprofen tablets is sometimes seen in a few days to a week but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required. Mild to moderate pain: 400 mg every 4 to 6 hours as necessary for relief of pain. In controlled analgesic clinical trials, doses of ibuprofen tablets greater than 400 mg were no more effective than the 400 mg dose. Dysmenorrhea: For the treatment of dysmenorrhea, beginning with the earliest onset of such pain, ibuprofen tablets should be given in a dose of 400 mg every 4 hours as necessary for the relief of pain."
      },
      {
        "code": "34069-5",
        "type": "HOW SUPPLIED SECTION",
        "title": "HOW SUPPLIED",
        "content": "Ibuprofen Tablets USP, 400 mg are white, round, biconvex, aqueous film-coated tablets, debossed \"IP 464\" on obverse and plain on reverse. Supplied as: Blister card of 9 Tablets NDC 83209-464-09 Blister card of 10 Tablets NDC 83209-464-10 Blister card of 12 Tablets NDC 83209-464-12 Blister card of 14 Tablets NDC 83209-464-14 Blister card of 15 Tablets NDC 83209-464-15 Blister card of 18 Tablets NDC 83209-464-18 Blister card of 20 Tablets NDC 83209-464-20 Blister card of 21 Tablets NDC 83209-464-21 Blister card of 24 Tablets NDC 83209-464-24 Blister card of 28 Tablets NDC 83209-464-28 Blister card of 30 Tablets NDC 83209-464-30 Blister card of 40 Tablets NDC 83209-464-40 Blister card of 60 Tablets NDC 83209-464-60 Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Avoid excessive heat 40\u00b0C (104\u00b0F)."
      },
      {
        "code": "68498-5",
        "type": "PATIENT MEDICATION INFORMATION SECTION",
        "content": "Medication Guide for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Ibuprofen (eye\" bue proe' fen) Tablets, USP What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)? NSAIDs can cause serious side effects, including: Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase: with increasing doses of NSAIDs with longer use of NSAIDs Do not take NSAIDs right before or after a heart surgery called a \u201ccoronary artery bypass graft (CABG).\u201d Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines: anytime during use without warning symptoms that may cause death The risk of getting an ulcer or bleeding increases with: past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs taking medicines called \u201ccorticosteroids\u201d, \u201canticoagulants\u201d, \u201cSSRIs\u201d, or \u201cSNRIs\u201d increasing doses of NSAIDs longer use of NSAIDs smoking drinking alcohol older age poor health advanced liver disease bleeding problems NSAIDs should only be used: exactly as prescribed at the lowest dose possible for your treatment for the shortest time needed What are NSAIDs? NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain. Who should not take NSAIDs? Do not take NSAIDs: if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs. right before or after heart bypass surgery. Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you: have liver or kidney problems have high blood pressure have asthma are pregnant or plan to become pregnant. Taking NSAIDs at about 20 weeks of pregnancy or later may harm your unborn baby. If you need to take NSAIDs for more than 2 days when you are between 20 and 30 weeks of pregnancy, your healthcare provider may need to monitor the amount of fluid in your womb around your baby. You should not take NSAIDs after about 30 weeks of pregnancy. are breastfeeding or plan to breast feed. Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. NSAIDs and some other medicines can interact with each other and cause serious side effects. Do not start taking any new medicine without talking to your healthcare provider first. What are the possible side effects of NSAIDs? NSAIDs can cause serious side effects, including: See \u201cWhat is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?\u201d new or worse high blood pressure heart failure liver problems including liver failure kidney problems including kidney failure low red blood cells (anemia) life-threatening skin reactions life-threatening allergic reactions Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting and dizziness. Get emergency help right away if you get any of the following symptoms: shortness of breath or trouble breathing chest pain weakness in one part or side of your body slurred speech swelling of the face or throat Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms: nausea more tired or weaker than usual diarrhea itching your skin or eyes look yellow indigestion or stomach pain flu-like symptoms vomit blood there is blood in your bowel movement or it is black and sticky like tar unusual weight gain skin rash or blisters with fever swelling of the arms, legs, hands, and feet If you take too much of your NSAID, call your healthcare provider or get medical help right away. These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Other information about NSAIDs Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines. Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days. General information about the safe and effective use of NSAIDs Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals."
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PRINCIPAL DISPLAY PANEL",
        "content": ""
      }
    ],
    "category": "Prescription"
  },
  {
    "filename": "prescription_41375a05-871b-6afb-e063-6294a90a48f9.xml",
    "document_id": "41375a05-871b-6afb-e063-6294a90a48f9",
    "document_type": "HUMAN PRESCRIPTION DRUG LABEL",
    "title": "These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.\n ",
    "effective_date": "20251015",
    "version": "34",
    "author": {
      "name": "PD-Rx Pharmaceuticals, Inc.",
      "id": "156893695"
    },
    "product": {
      "ndc": "43063-125",
      "name": "Carvedilol",
      "form": "TABLET, FILM COATED",
      "generic_name": "Carvedilol",
      "active_ingredients": [
        {
          "name": "CARVEDILOL",
          "code": "0K47UL67F2",
          "strength": "12.5 mg",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [
        "LACTOSE MONOHYDRATE",
        "SILICON DIOXIDE",
        "CROSPOVIDONE",
        "POVIDONE K30",
        "SUCROSE",
        "MAGNESIUM STEARATE",
        "POLYETHYLENE GLYCOL 400",
        "POLYSORBATE 80",
        "TITANIUM DIOXIDE",
        "HYPROMELLOSE 2910 (5 MPA.S)"
      ],
      "packaging": [
        {
          "quantity": "90 1",
          "ndc": "43063-125-90",
          "container": "BOTTLE, PLASTIC"
        },
        {
          "quantity": "180 1",
          "ndc": "43063-125-93",
          "container": "BOTTLE, PLASTIC"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20240731",
      "approval_status": "ANDA",
      "color": "white",
      "shape": "OVAL",
      "size": "11 mm",
      "imprint": "E;03"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "1 INDICATIONS AND USAGE"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "1.1 Heart Failure",
        "content": "Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ] ."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "1.2 Left Ventricular Dysfunction following Myocardial Infarction",
        "content": "Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2) ] ."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "1.3 Hypertension",
        "content": "Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies (14.3 , 14.4) ] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2) ] ."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "2 DOSAGE AND ADMINISTRATION",
        "content": "Carvedilol tablets should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "2.1 Heart Failure",
        "content": "DOSAGE MUST BE INDIVIDUALIZED AND CLOSELY MONITORED BY A PHYSICIAN DURING UP-TITRATION. Prior to initiation of carvedilol tablets, it is recommended that fluid retention be minimized. The recommended starting dose of carvedilol tablets is 3.125 mg twice daily for 2 weeks. If tolerated, patients may have their dose increased to 6.25, 12.5, and 25 mg twice daily over successive intervals of at least 2 weeks. Patients should be maintained on lower doses if higher doses are not tolerated. A maximum dose of 50 mg twice daily has been administered to patients with mild-to-moderate heart failure weighing over 85 kg (187 lbs). Patients should be advised that initiation of treatment and (to a lesser extent) dosage increases may be associated with transient symptoms of dizziness or lightheadedness (and rarely syncope) within the first hour after dosing. During these periods, patients should avoid situations such as driving or hazardous tasks, where symptoms could result in injury. Vasodilatory symptoms often do not require treatment, but it may be useful to separate the time of dosing of carvedilol tablets from that of the ACE inhibitor or to reduce temporarily the dose of the ACE inhibitor. The dose of carvedilol tablets should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized. Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics. The dose of carvedilol tablets should be reduced if patients experience bradycardia (heart rate less than 55 beats per minute). Episodes of dizziness or fluid retention during initiation of carvedilol tablets can generally be managed without discontinuation of treatment and do not preclude subsequent successful titration of, or a favorable response to, carvedilol."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "2.2 Left Ventricular Dysfunction following Myocardial Infarction",
        "content": "DOSAGE MUST BE INDIVIDUALIZED AND MONITORED DURING UP-TITRATION. Treatment with carvedilol tablets may be started as an inpatient or outpatient and should be started after the patient is hemodynamically stable and fluid retention has been minimized. It is recommended that carvedilol tablets be started at 6.25 mg twice daily and increased after 3 to 10 days, based on tolerability, to 12.5 mg twice daily, then again to the target dose of\u00a025 mg twice daily. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). Patients should be maintained on lower doses if higher doses are not tolerated. The recommended dosing regimen need not be altered in patients who received treatment with an IV or oral \u03b2-blocker during the acute phase of the myocardial infarction."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "2.3 Hypertension",
        "content": "DOSAGE MUST BE INDIVIDUALIZED. The recommended starting dose of carvedilol tablets is 6.25 mg twice daily. If this dose is tolerated, using standing systolic pressure measured about \u00a01 hour after dosing as a guide, the dose should be maintained for 7 to 14 days, and then increased to 12.5 mg twice daily if needed, based on trough blood pressure, again using standing systolic pressure 1 hour after dosing as a guide for tolerance. This dose should also be maintained for 7 to 14 days and can then be adjusted upward to 25 mg twice daily if tolerated and needed. The full antihypertensive effect of carvedilol tablets is seen within 7 to 14 days. Total daily dose should not exceed 50 mg. Concomitant administration with a diuretic can be expected to produce additive effects and exaggerate the orthostatic component of carvedilol action."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "2.4 Hepatic Impairment",
        "content": "Carvedilol tablets should not be given to patients with severe hepatic impairment [see Contraindications (4) ] ."
      },
      {
        "code": "43678-2",
        "type": "DOSAGE FORMS & STRENGTHS SECTION",
        "title": "3 DOSAGE FORMS AND STRENGTHS",
        "content": "Carvedilol tablets, USP\u00a03.125 mg are white to off-white, oval shaped, film-coated tablets debossed with \u2018E\u2019 on one side and \u201801\u2019 on the other side. The 6.25 mg are white to off-white, oval shaped, film-coated tablets debossed with \u2018E\u2019 on one side and \u201802\u2019 on the other side. The 12.5 mg are white to off-white, oval shaped, film-coated tablets debossed with \u2018E\u2019 on one side and \u201803\u2019 on the other side. The 25 mg are white to off-white, oval shaped, film-coated tablets debossed with \u2018E\u2019 on one side and \u201804\u2019 on the other side."
      },
      {
        "code": "34070-3",
        "type": "CONTRAINDICATIONS SECTION",
        "title": "4 CONTRAINDICATIONS",
        "content": "Carvedilol tablets are contraindicated in the following conditions: Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of carvedilol tablets. Second- or third-degree AV block. Sick sinus syndrome. Severe bradycardia (unless a permanent pacemaker is in place). Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating carvedilol tablets. Patients with severe hepatic impairment. Patients with a history of\u00a0a serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to\u00a0any\u00a0component of this medication or other medications\u00a0containing carvedilol."
      },
      {
        "code": "43685-7",
        "type": "WARNINGS AND PRECAUTIONS SECTION",
        "title": "5 WARNINGS AND PRECAUTIONS"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.1 Cessation of Therapy",
        "content": "Patients with coronary artery disease, who are being treated with carvedilol, should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in patients with angina following the abrupt discontinuation of therapy with \u03b2-blockers. The last 2 complications may occur with or without preceding exacerbation of the angina pectoris. As with other \u03b2-blockers, when discontinuation of carvedilol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. Carvedilol should be discontinued over 1 to 2 weeks whenever possible. If the angina worsens or acute coronary insufficiency develops, it is recommended that carvedilol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue therapy with carvedilol abruptly even in patients treated only for hypertension or heart failure."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.2 Bradycardia",
        "content": "In clinical trials, carvedilol caused bradycardia in about 2% of hypertensive subjects, 9% of subjects with heart failure, and 6.5% of subjects with myocardial infarction\u00a0and left ventricular dysfunction. If pulse rate drops below 55 beats per minute, the dosage should be reduced."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.3 Hypotension",
        "content": "In clinical trials of primarily mild-to-moderate heart failure, hypotension and postural hypotension occurred in 9.7% and syncope in 3.4% of subjects receiving carvedilol compared with 3.6% and 2.5% of placebo subjects, respectively. The risk for these events was highest during the first 30 days of dosing, corresponding to the up-titration period and was a cause for discontinuation of therapy in 0.7% of subjects receiving carvedilol, compared with 0.4% of placebo subjects. In a long-term, placebo-controlled trial in severe heart failure (COPERNICUS), hypotension and postural hypotension occurred in 15.1% and syncope in 2.9% of heart failure subjects receiving carvedilol compared with 8.7% and 2.3% of placebo subjects, respectively. These events were a cause for discontinuation of therapy in 1.1% of subjects receiving carvedilol, compared with 0.8% of placebo subjects. Postural hypotension occurred in 1.8% and syncope in 0.1% of hypertensive subjects, primarily following the initial dose or at the time of dose increase and was a cause for discontinuation of therapy in 1% of subjects. In the CAPRICORN trial of survivors of an acute myocardial infarction, hypotension or postural hypotension occurred in 20.2% of subjects receiving carvedilol compared with 12.6% of placebo subjects. Syncope was reported in 3.9% and 1.9% of subjects, respectively. These events were a cause for discontinuation of therapy in 2.5% of subjects receiving carvedilol, compared with 0.2% of placebo subjects. Starting with a low dose, administration with food, and gradual up-titration should decrease the likelihood of syncope or excessive hypotension [see Dosage and Administration (2.1 , 2.2 , 2.3) ] . During initiation of therapy, the patient should be cautioned to avoid situations such as driving or hazardous tasks, where injury could result should syncope occur."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.4 Heart Failure/Fluid Retention",
        "content": "Worsening heart failure or fluid retention may occur during up-titration of carvedilol. If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . Occasionally it is necessary to lower the carvedilol dose or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of, or a favorable response to, carvedilol. In a placebo-controlled trial of subjects with severe heart failure, worsening heart failure during the first 3 months was reported to a similar degree with carvedilol and with placebo. When treatment was maintained beyond 3 months, worsening heart failure was reported less frequently in subjects treated with carvedilol than with placebo. Worsening heart failure observed during long-term therapy is more likely to be related to the patients\u2019 underlying disease than to treatment with carvedilol."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.5 Non-allergic Bronchospasm",
        "content": "Patients with bronchospastic disease (e.g., chronic bronchitis, emphysema) should, in general, not receive \u03b2-blockers. Carvedilol may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. It is prudent, if carvedilol is used, to use the smallest effective dose, so that inhibition of endogenous or exogenous \u03b2-agonists is minimized. In clinical trials of subjects with heart failure, subjects with bronchospastic disease were enrolled if they did not require oral or inhaled medication to treat their bronchospastic disease. In such patients, it is recommended that carvedilol be used with caution. The dosing recommendations should be followed closely and the dose should be lowered if any evidence of bronchospasm is observed during up-titration."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.6 Effects on Blood Sugar",
        "content": "Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i.e., surgery, not eating regularly, or are vomiting). If severe hypoglycemia occurs, patients should be instructed to seek emergency treatment. In patients with heart failure and diabetes, carvedilol therapy may lead to worsening hyperglycemia, which responds to intensification of hypoglycemic therapy. It is recommended that blood glucose be monitored when carvedilol dosing is initiated, adjusted, or discontinued. Trials designed to examine the effects of carvedilol on glycemic control in patients with diabetes and heart failure have not been conducted. In a trial designed to examine the effects of carvedilol on glycemic control in a population with mild-to-moderate hypertension and well-controlled type 2 diabetes mellitus, carvedilol had no adverse effect on glycemic control, based on HbA1c measurements [see Clinical Studies (14.4) ] ."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.7 Peripheral Vascular Disease",
        "content": "\u03b2-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution should be exercised in such individuals."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.8 Deterioration of Renal Function",
        "content": "Rarely, use of carvedilol in patients with heart failure has resulted in deterioration of renal function. Patients at risk appear to be those with low blood pressure (systolic blood pressure less than 100 mm Hg), ischemic heart disease and diffuse vascular disease, and/or underlying renal insufficiency. Renal function has returned to baseline when carvedilol was stopped. In patients with these risk factors, it is recommended that renal function be monitored during up-titration of carvedilol and the drug discontinued or dosage reduced if worsening of renal function occurs."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.9 Major Surgery",
        "content": "Chronically administered \u03b2-blocking therapy should not be routinely withdrawn prior to major surgery; however,\u00a0the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.10 Thyrotoxicosis",
        "content": "\u03b2-adrenergic blockade may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of \u03b2-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.11 Pheochromocytoma",
        "content": "In patients with pheochromocytoma, an \u03b1-blocking agent should be initiated prior to the use of any \u03b2-blocking agent. Although carvedilol has both \u03b1- and \u03b2-blocking pharmacologic activities, there has been no experience with its use in this condition. Therefore, caution should be taken in the administration of carvedilol to patients suspected of having pheochromocytoma."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.12 Prinzmetal's Variant Angina",
        "content": "Agents with non-selective \u03b2-blocking activity may provoke chest pain in patients with Prinzmetal\u2019s variant angina. There has been no clinical experience with carvedilol in these patients although the \u03b1-blocking activity may prevent such symptoms. However, caution should be taken in the administration of carvedilol to patients suspected of having Prinzmetal\u2019s variant angina."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.13 Risk of Anaphylactic Reaction",
        "content": "While taking \u03b2-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.14 Intraoperative Floppy Iris Syndrome",
        "content": "Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery\u00a0in some patients treated with alpha-1 blockers (carvedilol is an alpha/beta blocker). This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient\u2019s ophthalmologist should be prepared for possible modifications to the surgical technique, such as utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to cataract surgery."
      },
      {
        "code": "34084-4",
        "type": "ADVERSE REACTIONS SECTION",
        "title": "6 ADVERSE REACTIONS"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "6.1 Clinical Studies Experience",
        "content": "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Carvedilol has been evaluated for safety in subjects with heart failure (mild, moderate, and severe), in subjects with left ventricular dysfunction following myocardial infarction and in hypertensive subjects. The observed adverse event profile was consistent with the pharmacology of the drug and the health status of the subjects in the clinical trials. Adverse events reported for each of these patient populations are provided below. Excluded are adverse events considered too general to be informative, and those not reasonably associated with the use of the drug because they were associated with the condition being treated or are very common in the treated population. Rates of adverse events were generally similar across demographic subsets (men and women, elderly and non-elderly, blacks and non-blacks). Heart Failure Carvedilol has been evaluated for safety in heart failure in more than 4,500 subjects worldwide of whom more than 2,100 participated in placebo-controlled clinical trials. Approximately 60% of the total treated population in placebo-controlled clinical trials received carvedilol for at least 6 months and 30% received carvedilol for at least 12 months. In the COMET trial, 1,511 subjects with mild-to-moderate heart failure were treated with carvedilol for up to 5.9 years (mean: 4.8 years). Both in U.S. clinical trials in mild-to-moderate heart failure that compared carvedilol in daily doses up to 100 mg (n = 765) with placebo (n = 437), and in a multinational clinical trial in severe heart failure (COPERNICUS) that compared carvedilol in daily doses up to 50 mg (n = 1,156) with placebo (n = 1,133), discontinuation rates for adverse experiences were similar in carvedilol and placebo subjects. In placebo-controlled clinical trials, the only cause of discontinuation greater than 1% and occurring more often on carvedilol was dizziness (1.3% on carvedilol, 0.6% on placebo in the COPERNICUS trial). Table 1 shows adverse events reported in subjects with mild-to-moderate heart failure enrolled in U.S. placebo-controlled clinical trials, and with severe heart failure enrolled in the COPERNICUS trial. Shown are adverse events that occurred more frequently in drug-treated subjects than placebo-treated subjects with an incidence of greater than 3% in subjects treated with carvedilol regardless of causality. Median trial medication exposure was 6.3 months for both carvedilol and placebo subjects in the trials of mild-to-moderate heart failure and 10.4 months in the trial of\u00a0subjects with severe heart failure. The adverse event profile of carvedilol observed in the long-term COMET trial was generally similar to that observed in the U.S. Heart Failure Trials. Table 1. Adverse Events (%) Occurring More Frequently with Carvedilol than with Placebo in Subjects with Mild-to-Moderate Heart Failure (HF) Enrolled in U.S. Heart Failure Trials or in Subjects with Severe Heart Failure in the COPERNICUS Trial (Incidence >3% in Subjects Treated with Carvedilol, Regardless of Causality) Body System/ Adverse Event Mild-to-Moderate HF Severe HF Carvedilol (n = 765) Placebo (n = 437) Carvedilol (n = 1,156) Placebo (n = 1,133) Body as a Whole Asthenia Fatigue Digoxin level increased Edema generalized Edema dependent 7 24 5 5 4 7 22 4 3 2 11 \u2014 2 6 \u2014 9 \u2014 1 5 \u2014 Cardiovascular Bradycardia Hypotension Syncope Angina pectoris 9 9 3 2 1 3 3 3 10 14 8 6 3 8 5 4 Central Nervous System Dizziness Headache 32 8 19 7 24 5 17 3 Gastrointestinal Diarrhea Nausea Vomiting 12 9 6 6 5 4 5 4 1 3 3 2 Metabolic Hyperglycemia Weight increase BUN increased NPN increased Hypercholesterolemia Edema peripheral 12 10 6 6 4 2 8 7 5 5 3 1 5 12 \u2014 \u2014 1 7 3 11 \u2014 \u2014 1 6 Musculoskeletal Arthralgia 6 5 1 1 Respiratory Cough increased Rales 8 4 9 4 5 4 4 2 Vision Vision abnormal 5 2 \u2014 \u2014 Cardiac failure and dyspnea were also reported in these trials, but the rates were equal or greater in subjects who received placebo. The following adverse events were reported with a frequency of greater than 1% but less than or equal to 3% and more frequently with carvedilol in either the U.S. placebo-controlled trials in subjects with mild-to-moderate heart failure or in subjects with severe heart failure in the COPERNICUS trial. Incidence greater than 1% to less than or equal to 3% Body as a Whole : Allergy, malaise, hypovolemia, fever, leg edema. Cardiovascular: Fluid overload, postural hypotension, aggravated angina pectoris, AV block, palpitation, hypertension. Central and Peripheral Nervous System : Hypesthesia, vertigo, paresthesia. Gastrointestinal : Melena, periodontitis. Liver and Biliary System : SGPT increased, SGOT increased. Metabolic and Nutritional: Hyperuricemia, hypoglycemia, hyponatremia, increased alkaline phosphatase, glycosuria, hypervolemia, diabetes mellitus, GGT increased, weight loss, hyperkalemia, creatinine increased. Musculoskeletal : Muscle cramps. Platelet, Bleeding, and Clotting : Prothrombin decreased, purpura, thrombocytopenia. Psychiatric : Somnolence. Reproductive, male: Impotence. Special Senses : Blurred vision. Urinary System : Renal insufficiency, albuminuria, hematuria. Left Ventricular Dysfunction following Myocardial Infarction Carvedilol has been evaluated for safety in survivors of an acute myocardial infarction with left ventricular dysfunction in the CAPRICORN trial which involved 969 subjects who received carvedilol and 980 who received placebo. Approximately 75% of the subjects received carvedilol for at least 6 months and 53% received carvedilol for at least 12 months. Subjects were treated for an average of 12.9 months and 12.8 months with carvedilol and placebo, respectively. The most common adverse events reported with carvedilol in the CAPRICORN trial were consistent with the profile of the drug in the U.S. heart failure trials and the COPERNICUS trial. The only additional adverse events reported in CAPRICORN in greater than 3% of the subjects and more commonly on carvedilol were dyspnea, anemia, and lung edema. The following adverse events were reported with a frequency of greater than 1% but less than or equal to 3% and more frequently with carvedilol: flu syndrome, cerebrovascular accident, peripheral vascular disorder, hypotonia, depression, gastrointestinal pain, arthritis, and gout. The overall rates of discontinuations due to adverse events were similar in both groups of subjects. In this database, the only cause of discontinuation greater than 1% and occurring more often on carvedilol was hypotension (1.5% on carvedilol, 0.2% on placebo). Hypertension Carvedilol has been evaluated for safety in hypertension in more than 2,193 subjects in U.S. clinical trials and in 2,976 subjects in international clinical trials. Approximately 36% of the total treated population received carvedilol for at least 6 months. Most adverse events reported during therapy with carvedilol were of mild to moderate severity. In U.S. controlled clinical trials directly comparing carvedilol in doses up to 50 mg (n = 1,142) with placebo (n = 462), 4.9% of subjects receiving carvedilol discontinued for adverse events versus 5.2% of placebo subjects. Although there was no overall difference in discontinuation rates, discontinuations were more common in the carvedilol group for postural hypotension (1% versus 0). The overall incidence of adverse events in U.S. placebo-controlled trials increased with increasing dose of carvedilol. For individual adverse events this could only be distinguished for dizziness, which increased in frequency from 2% to 5% as total daily dose increased from 6.25 mg to 50 mg. Table 2 shows adverse events in U.S. placebo-controlled clinical trials for hypertension that occurred with an incidence of greater than or equal to 1% regardless of causality and that were more frequent in drug-treated subjects than placebo-treated subjects. Table 2. Adverse Events (%) Occurring in U.S. Placebo-Controlled Hypertension Trials (Incidence \u22651%, Regardless of Causality) a a Shown are events with rate >1% rounded to nearest integer. Body System/ Adverse Event Carvedilol Placebo (n = 1,142) (n = 462) Cardiovascular Bradycardia Postural hypotension Peripheral edema 2 2 1 \u2014 \u2014 \u2014 Central Nervous System Dizziness Insomnia 6 2 5 1 Gastrointestinal Diarrhea 2 1 Hematologic Thrombocytopenia 1 \u2014 Metabolic Hypertriglyceridemia 1 \u2014 Dyspnea and fatigue were also reported in these trials, but the rates were equal or greater in subjects who received placebo. The following adverse events not described above were reported as possibly or probably related to carvedilol in worldwide open or controlled trials with carvedilol in subjects with hypertension or heart failure. Incidence greater than 0.1% to less than or equal to 1% Cardiovascular: Peripheral ischemia, tachycardia. Central and Peripheral Nervous System: Hypokinesia. Gastrointestinal: Bilirubinemia, increased hepatic enzymes (0.2% of hypertension patients and 0.4% of heart failure patients were discontinued from therapy because of increases in hepatic enzymes) [see Adverse Reactions (6.2) ] . Psychiatric: Nervousness, sleep disorder, aggravated depression, impaired concentration, abnormal thinking, paroniria, emotional lability. Respiratory System: Asthma [see Contraindications (4) ] . Reproductive, male: Decreased libido. Skin and Appendages: Pruritus, rash erythematous, rash maculopapular, rash psoriaform, photosensitivity reaction. Special Senses: Tinnitus. Urinary System: Micturition frequency increased. Autonomic Nervous System: Dry mouth, sweating increased. Metabolic and Nutritional: Hypokalemia, hypertriglyceridemia. Hematologic: Anemia, leukopenia. The following events were reported in less than or equal to 0.1% of subjects and are potentially important: complete AV block, bundle branch block, myocardial ischemia, cerebrovascular disorder, convulsions, migraine, neuralgia, paresis, anaphylactoid reaction, alopecia, exfoliative dermatitis, amnesia, GI hemorrhage, bronchospasm, pulmonary edema, decreased hearing, respiratory alkalosis, increased BUN, decreased HDL, pancytopenia, and atypical lymphocytes. Laboratory Abnormalities Reversible elevations in serum transaminases (ALT or AST) have been observed during treatment with carvedilol. Rates of transaminase elevations (2 to 3 times the upper limit of normal) observed during controlled clinical trials have generally been similar between subjects treated with carvedilol and those treated with placebo. However, transaminase elevations, confirmed by rechallenge, have been observed with carvedilol. In a long-term, placebo-controlled trial in severe heart failure, subjects treated with carvedilol had lower values for hepatic transaminases than subjects treated with placebo, possibly because improvements in cardiac function induced by carvedilol led to less hepatic congestion and/or improved hepatic blood flow. Carvedilol has not been associated with clinically significant changes in serum potassium, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine. No clinically relevant changes were noted in fasting serum glucose in hypertensive patients; fasting serum glucose was not evaluated in the heart failure clinical trials."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "6.2 Postmarketing Experience",
        "content": "The following adverse reactions have been identified during post-approval use of carvedilol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders Aplastic anemia. Immune System Disorders Hypersensitivity (e.g., anaphylactic reactions, angioedema, urticaria). Renal and Urinary Disorders Urinary incontinence. Respiratory, Thoracic, and Mediastinal Disorders Interstitial pneumonitis. Skin and Subcutaneous Tissue Disorders Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme."
      },
      {
        "code": "34073-7",
        "type": "DRUG INTERACTIONS SECTION",
        "title": "7 DRUG INTERACTIONS"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.1 CYP2D6 Inhibitors and Poor Metabolizers",
        "content": "Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ] . Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the \u03b1-blocking R(+) enantiomer."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.2 Hypotensive Agents",
        "content": "Patients taking a \u03b2-blocker and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia. Concomitant administration of clonidine with a \u03b2-blocker may cause hypotension and bradycardia. When concomitant treatment with a \u03b2-blocker and clonidine is to be terminated, the \u03b2-blocker should be discontinued first. Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.3 Cyclosporine",
        "content": "Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant subjects suffering from chronic vascular rejection. In about 30% of subjects, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed. On the average for the group, the dose of cyclosporine was reduced about 20% in these subjects. Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.4 Digitalis Glycosides",
        "content": "Both digitalis glycosides and \u03b2-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly. Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing carvedilol [see Clinical Pharmacology (12.5) ] ."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.5 Inducers/Inhibitors of Hepatic Metabolism",
        "content": "Rifampin reduced plasma concentrations of carvedilol by about 70% [see Clinical Pharmacology (12.5) ]. Cimetidine increased AUC by about 30% but caused no change in C max [see Clinical Pharmacology (12.5) ] ."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.6 Amiodarone",
        "content": "Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P-glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ] . The concomitant administration of amiodarone or other CYP2C9 inhibitors such as fluconazole with carvedilol may enhance the \u03b2-blocking activity, resulting in further slowing of the heart rate or cardiac conduction. Patients should be observed for signs of bradycardia or heart block, particularly when one agent is added to pre-existing treatment with the other."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.7 Calcium Channel Blockers",
        "content": "Conduction disturbance (rarely with hemodynamic compromise) has been observed when carvedilol is coadministered with diltiazem. As with other\u00a0\u03b2-blockers, if carvedilol is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.8 Insulin or Oral Hypoglycemics",
        "content": "\u03b2-blockers may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics. Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended [see Warnings and Precautions (5.6) ] ."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "7.9 Anesthesia",
        "content": "If treatment with carvedilol is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ] ."
      },
      {
        "code": "43684-0",
        "type": "USE IN SPECIFIC POPULATIONS SECTION",
        "title": "8 USE IN SPECIFIC POPULATIONS"
      },
      {
        "code": "42228-7",
        "type": "PREGNANCY SECTION",
        "title": "8.1 Pregnancy",
        "content": "Risk Summary Available data regarding use of carvedilol in pregnant women are insufficient to determine whether there are drug-associated risks of adverse developmental outcomes. There are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy. The use of beta blockers during the third trimester of pregnancy may increase the risk of hypotension, bradycardia, hypoglycemia, and respiratory depression in the neonate [see Clinical Considerations] . In animal reproduction studies, there was no evidence of adverse developmental outcomes at clinically relevant doses [see Data] . Oral administration of carvedilol to pregnant rats during organogenesis resulted in post-implantation loss, decreased fetal body weight, and an increased frequency of delayed fetal skeletal development at maternally toxic doses that were 50 times the maximum recommended human dose (MRHD). In addition, oral administration of carvedilol to pregnant rabbits during organogenesis resulted in increased post-implantation loss at doses 25 times the MRHD [see Data]. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk: Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal Adverse Reactions: Neonates of women with hypertension who are treated with beta-blockers during the third trimester of pregnancy may be at increased risk for hypotension, bradycardia, hypoglycemia, and respiratory depression. Observe newborns for symptoms of hypotension, bradycardia, hypoglycemia, and respiratory depression and manage accordingly. Data Animal Data: Studies performed in rats and rabbits given carvedilol during fetal organogenesis revealed increased post-implantation loss in rats at a maternally toxic dose of 300 mg per kg per day (50 times the MRHD as mg per m 2 ) and in rabbits (in the absence of maternal toxicity) at doses of 75 mg per kg per day (25 times the MRHD as mg per m 2 ). In the rats, there was also a decrease in fetal body weight at 300 mg per kg per day (50 times the MRHD as mg per m 2 ) accompanied by an increased incidence of fetuses with delayed skeletal development. In rats, the no-effect level for embryo-fetal toxicity was 60 mg per kg per day (10 times the MRHD as mg per m 2 ); in rabbits, it was 15 mg per kg per day (5 times the MRHD as mg per m 2 ). In a pre-and post-natal development study in rats administered carvedilol from late gestation through lactation, increased embryo-lethality was observed at a maternally toxic dose of 200 mg per kg per day (approximately 32 times the MRHD as mg per m 2 ), and pup mortality and delays in physical growth/development were observed at 60 mg per kg per day (10 times the MRHD as mg per m 2 ) in the absence of maternal toxicity. The no-effect level was 12 mg per kg per day (2 times the MRHD as mg per m 2 ). Carvedilol was present in fetal rat tissue."
      },
      {
        "code": "34079-4",
        "type": "LABOR & DELIVERY SECTION",
        "title": "8.2 Lactation",
        "content": "Risk Summary There are no data on the presence of carvedilol in human milk, the effects on the breastfed infant, or the effects on milk production. Carvedilol is present in the milk of lactating rats. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for carvedilol and any potential adverse effects on the breastfed infant from carvedilol or from the underlying maternal condition."
      },
      {
        "code": "34081-0",
        "type": "PEDIATRIC USE SECTION",
        "title": "8.4 Pediatric Use",
        "content": "Effectiveness of carvedilol in patients younger than 18 years has not been established. In a double-blind trial, 161 children (mean age: 6 years; range: 2 months to 17 years; 45% younger than 2 years) with chronic heart failure [NYHA class II to IV, left ventricular ejection fraction less than 40% for children with a systemic left ventricle (LV), and moderate-severe ventricular dysfunction qualitatively by echo for those with a systemic ventricle that was not an LV] who were receiving standard background treatment were randomized to placebo or to 2 dose levels of carvedilol. These dose levels produced placebo-corrected heart rate reduction of 4 to 6 heart beats per minute, indicative of \u03b2-blockade activity. Exposure appeared to be lower in pediatric subjects than adults. After 8 months of follow-up, there was no significant effect of treatment on clinical outcomes. Adverse reactions in this trial that occurred in greater than 10% of subjects treated with carvedilol and at twice the rate of placebo-treated subjects included chest pain (17% versus 6%), dizziness (13% versus 2%), and dyspnea (11% versus 0%)."
      },
      {
        "code": "34082-8",
        "type": "GERIATRIC USE SECTION",
        "title": "8.5 Geriatric Use",
        "content": "Of the 765 subjects with heart failure randomized to carvedilol in U.S. clinical trials, 31% (235) were aged 65 years or older, and 7.3% (56) were aged 75 years or older. Of the 1,156 subjects randomized to carvedilol in a long-term, placebo-controlled trial in severe heart failure, 47%\u00a0(547) were aged 65 years or older, and 15% (174)\u00a0 were aged 75 years or older. Of 3,025 subjects receiving carvedilol in heart failure trials worldwide, 42% were aged 65 years or older. Of the 975\u00a0subjects with myocardial infarction randomized to carvedilol in the CAPRICORN trial, 48% (468) were aged 65 years or older, and 11% (111) were aged 75 years or older. Of the 2,065 hypertensive subjects in U.S. clinical trials of efficacy or safety who were treated with carvedilol, 21% (436) were aged 65 years or older. Of 3,722 subjects receiving carvedilol in hypertension clinical trials conducted worldwide, 24% were aged 65 years or older. With the exception of dizziness in hypertensive subjects (incidence 8.8% in the elderly versus 6% in younger subjects), no overall differences in the safety or effectiveness (see Figures 2 and 4) were observed between the older subjects and younger subjects in each of these populations. Similarly, other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out."
      },
      {
        "code": "34088-5",
        "type": "OVERDOSAGE SECTION",
        "title": "10 OVERDOSAGE",
        "content": "Overdosage may cause severe hypotension, bradycardia, cardiac insufficiency, cardiogenic shock, and cardiac arrest. Respiratory problems, bronchospasms, vomiting, lapses of consciousness, and generalized seizures may also occur. The patient should be placed in a supine position and, where necessary, kept under observation and treated under intensive-care conditions. The following agents may be administered: For excessive bradycardia: Atropine, 2 mg IV. To support cardiovascular function: Glucagon, 5 to 10 mg IV rapidly over 30 seconds, followed by a continuous infusion of 5 mg per hour; sympathomimetics (dobutamine, isoprenaline, adrenaline) at doses according to body weight and effect. If peripheral vasodilation dominates, it may be necessary to administer adrenaline or noradrenaline with continuous monitoring of circulatory conditions. For therapy-resistant bradycardia, pacemaker therapy should be performed. For bronchospasm, \u03b2-sympathomimetics (as aerosol or IV) or aminophylline IV should be given. In the event of seizures, slow IV injection of diazepam or clonazepam is recommended. NOTE: In the event of severe intoxication where there are symptoms of shock, treatment with antidotes must be continued for a sufficiently long period of time consistent with the 7- to 10-hour half-life of carvedilol. Cases of overdosage with carvedilol alone or in combination with other drugs have been reported. Quantities ingested in some cases exceeded 1,000 milligrams. Symptoms experienced included low blood pressure and heart rate. Standard supportive treatment was provided and individuals recovered."
      },
      {
        "code": "34089-3",
        "type": "DESCRIPTION SECTION",
        "title": "11 DESCRIPTION",
        "content": "Carvedilol is a nonselective \u03b2-adrenergic blocking agent with \u03b1 1 -blocking activity. It is (\u00b1)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure: Carvedilol tablets, USP are white, oval, film-coated tablets containing 3.125 mg, 6.25 mg,\u00a012.5 mg, or 25 mg of carvedilol. Inactive ingredients consist of lactose monohydrate, colloidal silicon dioxide, crospovidone, povidone, sucrose, magnesium stearate, polyethylene glycol 400, polysorbate 80, titanium dioxide, and hypromellose. Carvedilol USP\u00a0is a white to off-white powder with a molecular weight of 406.5 and a molecular formula of C 24 H 26 N 2 O 4 . It is freely soluble in dimethylsulfoxide; soluble in methylene chloride and methanol; sparingly soluble in 95% ethanol and isopropanol; slightly soluble in ethyl ether; and practically insoluble in water, gastric fluid (simulated, TS, pH 1.1), and intestinal fluid (simulated, TS without pancreatin, pH 7.5). Meets USP Dissolution Test 2."
      },
      {
        "code": "34090-1",
        "type": "CLINICAL PHARMACOLOGY SECTION",
        "title": "12 CLINICAL PHARMACOLOGY"
      },
      {
        "code": "43679-0",
        "type": "MECHANISM OF ACTION SECTION",
        "title": "12.1 Mechanism of Action",
        "content": "Carvedilol is a racemic mixture in which nonselective \u03b2-adrenoreceptor blocking activity is present in the S(-) enantiomer and \u03b1 1 -adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity."
      },
      {
        "code": "43681-6",
        "type": "PHARMACODYNAMICS SECTION",
        "title": "12.2 Pharmacodynamics",
        "content": "Heart Failure The basis for the beneficial effects of carvedilol in heart failure is not established. Two placebo-controlled trials compared the acute hemodynamic effects of carvedilol with baseline measurements in 59 and 49 subjects with NYHA class II to IV heart failure receiving diuretics, ACE inhibitors, and digitalis. There were significant reductions in systemic blood pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, and heart rate. Initial effects on cardiac output, stroke volume index, and systemic vascular resistance were small and variable. These trials measured hemodynamic effects again at 12 to 14 weeks. Carvedilol significantly reduced systemic blood pressure, pulmonary artery pressure, right atrial pressure, systemic vascular resistance, and heart rate, while stroke volume index was increased. Among 839 subjects with NYHA class II to III heart failure treated for 26 to 52 weeks in 4 U.S. placebo-controlled trials, average left ventricular ejection fraction (EF) measured by radionuclide ventriculography increased by 9 EF units (%) in subjects receiving carvedilol and by 2 EF units in placebo subjects at a target dose of 25 to 50 mg twice daily. The effects of carvedilol on ejection fraction were related to dose. Doses of 6.25 mg twice daily, 12.5 mg twice daily, and 25 mg twice daily were associated with placebo-corrected increases in EF of 5 EF units, 6 EF units, and 8 EF units, respectively; each of these effects were nominally statistically significant. Left Ventricular Dysfunction following Myocardial Infarction The basis for the beneficial effects of carvedilol in patients with left ventricular dysfunction following an acute myocardial infarction is not established. Hypertension The mechanism by which \u03b2-blockade produces an antihypertensive effect has not been established. \u03b2-adrenoreceptor blocking activity has been demonstrated in animal and human studies showing that carvedilol (1) reduces cardiac output in normal subjects, (2) reduces exercise- and/or isoproterenol-induced tachycardia, and (3) reduces reflex orthostatic tachycardia. Significant \u03b2-adrenoreceptor blocking effect is usually seen within 1 hour of drug administration. \u03b1 1 -adrenoreceptor blocking activity has been demonstrated in human and animal studies, showing that carvedilol (1) attenuates the pressor effects of phenylephrine, (2) causes vasodilation, and (3) reduces peripheral vascular resistance. These effects contribute to the reduction of blood pressure and usually are seen within 30 minutes of drug administration. Due to the \u03b1 1 -receptor blocking activity of carvedilol, blood pressure is lowered more in the standing than in the supine position, and symptoms of postural hypotension (1.8%), including rare instances of syncope, can occur. Following oral administration, when postural hypotension has occurred, it has been transient and is uncommon when carvedilol is administered with food at the recommended starting dose and titration increments are closely followed [see Dosage and Administration (2) ] . In hypertensive patients with normal renal function, therapeutic doses of carvedilol decreased renal vascular resistance with no change in glomerular filtration rate or renal plasma flow. Changes in excretion of sodium, potassium, uric acid, and phosphorus in hypertensive patients with normal renal function were similar after carvedilol and placebo. Carvedilol has little effect on plasma catecholamines, plasma aldosterone, or electrolyte levels, but it does significantly reduce plasma renin activity when given for at least 4 weeks. It also increases levels of atrial natriuretic peptide."
      },
      {
        "code": "43682-4",
        "type": "PHARMACOKINETICS SECTION",
        "title": "12.3 Pharmacokinetics",
        "content": "Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism. Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours. Plasma concentrations achieved are proportional to the oral dose administered. When administered with food, the rate of absorption is slowed, as evidenced by a delay in the time to reach peak plasma levels, with no significant difference in extent of bioavailability. Taking carvedilol with food should minimize the risk of orthostatic hypotension. Carvedilol is extensively metabolized. Following oral administration of radiolabelled carvedilol to healthy volunteers, carvedilol accounted for only about 7% of the total radioactivity in plasma as measured by area under the curve (AUC). Less than 2% of the dose was excreted unchanged in the urine. Carvedilol is metabolized primarily by aromatic ring oxidation and glucuronidation. The oxidative metabolites are further metabolized by conjugation via glucuronidation and sulfation. The metabolites of carvedilol are excreted primarily via the bile into the feces. Demethylation and hydroxylation at the phenol ring produce 3 active metabolites with \u03b2-receptor blocking activity. Based on preclinical studies, the 4'-hydroxyphenyl metabolite is approximately 13 times more potent than carvedilol for \u03b2-blockade. Compared with carvedilol, the 3 active metabolites exhibit weak vasodilating activity. Plasma concentrations of the active metabolites are about one-tenth of those observed for carvedilol and have pharmacokinetics similar to the parent. Carvedilol undergoes stereoselective first-pass metabolism with plasma levels of R(+)-carvedilol approximately 2 to 3 times higher than S(-)-carvedilol following oral administration in healthy subjects. The mean apparent terminal elimination half-lives for R(+)-carvedilol range from 5 to 9 hours compared with 7 to 11 hours for the S(-)-enantiomer. The primary P450 enzymes responsible for the metabolism of both R(+) and S(-)-carvedilol in human liver microsomes were CYP2D6 and CYP2C9 and to a lesser extent CYP3A4, 2C19, 1A2, and 2E1. CYP2D6 is thought to be the major enzyme in the 4\u2019- and 5\u2019-hydroxylation of carvedilol, with a potential contribution from 3A4. CYP2C9 is thought to be of primary importance in the O-methylation pathway of S(-)-carvedilol. Carvedilol is subject to the effects of genetic polymorphism with poor metabolizers of debrisoquin (a marker for cytochrome P450 2D6) exhibiting 2- to 3-fold higher plasma concentrations of R(+)-carvedilol compared with extensive metabolizers. In contrast, plasma levels of S(-)-carvedilol are increased only about 20% to 25% in poor metabolizers, indicating this enantiomer is metabolized to a lesser extent by cytochrome P450 2D6 than R(+)-carvedilol. The pharmacokinetics of carvedilol do not appear to be different in poor metabolizers of S-mephenytoin (patients deficient in cytochrome P450 2C19). Carvedilol is more than 98% bound to plasma proteins, primarily with albumin. The plasma-protein binding is independent of concentration over the therapeutic range. Carvedilol is a basic, lipophilic compound with a steady-state volume of distribution of approximately 115 L, indicating substantial distribution into extravascular tissues. Plasma clearance ranges from 500 to 700 mL/min."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "12.4 Specific Populations",
        "content": "Heart Failure Steady-state plasma concentrations of carvedilol and its enantiomers increased proportionally over the 6.25- to 50- mg dose range in subjects with heart failure. Compared with healthy subjects,\u00a0subjects with heart failure\u00a0had increased mean AUC and C max values for carvedilol and its enantiomers, with up to 50% to 100% higher values observed in 6 subjects with NYHA class IV heart failure. The mean apparent terminal elimination half-life for carvedilol was similar to that observed in healthy subjects. Geriatric Plasma levels of carvedilol average about 50% higher in the elderly compared with young subjects. Hepatic Impairment Compared with healthy subjects, patients with severe liver impairment (cirrhosis) exhibit a 4- to 7-fold increase in carvedilol levels. Carvedilol is contraindicated in patients with severe liver impairment. Renal Impairment Although carvedilol is metabolized primarily by the liver, plasma concentrations of carvedilol have been reported to be increased in patients with renal impairment. Based on mean AUC data, approximately 40% to 50% higher plasma concentrations of carvedilol were observed in subjects with hypertension and moderate to severe renal impairment compared with a control group of\u00a0subjects with hypertension and normal renal function. However, the ranges of AUC values were similar for both groups. Changes in mean peak plasma levels were less pronounced, approximately 12% to 26% higher in subjects with impaired renal function. Consistent with its high degree of plasma protein-binding, carvedilol does not appear to be cleared significantly by hemodialysis."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "12.5 Drug-Drug Interactions",
        "content": "Since carvedilol undergoes substantial oxidative metabolism, the metabolism and pharmacokinetics of carvedilol may be affected by induction or inhibition of cytochrome P450 enzymes. Amiodarone In a pharmacokinetic trial conducted in 106 Japanese subjects with heart failure, coadministration of small loading and maintenance doses of amiodarone with carvedilol resulted in at least a 2-fold increase in the steady-state trough concentrations of \u00a0S(-)-carvedilol [see Drug Interactions (7.6) ] . Cimetidine In a pharmacokinetic trial conducted in 10 healthy male subjects, cimetidine \u00a0\u00a0(1,000 mg per day) increased the steady-state AUC of carvedilol by 30% with no change in C max [see Drug Interactions (7.5) ] . Digoxin Following concomitant administration of carvedilol (25 mg once daily) and digoxin (0.25 mg once daily) for 14 days, steady-state AUC and trough concentrations of digoxin were increased by 14% and 16%, respectively, in 12\u00a0subjects with hypertension [see Drug Interactions (7.4) ] . Glyburide In 12 healthy subjects, combined administration of carvedilol (25 mg once daily) and a single dose of glyburide did not result in a clinically relevant pharmacokinetic interaction for either compound. Hydrochlorothiazide A single oral dose of carvedilol 25 mg did not alter the pharmacokinetics of a single oral dose of hydrochlorothiazide 25 mg in 12 subjects with hypertension. Likewise, hydrochlorothiazide had no effect on the pharmacokinetics of carvedilol. Rifampin In a pharmacokinetic trial conducted in 8 healthy male subjects, rifampin (600 mg daily for 12 days) decreased the AUC and C max of carvedilol by about 70% [see Drug Interactions (7.5) ] . Torsemide In a trial of 12 healthy subjects, combined oral administration of carvedilol 25 mg once daily and torsemide 5 mg once daily for 5 days did not result in any significant differences in their pharmacokinetics compared with administration of the drugs alone. Warfarin Carvedilol (12.5 mg twice daily) did not have an effect on the steady-state prothrombin time ratios and did not alter the pharmacokinetics of R(+)- and S(-)-warfarin following concomitant administration with warfarin in 9 healthy volunteers."
      },
      {
        "code": "43680-8",
        "type": "NONCLINICAL TOXICOLOGY SECTION",
        "title": "13 NONCLINICAL TOXICOLOGY"
      },
      {
        "code": "34083-6",
        "type": "CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION",
        "title": "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility",
        "content": "In 2-year studies conducted in rats given carvedilol at doses up to 75 mg per kg per day (12 times the MRHD as mg per m 2 ) or in mice given up to 200 mg per kg per day (16 times the MRHD as mg per m 2 ), carvedilol had no carcinogenic effect. Carvedilol was negative when tested in a battery of genotoxicity assays, including the Ames and the CHO/HGPRT assays for mutagenicity and the in vitro hamster micronucleus and in vivo human lymphocyte cell tests for clastogenicity. In a combined fertility/developmental/post-natal toxicity study, rats were given carvedilol (12, 60, 300 mg per kg per day) orally by gavage for 2 weeks before mating and through mating, gestation, and weaning for females and for 62 days prior to and through mating for males. At a dosage of 300 mg per kg per day (greater than or equal to 50 times the MRHD as mg per m 2 ) carvedilol was toxic to adult rats (sedation, reduced weight gain) and was associated with a reduced number of successful matings, prolonged mating time, fewer corpora lutea and implants per dam, fewer live pups per litter, and delays in physical growth/development. The no-effect level for overt toxicity and impairment of fertility was 60 mg per kg per day (10 times the MRHD as mg per m 2 )."
      },
      {
        "code": "34092-7",
        "type": "CLINICAL STUDIES SECTION",
        "title": "14 CLINICAL STUDIES"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "14.1 Heart Failure",
        "content": "A total of 6,975 subjects with mild-to-severe heart failure were evaluated in placebo-controlled trials of carvedilol. Mild-to-Moderate Heart Failure Carvedilol was studied in 5 multicenter, placebo-controlled trials, and in 1 active-controlled trial (COMET trial) involving subjects with mild-to-moderate heart failure. Four U.S. multicenter, double-blind, placebo-controlled trials enrolled 1,094 subjects (696 randomized to carvedilol) with NYHA class II to III heart failure and ejection fraction less than or equal to 0.35. The vast majority were on digitalis, diuretics, and an ACE inhibitor at trial entry. Patients were assigned to the trials based upon exercise ability. An Australia-New Zealand double-blind, placebo-controlled trial enrolled 415 subjects (half randomized to carvedilol) with less severe heart failure. All protocols excluded subjects expected to undergo cardiac transplantation during the 7.5 to 15 months of double-blind follow-up. All randomized subjects had tolerated a 2-week course on carvedilol 6.25 mg twice daily. In each trial, there was a primary end point, either progression of heart failure (1 U.S. trial) or exercise tolerance (2 U.S. trials meeting enrollment goals and the Australia-New Zealand trial). There were many secondary end points specified in these trials, including NYHA classification, patient and physician global assessments, and cardiovascular hospitalization. Other analyses not prospectively planned included the sum of deaths and total cardiovascular hospitalizations. In situations where the primary end points of a trial do not show a significant benefit of treatment, assignment of significance values to the other results is complex, and such values need to be interpreted cautiously. The results of the U.S. and Australia-New Zealand trials were as follows: Slowing Progression of Heart Failure : One U.S. multicenter trial (366 subjects) had as its primary end point the sum of cardiovascular mortality, cardiovascular hospitalization, and sustained increase in heart failure medications. Heart failure progression was reduced, during an average follow-up of 7 months, by 48% ( P = 0.008). In the Australia-New Zealand trial, death and total hospitalizations were reduced by about 25% over 18 to 24 months. In the 3 largest U.S. trials, death and total hospitalizations were reduced by 19%, 39%, and 49%, nominally statistically significant in the last 2 trials. The Australia-New Zealand results were statistically borderline. Functional Measures: None of the multicenter trials had NYHA classification as a primary end point, but all such trials had it as a secondary end point. There was at least a trend toward improvement in NYHA class in all trials. Exercise tolerance was the primary end point in 3 trials; in none was a statistically significant effect found. Subjective Measures : Health-related quality of life, as measured with a standard questionnaire (a primary end point in 1 trial), was unaffected by carvedilol. However, patients\u2019 and investigators\u2019 global assessments showed significant improvement in most trials. Mortality : Death was not a pre-specified end point in any trial, but was analyzed in all trials. Overall, in these 4 U.S. trials, mortality was reduced, nominally significantly so in 2 trials. The COMET Trial In this double-blind trial, 3,029 subjects with NYHA class II to IV heart failure (left ventricular ejection fraction less than or equal to 35%) were randomized to receive either carvedilol (target dose: 25 mg twice daily) or immediate-release metoprolol tartrate (target dose: 50 mg twice daily). The mean age of the subjects was approximately 62 years, 80% were males, and the mean left ventricular ejection fraction at baseline was 26%. Approximately 96% of the subjects had NYHA class II or III heart failure. Concomitant treatment included diuretics (99%), ACE inhibitors (91%), digitalis (59%), aldosterone antagonists (11%), and \u201cstatin\u201d lipid-lowering agents (21%). The mean duration of follow-up was 4.8 years. The mean dose of carvedilol was 42 mg per day. The trial had 2 primary end points: all-cause mortality and the composite of death plus hospitalization for any reason. The results of COMET are presented in Table 3 below. All-cause mortality carried most of the statistical weight and was the primary determinant of the trial size. All-cause mortality was 34% in the subjects treated with carvedilol and was 40% in the immediate-release metoprolol group ( P = 0.0017; hazard ratio = 0.83, 95% CI: 0.74 to 0.93). The effect on mortality was primarily due to a reduction in cardiovascular death. The difference between the 2 groups with respect to the composite end point was not significant ( P = 0.122). The estimated mean survival was 8 years with carvedilol and 6.6 years with immediate-release metoprolol. Table 3. Results of COMET End Point Carvedilol n\u00a0= 1,511 Metoprolol n\u00a0= 1,518 Hazard Ratio (95% CI) All-cause mortality 34% 40% 0.83 0.74 \u2013 0.93 Mortality + all hospitalization 74% 76% 0.94 0.86 \u2013 1.02 Cardiovascular death 30% 35% 0.8 0.7 \u2013 0.9 Sudden death Death due to circulatory failure Death due to stroke 14% 11% 0.9% 17% 13% 2.5% 0.81 0.83 0.33 0.68 \u2013 0.97 0.67 \u2013 1.02 0.18 \u2013 0.62 It is not known whether this formulation of metoprolol at any dose or this low dose of metoprolol in any formulation has any effect on survival or hospitalization in patients with heart failure. Thus, this trial extends the time over which carvedilol manifests benefits on survival in heart failure, but it is not evidence that carvedilol improves outcome over the formulation of metoprolol (TOPROL-XL) with benefits in heart failure. Severe Heart Failure (COPERNICUS) In a double-blind trial (COPERNICUS), 2,289 subjects with heart failure at rest or with minimal exertion and left ventricular ejection fraction less than 25% (mean 20%), despite digitalis (66%), diuretics (99%), and ACE inhibitors (89%), were randomized to placebo or carvedilol. Carvedilol was titrated from a starting dose of 3.125 mg twice daily to the maximum tolerated dose or up to 25 mg twice daily over a minimum of 6 weeks. Most subjects achieved the target dose of 25 mg. The trial was conducted in Eastern and Western Europe, the United States, Israel, and Canada. Similar numbers of subjects per group (about 100) withdrew during the titration period. The primary end point of the trial was all-cause mortality, but cause-specific mortality and the risk of death or hospitalization (total, cardiovascular [CV], or heart failure [HF]) were also examined. The developing trial data were followed by a data monitoring committee, and mortality analyses were adjusted for these multiple looks. The trial was stopped after a median follow-up of 10 months because of an observed 35% reduction in mortality (from 19.7% per patient-year on placebo to 12.8% on carvedilol; hazard ratio 0.65, 95% CI: 0.52 to 0.81, P = 0.0014, adjusted) (see Figure 1). The results of COPERNICUS are shown in Table 4. Table 4. Results of COPERNICUS Trial in Subjects with Severe Heart Failure End Point Placebo (n = 1,133) Carvedilol (n = 1,156) Hazard Ratio (95% CI) % Reduction Nominal P value Mortality 190 130 0.65 (0.52 \u2013 0.81) 35 0.00013 Mortality + all hospitalization 507 425 0.76 (0.67 \u2013 0.87) 24 0.00004 Mortality + CV hospitalization 395 314 0.73 (0.63 \u2013 0.84) 27 0.00002 Mortality + HF hospitalization 357 271 0.69 (0.59 \u2013 0.81) 31 0.000004 Cardiovascular = CV; Heart failure = HF. The effect on mortality was principally the result of a reduction in the rate of sudden death among subjects without worsening heart failure. Patients' global assessments, in which carvedilol-treated subjects were compared with placebo, were based on pre-specified, periodic patient self-assessments regarding whether clinical status post-treatment showed improvement, worsening, or no change compared with baseline. Subjects treated with carvedilol showed significant improvements in global assessments compared with those treated with placebo in COPERNICUS. The protocol also specified that hospitalizations would be assessed. Fewer subjects on carvedilol than on placebo were hospitalized for any reason (372 versus 432, P = 0.0029), for cardiovascular reasons (246 versus 314, P = 0.0003), or for worsening heart failure (198 versus 268, P = 0.0001). Carvedilol had a consistent and beneficial effect on all-cause mortality as well as the combined end points of all-cause mortality plus hospitalization (total, CV, or for heart failure) in the overall trial population and in all subgroups examined, including men and women, elderly and non-elderly, blacks and non-blacks, and diabetics and non-diabetics (see Figure 2)."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "14.2 Left Ventricular Dysfunction following Myocardial Infarction",
        "content": "CAPRICORN was a double-blind\u00a0trial comparing carvedilol and placebo in 1,959\u00a0subjects with a recent myocardial infarction (within 21 days) and left ventricular ejection fraction of less than or equal to 40%, with (47%) or without symptoms of heart failure.\u00a0Subjects given carvedilol received 6.25 mg twice daily, titrated as tolerated to 25 mg twice daily.\u00a0Subjects had to have a systolic blood pressure greater than 90 mm Hg, a sitting heart rate greater than 60 beats per minute, and no contraindication to \u03b2-blocker use. Treatment of the index infarction included aspirin (85%), IV or oral \u03b2-blockers (37%), nitrates (73%), heparin (64%), thrombolytics (40%), and acute angioplasty (12%). Background treatment included ACE inhibitors or angiotensin-receptor blockers (97%), anticoagulants (20%), lipid-lowering agents (23%), and diuretics (34%). Baseline population characteristics included an average age of 63 years, 74% male, 95% Caucasian, mean blood pressure 121/74 mm Hg, 22% with diabetes, and 54% with a history of hypertension. Mean dosage achieved of carvedilol was 20 mg twice daily; mean duration of follow-up was 15 months. All-cause mortality was 15% in the placebo group and 12% in the carvedilol group, indicating a 23% risk reduction in\u00a0subjects treated with carvedilol (95% CI: 2% to 40%, P = 0.03), as shown in Figure 3. The effects on mortality in various subgroups are shown in Figure 4. Nearly all deaths were cardiovascular (which were reduced by 25% by carvedilol), and most of these deaths were sudden or related to pump failure (both types of death were reduced by carvedilol). Another\u00a0trial end point, total mortality and all-cause hospitalization, did not show a significant improvement. There was also a significant 40% reduction in fatal or non-fatal myocardial infarction observed in the group treated with carvedilol (95% CI: 11% to 60%, P = 0.01). A similar reduction in the risk of myocardial infarction was also observed in a meta-analysis of placebo-controlled trials of carvedilol in heart failure."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "14.3 Hypertension",
        "content": "Carvedilol was studied in 2 placebo-controlled trials that utilized twice-daily dosing at total daily doses of 12.5 to 50 mg. In these and other trials, the starting dose did not exceed \u00a0\u00a012.5 mg. At 50 mg per day, carvedilol reduced sitting trough (12-hour) blood pressure by about 9/5.5 mm Hg; at 25 mg per day the effect was about 7.5/3.5 mm Hg. Comparisons of trough-to-peak blood pressure showed a trough-to-peak ratio for blood pressure response of about 65%. Heart rate fell by about 7.5 beats per minute at 50 mg per day. In general, as is true for other \u03b2-blockers, responses were smaller in black than non-black subjects. There were no age- or gender-related differences in response. The peak antihypertensive effect occurred 1 to 2 hours after a dose. The dose-related blood pressure response was accompanied by a dose-related increase in adverse effects [see Adverse Reactions (6) ] ."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "14.4 Hypertension with Type 2 Diabetes Mellitus",
        "content": "In a double-blind trial (GEMINI), carvedilol, added to an ACE inhibitor or angiotensin-receptor blocker, was evaluated in a population with mild-to-moderate hypertension and well-controlled type 2 diabetes mellitus. The mean HbA1c at baseline was 7.2%. Carvedilol was titrated to a mean dose of 17.5 mg twice daily and maintained for 5 months. Carvedilol had no adverse effect on glycemic control, based on HbA1c measurements (mean change from baseline of 0.02%, 95% CI: -0.06 to 0.1, P = NS) [see Warnings and Precautions (5.6) ]."
      },
      {
        "code": "34069-5",
        "type": "HOW SUPPLIED SECTION",
        "title": "16 HOW SUPPLIED/STORAGE AND HANDLING",
        "content": "Carvedilol Tablets USP, 12.5 mg are white to off-white, oval shaped, film-coated tablets debossed with \u2018E\u2019 on one side and \u201803\u2019 on the other side. Bottles of 90  NDC   43063-125-90 Bottles of 180  NDC 43063-125-93 Store at 20 to 25\u00b0C (68 to 77\u00b0F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container. ."
      },
      {
        "code": "34076-0",
        "type": "INFORMATION FOR PATIENTS SECTION",
        "title": "17 PATIENT COUNSELING INFORMATION",
        "content": "Advise the patient to read the FDA-approved patient labeling (Patient Information). Patients taking carvedilol should be advised of the following: Patients should take carvedilol with food. Patients should not interrupt or discontinue using carvedilol without a physician\u2019s advice. Patients with heart failure should consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath. Patients may experience a drop in blood pressure when standing, resulting in dizziness and, rarely, fainting. Patients should sit or lie down when these symptoms of lowered blood pressure occur. If experiencing dizziness or fatigue, patients should avoid driving or hazardous tasks. Patients should consult a physician if they experience dizziness or faintness, in case the dosage should be adjusted. Inform patients or caregivers that there is a risk of hypoglycemia when carvedilol is given to patients who are fasting or who are vomiting. Instruct patients or caregivers how to monitor for syns of hypoglycemia [see Warnings and Precautions (5.6) ]. Contact lens wearers may experience decreased lacrimation."
      },
      {
        "code": "42230-3",
        "type": "SPL PATIENT PACKAGE INSERT SECTION",
        "title": "PATIENT INFORMATION",
        "content": "Carvedilol Tablets, USP (kar' ve dil'' ol) Read the Patient Information that comes with carvedilol tablets before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about carvedilol tablets, ask your doctor or pharmacist. What are carvedilol tablets? Carvedilol tablets are a prescription medicine that belongs to a group of medicines called \u201cbeta-blockers\u201d. Carvedilol tablets are used, often with other medicines, for the following conditions: to treat patients with certain types of heart failure to treat patients who had a heart attack that worsened how well the heart pumps to treat patients with high blood pressure (hypertension) Carvedilol tablets are not approved for use in children under 18 years of age. Who should not take carvedilol tablets? Do not take carvedilol tablets if you: have severe heart failure and are hospitalized in the intensive care unit or require certain intravenous medications that help support circulation (inotropic medications). are prone to asthma or other breathing problems. have a slow heartbeat or a heart that skips a beat (irregular heartbeat). have liver problems. are allergic to any of the ingredients in carvedilol tablets. The active ingredient is carvedilol. See the end of this leaflet for a list of all the ingredients in carvedilol tablets. What should I tell my doctor before taking carvedilol tablets? Tell your doctor about all of your medical conditions, including if you: have asthma or other lung problems (such as bronchitis or emphysema). have problems with blood flow in your feet and legs (peripheral vascular disease). Carvedilol tablets can make some of your symptoms worse. have diabetes. have thyroid problems. have a condition called pheochromocytoma. have had severe allergic reactions. are pregnant or trying to become pregnant. It is not known if carvedilol tablets are safe for your unborn baby. You and your doctor should talk about the best way to control your high blood pressure during pregnancy. are breastfeeding. It is not known if carvedilol passes into your breast milk. Talk with your doctor\u00a0about the best way to feed your baby if you are taking\u00a0carvedilol tablets. are scheduled for surgery and will be given anesthetic agents. are scheduled for cataract surgery and have taken or are currently taking carvedilol tablets. are taking prescription or\u00a0over-the-counter\u00a0medicines, vitamins, and herbal supplements. Carvedilol tablets and certain other medicines can affect each other and cause serious side effects. Carvedilol tablets may affect the way other medicines work. Also, other medicines may affect how well carvedilol tablets work. Keep a list of all the medicines you take. Show this list to your doctor and pharmacist before you start a new medicine. How should I take carvedilol tablets? It is important for you to take your medicine every day as directed by your doctor. If you stop taking carvedilol tablets suddenly, you could have chest pain and/or a heart attack.\u00a0 If your doctor decides that you should stop taking carvedilol tablets, your doctor may slowly lower your dose over a period of time before stopping it completely. Take carvedilol tablets exactly as prescribed. Your doctor will tell you how many tablets to take and how often. In order to minimize possible side effects, your doctor might begin with a low dose and then slowly increase the dose. Do not stop taking carvedilol tablets and do not change the amount of carvedilol tablets you take without talking to your doctor. Tell your doctor if you gain weight or have trouble breathing while taking carvedilol tablets. Take carvedilol tablets with food. If you miss a dose of carvedilol tablets, take your dose as soon as you remember, unless it is time to take your next dose. Take your next dose at the usual time. Do not take 2 doses at the same time. If you take too much carvedilol, call your doctor or poison control center right away. What should I avoid while taking carvedilol tablets? Carvedilol tablets can cause you to feel dizzy, tired, or faint. Do not drive a car, use machinery, or do anything that needs you to be alert if you have these symptoms. What are possible side effects of carvedilol tablets? Low blood pressure (which may cause dizziness or fainting when you stand up). If these happen, sit or lie down right away and tell your doctor. Tiredness. If you feel tired or dizzy you should not drive, use machinery, or do anything that needs you to be alert. Slow heartbeat. Changes in your blood sugar. If you have diabetes, tell your doctor if you have any changes in your blood sugar levels. Carvedilol tablets may hide some of the symptoms of low blood sugar, especially a fast heartbeat. Carvedilol tablets may mask the symptoms of hyperthyroidism (overactive thyroid). Worsening of severe allergic reactions. Rare but serious allergic reactions (including hives or swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing) have happened in patients who were on carvedilol tablets. These reactions can be life-threatening. Other side effects of carvedilol tablets include shortness of breath, weight gain, diarrhea, and fewer tears or dry eyes that become bothersome if you wear contact lenses. Call your doctor if you have any side effects that bother you or don\u2019t go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store carvedilol tablets? Store carvedilol tablets at 20 to 25\u00b0C (68 to 77\u00b0F). Keep the tablets dry. Safely, throw away carvedilol tablets that are out of date or no longer needed. Keep carvedilol tablets and all medicines out of the reach of children. General Information about carvedilol tablets Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use carvedilol tablets for a condition for which it was not prescribed. Do not give carvedilol tablets to other people, even if they have the same symptoms you have. It may harm them. This leaflet summarizes the most important information about carvedilol tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about carvedilol tablets that is written for healthcare professionals. What are the ingredients in carvedilol tablets? Active Ingredient: Carvedilol. Inactive Ingredients: lactose monohydrate, colloidal silicon dioxide, crospovidone, povidone, sucrose, magnesium stearate, polyethylene glycol 400, polysorbate 80, titanium dioxide, and hypromellose. Carvedilol tablets come in the following strengths: 3.125 mg, 6.25 mg, 12.5 mg,\u00a025 mg. What is high blood pressure (hypertension)? Blood pressure is the force of blood in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. High blood pressure makes the heart work harder to pump blood through the body and causes damage to blood vessels. Carvedilol tablets can help your blood vessels relax so your blood pressure is lower. Medicines that lower blood pressure may lower your chance of having a stroke or heart attack. The brands listed are trademarks of their respective owners and are not trademarks of Aurobindo Pharma Limited. Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 08/2023"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 12.5 mg",
        "content": "Rx only Carvedilol Tablets, USP 12.5 mg"
      }
    ],
    "category": "Prescription"
  },
  {
    "filename": "prescription_4221a53d-0185-7219-e063-6394a90a7ff7.xml",
    "document_id": "4221a53d-0185-7219-e063-6394a90a7ff7",
    "document_type": "HUMAN PRESCRIPTION DRUG LABEL",
    "title": "Oxycodone and Acetaminophen Tablets USP CII\n ",
    "effective_date": "20251028",
    "version": "18",
    "author": {
      "name": "Granules Pharmaceuticals Inc.",
      "id": "079825711"
    },
    "product": {
      "ndc": "70010-667",
      "name": "Oxycodone and Acetaminophen",
      "form": "TABLET",
      "generic_name": "Oxycodone and Acetaminophen",
      "active_ingredients": [
        {
          "name": "ACETAMINOPHEN",
          "code": "362O9ITL9D",
          "strength": "325 mg",
          "per": "1 1"
        },
        {
          "name": "OXYCODONE HYDROCHLORIDE",
          "code": "C1ENJ2TE6C",
          "strength": "2.5 mg",
          "per": "1 1"
        }
      ],
      "inactive_ingredients": [
        "SODIUM STARCH GLYCOLATE TYPE A POTATO",
        "POVIDONE K30",
        "STARCH, CORN",
        "STEARIC ACID",
        "SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY)",
        "CROSPOVIDONE"
      ],
      "packaging": [
        {
          "quantity": "100 1",
          "ndc": "70010-667-01",
          "container": "BOTTLE"
        },
        {
          "quantity": "500 1",
          "ndc": "70010-667-05",
          "container": "BOTTLE"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20220101",
      "approval_status": "ANDA",
      "color": "white",
      "shape": "ROUND",
      "size": "11 mm",
      "imprint": "10;670"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "34066-1",
        "type": "BOXED WARNING SECTION",
        "content": "WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of Oxycodone and Acetaminophen Tablet exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient\u2019s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see WARNINGS ]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Oxycodone and Acetaminophen Tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Oxycodone and Acetaminophen Tablets are essential [see WARNINGS ]. Accidental Ingestion Accidental ingestion of even one dose of Oxycodone and Acetaminophen Tablets, especially by children, can result in a fatal overdose of Oxycodone [see WARNINGS ]. Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of Oxycodone and Acetaminophen Tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see WARNINGS , PRECAUTIONS ; Drug Interactions ]. Neonatal Opioid Withdrawal Syndrome (NOWS) Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome,  which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see WARNINGS ]. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see WARNINGS ]. Cytochrome P450 3A4 Interaction The concomitant use of Oxycodone and Acetaminophen Tablets with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving Oxycodone and Acetaminophen Tablets and any CYP3A4 inhibitor or inducer [see CLINICAL PHARMACOLOGY , WARNINGS , PRECAUTIONS ; Drug Interactions ]. Hepatotoxicity Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product."
      },
      {
        "code": "34089-3",
        "type": "DESCRIPTION SECTION",
        "title": "\n                  ",
        "content": "Oxycodone Hydrochloride and Acetaminophen is available in tablets for oral administration. Each tablet for oral administration, contains oxycodone hydrochloride and acetaminophen in the following strengths: Oxycodone Hydrochloride, USP 2.5 mg* (*2.5 mg oxycodone hydrochloride is equivalent to 2.2409 mg of oxycodone.) Acetaminophen, USP 325 mg Oxycodone Hydrochloride, USP 5 mg* (*5 mg oxycodone hydrochloride is equivalent to 4.4815 mg of oxycodone.) Acetaminophen, USP 325 mg Oxycodone Hydrochloride, USP 7.5 mg* (*7.5 mg oxycodone hydrochloride is equivalent to 6.7228 mg of oxycodone.) Acetaminophen, USP 325 mg Oxycodone Hydrochloride, USP 10 mg* (*10 mg oxycodone hydrochloride is equivalent to 8.9637 mg of oxycodone.) Acetaminophen, USP 325 mg All strengths of Oxycodone and Acetaminophen Tablets, USP also contain the following inactive ingredients: crospovidone, povidone, pregelatinized maize starch, silicified microcrystalline cellulose, sodium starch glycolate, and stearic acid. Oxycodone and Acetaminophen Tablets, USP contain oxycodone, 14-hydroxydihydrocodeinone, a semisynthetic opioid analgesic which occurs as a white to off-white fine crystalline powder. The molecular formula for oxycodone hydrochloride is C 18 H 21 NO 4 \u2022 HCl and the molecular weight is 351.82. It is derived from the opium alkaloid, thebaine, and may be represented by the following structural formula: Oxycodone and Acetaminophen Tablets, USP contain acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder. The molecular formula for acetaminophen is C 8 H 9 NO 2 and the molecular weight is 151.16. It may be represented by the following structural formula:"
      },
      {
        "code": "34090-1",
        "type": "CLINICAL PHARMACOLOGY SECTION",
        "title": "\n                  ",
        "content": "NA"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Effects on the Central Nervous System Oxycodone produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation. Oxycodone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations. Therapeutic doses of acetaminophen have negligible effects on the cardiovascular or respiratory systems; however, toxic doses may cause circulatory failure and rapid, shallow breathing. Effects on the Gastrointestinal Tract and Other Smooth Muscle Oxycodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm, resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, transient elevations in serum amylase, and opioid-induced esophageal dysfunction (OIED). Effects on the Cardiovascular System Oxycodone produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension. Effects on the Endocrine System Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans [see ADVERSE REACTIONS ]. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon. Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [see ADVERSE REACTIONS ]. Effects on the Immune System Opioids have been shown to have a variety of effects on components of the immune system. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive. Concentration\u2013Efficacy Relationships The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with opioid agonists. The minimum effective analgesic concentration of oxycodone for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome, and/or the development of analgesic tolerance [see DOSAGE AND ADMINISTRATION ]. Concentration\u2013Adverse Reaction Relationships There is a relationship between increasing oxycodone plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions [see DOSAGE AND ADMINISTRATION ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Absorption and Distribution The mean absolute oral bioavailability of oxycodone in cancer patients was reported to be about 87%. Oxycodone has been shown to be 45% bound to human plasma proteins in vitro . The volume of distribution after intravenous administration is 211.9 \u00b1186.6 L. Absorption of acetaminophen is rapid and almost complete from the GI tract after oral administration. With overdosage, absorption is complete in 4 hours. Acetaminophen is relatively uniformly distributed throughout most body fluids. Binding of the drug to plasma proteins is variable; only 20% to 50% may be bound at the concentrations encountered during acute intoxication. Metabolism and Elimination Oxycodone In humans, oxycodone is extensively metabolized to noroxycodone by means of CYP3A-mediated N-demethylation, oxymorphone by means of CYP2D6-mediated O-demethylation, and their glucuronides [see PRECAUTIONS ; Drug Interactions ]. Acetaminophen Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. A small fraction (10 to 25%) of acetaminophen is bound to plasma proteins. The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Acetaminophen is primarily metabolized in the liver by first-order kinetics and involves three principal separate pathways: conjugation with glucuronide; conjugation with sulfate; and oxidation via the cytochrome, P450-dependent, mixed-function oxidase enzyme pathway to form a reactive intermediate metabolite, which conjugates with glutathione and is then further metabolized to form cysteine and mercapturic acid conjugates. The principal cytochrome P450 isoenzyme involved appears to be CYP2E1, with CYP1A2 and CYP3A4 as additional pathways. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug [see OVERDOSAGE ] for toxicity information."
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "\n                  ",
        "content": "Oxycodone and Acetaminophen Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use : \u2022 Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see WARNINGS ], reserve opioid analgesics, including Oxycodone and Acetaminophen Tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain."
      },
      {
        "code": "34070-3",
        "type": "CONTRAINDICATIONS SECTION",
        "title": "\n                  ",
        "content": "Oxycodone and Acetaminophen Tablets are contraindicated in patients with: \u2022 Significant respiratory depression [see WARNINGS ] \u2022 Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see WARNINGS ] \u2022 Known or suspected gastrointestinal obstruction, including paralytic ileus [see WARNINGS ] \u2022 Hypersensitivity to oxycodone, acetaminophen, or any other component of the product (e.g., anaphylaxis) [see WARNINGS , ADVERSE REACTIONS ]"
      },
      {
        "code": "34071-1",
        "type": "WARNINGS SECTION",
        "title": "\n                  ",
        "content": "NA"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Oxycodone and Acetaminophen Tablets contain oxycodone, a Schedule II controlled substance. As an opioid, Oxycodone and Acetaminophen Tablets expose users to the risks of addiction, abuse, and misuse [see DRUG ABUSE AND DEPENDENCE ]. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Oxycodone and Acetaminophen Tablets. Addiction can occur at recommended dosages and if the drug is misused or abused. The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy. In postmarketing studies, addiction, abuse, misuse, and fatal and non-fatal opioid overdose were observed in patients with long-term opioid use [see ADVERSE REACTIONS ]. Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing Oxycodone and Acetaminophen Tablets, and reassess all patients receiving Oxycodone and Acetaminophen Tablets for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as Oxycodone and Acetaminophen Tablets, but use in such patients necessitates intensive counseling about the risks and proper use of Oxycodone and Acetaminophen Tablets along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider recommending or prescribing an opioid overdose reversal agent [see WARNINGS , DOSAGE AND ADMINISTRATION ]. Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing Oxycodone and Acetaminophen Tablets. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid overdose reversal agents, depending on the patient's clinical status [see OVERDOSAGE ]. Carbon dioxide (CO 2 ) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of Oxycodone and Acetaminophen Tablets, the risk is greatest during the initiation of therapy or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Oxycodone and Acetaminophen Tablets are essential [see DOSAGE AND ADMINISTRATION ]. Overestimating the Oxycodone and Acetaminophen Tablets dosage when converting patients from another opioid product can result in a fatal overdose with the first dose. Accidental ingestion of Oxycodone and Acetaminophen Tablets, especially by children, can result in respiratory depression and death due to an overdose of Oxycodone and Acetaminophen Tablets. Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [ see PRECAUTIONS , Information for Patients/Caregivers ]. Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see DOSAGE AND ADMINISTRATION ]. Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose. The presence of risk factors for overdose should not prevent the management of pain in any patient [see WARNINGS ]. Discuss the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program). There are important differences among the opioid overdose reversal agents, such as route of administration, product strength, approved patient age range, and pharmacokinetics. Be familiar with these differences, as outlined in the approved labeling for those products, prior to recommending or prescribing such an agent. Educate patients and caregivers on how to recognize respiratory depression, and how to use an opioid overdose reversal agent for the emergency treatment of opioid overdose. Emphasize the importance of calling 911 or getting emergency medical help, even if an opioid overdose reversal agent is administered [see WARNINGS , OVERDOSAGE ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Oxycodone and Acetaminophen Tablets with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see PRECAUTIONS ; Drug Interactions ]. If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Monitor patients closely for signs and symptoms of respiratory depression and sedation. If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent [see WARNINGS , DOSAGE AND ADMINISTRATION , and OVERDOSAGE ]. Advise both patients and caregivers about the risks of respiratory depression and sedation when Oxycodone and Acetaminophen Tablets are used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Use of Oxycodone and Acetaminophen Tablets for an extended period of time during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for an extended period of time of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see PRECAUTIONS; Information for Patients/Caregivers, Pregnancy ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to do all of the following: Complete a REMS-compliant education program offered by an accredited provider of continuing education (CE) or another education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain. Discuss the safe use, serious risks, and proper storage and disposal of opioid analgesics with patients and/or their caregivers every time these medicines are prescribed. The Patient Counseling Guide (PCG) can be obtained at this link: www.fda.gov/OpioidAnalgesicREMSPCG. Emphasize to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an opioid analgesic is dispensed to them. Consider using other tools to improve patient, household, and community safety, such as patient-prescriber agreements that reinforce patient-prescriber responsibilities. To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 800-503-0784, or log on to www.opioidanalgesicrems.com . The FDA Blueprint can be found at www.fda.gov/OpioidAnalgesicREMSBlueprint ."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Concomitant use of Oxycodone and Acetaminophen Tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of oxycodone hydrochloride and prolong opioid adverse reactions, which may cause potentially fatal respiratory depression [see WARNINGS ], particularly when an inhibitor is added after a stable dose of Oxycodone and Acetaminophen Tablets is achieved. Similarly, discontinuation of a CYP3A4 inducer, such as rifampin, carbamazepine, and phenytoin, in Oxycodone and Acetaminophen Tablets-treated patients may increase oxycodone plasma concentrations and prolong opioid adverse reactions. When using Oxycodone and Acetaminophen Tablets with CYP3A4 inhibitors or discontinuing CYP3A4 inducers in Oxycodone and Acetaminophen Tablets-treated patients, evaluate patients at frequent intervals and consider dosage reduction of Oxycodone and Acetaminophen Tablets until stable drug effects are achieved [see PRECAUTIONS ; Drug Interactions ]. Concomitant use of Oxycodone and Acetaminophen Tablets with CYP3A4 inducers or discontinuation of an CYP3A4 inhibitor could decrease oxycodone hydrochloride plasma concentrations, decrease opioid efficacy or, possibly, lead to a withdrawal syndrome in a patient who had developed physical dependence to oxycodone hydrochloride. When using Oxycodone and Acetaminophen Tablets with CYP3A4 inducers or discontinuing CYP3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur [see PRECAUTIONS ; Drug Interactions ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products. The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen. Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect [see DEPENDENCE ]. Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior. Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics. Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated. Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia. If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety) [see DOSAGE AND ADMINISTRATION , WARNINGS ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "The use of Oxycodone and Acetaminophen Tablets in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated. Patients with Chronic Pulmonary Disease : Oxycodone and Acetaminophen Tablets-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Oxycodone and Acetaminophen Tablets [see WARNINGS ; Life Threatening Respiratory Depression ]. Elderly Cachectic, or Debilitated Patients : Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see WARNINGS ; Life Threatening Respiratory Depression ]. Monitor such patients closely, particularly when initiating and titrating Oxycodone and Acetaminophen Tablets and when Oxycodone and Acetaminophen Tablets are given concomitantly with other drugs that depress respiration [see WARNINGS ; Life-Threatening Respiratory Depression ]. Alternatively, consider the use of non-opioid analgesics in these patients."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Oxycodone and Acetaminophen Tablets may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [see PRECAUTIONS ; Drug Interactions ]. Regularly evaluate these patients for signs of hypotension after initiating or titrating the dosage of Oxycodone and Acetaminophen Tablets. In patients with circulatory shock Oxycodone and Acetaminophen Tablets may cause vasodilatation that can further reduce cardiac output and blood pressure. Avoid the use of Oxycodone and Acetaminophen Tablets with circulatory shock."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue Oxycodone and Acetaminophen Tablets immediately and seek medical care if they experience these symptoms. Do not prescribe Oxycodone and Acetaminophen Tablets for patients with acetaminophen allergy [see PRECAUTIONS; Information for Patients/Caregivers ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "In patients who may be susceptible to the intracranial effects of CO 2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), Oxycodone and Acetaminophen Tablets may reduce respiratory drive, and the resultant CO 2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with Oxycodone and Acetaminophen Tablets. Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of Oxycodone and Acetaminophen Tablets in patients with impaired consciousness or coma."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Oxycodone and Acetaminophen Tablets are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus. The administration of Oxycodone and Acetaminophen Tablets, or other opioids may obscure the diagnosis or clinical course in patients with acute abdominal conditions. The oxycodone in Oxycodone and Acetaminophen Tablets may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms. Cases of opioid-induced esophageal dysfunction (OIED) have been reported in patients taking opioids. The risk of OIED may increase as the dose and/or duration of opioids increases. Regularly evaluate patients for signs and symptoms of OIED (e.g., dysphagia, regurgitation, non-cardiac chest pain), and, if necessary, adjust opioid therapy as clinically appropriate [see CLINICAL PHARMACOLOGY ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "The oxycodone in Oxycodone and Acetaminophen Tablets may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Regularly evaluate patients with a history of seizure disorders for worsened seizure control during Oxycodone and Acetaminophen Tablets therapy."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Do not rapidly reduce or abruptly discontinue Oxycodone and Acetaminophen Tablets in a patient physically dependent on opioids. When discontinuing Oxycodone and Acetaminophen Tablets in a physically dependent patient, gradually taper the dosage. Rapid tapering of Oxycodone and Acetaminophen Tablets in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain [see DOSAGE AND ADMINISTRATION , DRUG ABUSE AND DEPENDENCE ]. Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including Oxycodone and Acetaminophen Tablets. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms [see PRECAUTIONS / Drug Interactions ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Oxycodone and Acetaminophen Tablets may impair the mental or physical abilities needed to perform potentially hazardous   activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of Oxycodone and Acetaminophen Tablets and know how they will react to the medication [see PRECAUTIONS; Information for Patients/Caregivers ]."
      },
      {
        "code": "42232-9",
        "type": "PRECAUTIONS SECTION",
        "title": "\n                  ",
        "content": "NA"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Advise the patient to read the FDA-approved patient labeling (Medication Guide). Storage and Disposal: Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store Oxycodone and Acetaminophen Tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Inform patients that leaving Oxycodone and Acetaminophen Tablets unsecured can pose a deadly risk to others in the home [see WARNINGS , DRUG ABUSE AND DEPENDENCE ]. Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Expired, unwanted, or unused Oxycodone and Acetaminophen Tablets should be disposed of by flushing the unused medication down the toilet if a drug take-back option is not readily available. Inform patients that they can visit www.fda.gov/drugdisposal for a complete list of medicines recommended for disposal by flushing, as well as additional information on disposal of unused medicines. Addiction, Abuse, and Misuse Inform patients that the use of Oxycodone and Acetaminophen Tablets, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [see WARNINGS ]. Instruct patients not to share oxycodone and acetaminophen tablets with others and to take steps to protect oxycodone and acetaminophen tablets from theft or misuse. Life-Threatening Respiratory Depression Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting Oxycodone and Acetaminophen Tablets or when the dosage is increased, and that it can occur even at recommended dosages. Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see WARNINGS, Life Threatening Respiratory Depression ]. Accidental Ingestion Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death [see WARNINGS ]. Interactions with Benzodiazepines and Other CNS Depressants Inform patients and caregivers that potentially fatal additive effects may occur if Oxycodone and Acetaminophen Tablets are used with benzodiazepines and other CNS depressants, including alcohol (e.g., non-benzodiazepine, sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids), and not to use these concomitantly unless supervised by a health care provider [see WARNINGS , PRECAUTIONS ; Drug Interactions ]. Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose. Discuss with the patient the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program) [see WARNINGS , DOSAGE AND ADMINISTRATION ]. Educate patients and caregivers on how to recognize the signs and symptoms of an overdose. Explain to patients and caregivers that effects of opioid overdose reversal agents like naloxone and nalmefene are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if an opioid overdose reversal agent is administered [see OVERDOSAGE ]. Advise patients and caregivers: \u2022 how to treat with the overdose reversal agent in the event of an opioid overdose \u2022 to tell family and friends about the opioid overdose reversal agent, and to keep it in a place where family and friends can access it in an emergency \u2022 to read the Patient Information (or other educational material) that will come with their opioid overdose reversal agent. Emphasize the importance of doing this before an opioid emergency happens, so the patient and caregiver will know what to do. Hyperalgesia and Allodynia Inform patients and caregivers not to increase opioid dosage without first consulting a clinician. Advise patients to seek medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see WARNINGS , ADVERSE REACTIONS ]. Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare providers if they are taking, or plan to take serotonergic medications [see PRECAUTIONS ; Drug Interactions ]. Monoamine Oxidase Inhibitor (MAOI) Interaction Inform patients to avoid taking Oxycodone and Acetaminophen Tablets while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking Oxycodone and Acetaminophen Tablets [see PRECAUTIONS ; Drug Interactions ]. Important Administration Instructions Instruct patients how to properly take Oxycodone and Acetaminophen Tablets [see DOSAGE AND ADMINISTRATION , WARNINGS ]. Advise patients not to adjust the medication dose themselves and to consult with their healthcare provider prior to any dosage adjustment. Advise patients who are treated with Oxycodone and Acetaminophen Tablets for more than a few weeks not to abruptly discontinue the medication. Advise patients to consult with their physician for a gradual discontinuation dose schedule to taper off the medication. Important Discontinuation Instructions In order to avoid developing withdrawal symptoms, instruct patients not to discontinue Oxycodone and Acetaminophen Tablets without first discussing a tapering plan with the prescriber [see DOSAGE AND ADMINISTRATION ]. Maximum Daily Dose of Acetaminophen Inform patients to not take more than 4000 milligrams of acetaminophen per day. Advise patients to call their prescriber if they take more than the recommended dose. Driving or Operating Heavy Machinery Inform patients that Oxycodone and Acetaminophen Tablets may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication [see PRECAUTIONS ]. Constipation Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention [see ADVERSE REACTIONS , CLINICAL PHARMACOLOGY ]. Adrenal Insufficiency Inform patients that opioids could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms [see WARNINGS ]. Hypotension Inform patients that Oxycodone and Acetaminophen Tablets may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) [see WARNINGS ]. Anaphylaxis Inform patients that anaphylaxis have been reported with ingredients contained in Oxycodone and Acetaminophen Tablets. Advise patients how to recognize such a reaction and when to seek medical attention [see CONTRAINDICATIONS , ADVERSE REACTIONS ]. Pregnancy Neonatal Opioid Withdrawal Syndrome Inform female patients of reproductive potential that use of Oxycodone and Acetaminophen Tablets for an extended period of time during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [see WARNINGS , PRECAUTIONS ; Pregnancy ]. Embryo-Fetal Toxicity Inform female patients of reproductive potential that Oxycodone and Acetaminophen Tablets can cause fetal harm and to inform the healthcare provider of a known or suspected pregnancy [see PRECAUTIONS ; Pregnancy ]. Lactation Advise breastfeeding women using Oxycodone and Acetaminophen Tablets to carefully observe infants for increased sleepiness (more than usual), breathing difficulties, or limpness. Instruct breastfeeding women to seek immediate medical care if they notice these signs [see PRECAUTIONS ; Nursing Mothers ]. Infertility Inform patients that use of opioids for an extended period of time may cause reduced fertility. It is not known whether these effects on fertility are reversible [see ADVERSE REACTIONS ]."
      },
      {
        "code": "34075-2",
        "type": "LABORATORY TESTS SECTION",
        "title": "\n                        ",
        "content": "Although oxycodone may cross-react with some drug urine tests, no available studies were found   which determined the duration of detectability of oxycodone in urine drug screens. However, based on pharmacokinetic data, the approximate duration of detectability for a single dose of oxycodone is roughly estimated to be one to two days following drug   exposure. Urine testing for opiates may be performed to determine illicit drug use and for medical reasons such as evaluation of patients with altered states of consciousness or monitoring efficacy of drug rehabilitation efforts. The preliminary identification of opiates in urine involves the use of an immunoassay screening and thin-layer chromatography (TLC). Gas chromatography/mass spectrometry (GC/MS) may be utilized as a third-stage identification step in the medical investigational sequence for opiate testing after immunoassay and TLC. The identities of 6-keto opiates (e.g., oxycodone) can further be differentiated by the analysis of their methoximetrimethylsilyl (MO-TMS) derivative."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "Inhibitors of CYP3A4 and CYP2D6 The concomitant use of Oxycodone and Acetaminophen Tablets and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of Oxycodone and Acetaminophen Tablets and CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of Oxycodone and Acetaminophen Tablets is achieved [see WARNINGS ]. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease [see CLINICAL PHARMACOLOGY ], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to Oxycodone and Acetaminophen Tablets. If concomitant use is necessary, consider dosage reduction of Oxycodone and Acetaminophen Tablets until stable drug effects are achieved. Evaluate patients at frequent intervals for respiratory depression and sedation. If a CYP3A4 inhibitor is discontinued, consider increasing the Oxycodone and Acetaminophen Tablets dosage until stable drug effects are achieved. Assess for signs of opioid withdrawal. Inducers of CYP3A4 The concomitant use of Oxycodone and Acetaminophen Tablets and CYP3A4 inducers, such as rifampin, carbamazepine, and phenytoin, can decrease the plasma concentration of oxycodone [see CLINICAL PHARMACOLOGY ], resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to Oxycodone and Acetaminophen Tablets [see WARNINGS ]. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the oxycodone plasma concentration will increase [see CLINICAL PHARMACOLOGY ], which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression. If concomitant use is necessary, consider increasing the Oxycodone and Acetaminophen Tablets dosage until stable drug effects are achieved. Assess for sign of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider Oxycodone and Acetaminophen Tablets dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation. Benzodiazepines and Other Central Nervous System (CNS) Depressants Due to additive pharmacologic effect, the concomitant use of benzodiazepines and other CNS depressants such as benzodiazepines and other sedative hypnotics, anxiolytics, and tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), and other opioids, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider recommending or prescribing an opioid overdose reversal agent [see WARNINGS , DOSAGE AND ADMINISTRATION ]. Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome. [see PRECAUTIONS; Information for Patients/Caregivers ]. If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue Oxycodone and Acetaminophen Tablets if serotonin syndrome is suspected. Monoamine Oxidase Inhibitors (MAOIs) The concomitant use of opioids and MAOIs, such as phenelzine, tranylcypromine, linezolid, may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see WARNINGS ]. The use of Oxycodone and Acetaminophen Tablets are not recommended for patients taking MAOIs or within 14 days of stopping such treatment. If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics The concomitant use of opioids with other opioid analgesics, such as butorphanol, nalbuphine, pentazocine, may reduce the analgesic effect of Oxycodone and Acetaminophen Tablets and/or precipitate withdrawal symptoms. Advise patient to avoid concomitant use of these drugs. Muscle Relaxants Oxycodone and Acetaminophen may enhance the neuromuscular-blocking action of skeletal muscle relaxants and produce an increase in the degree of respiratory depression. Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Oxycodone and Acetaminophen Tablets and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider recommending or prescribing an opioid overdose reversal agent [see WARNINGS , DOSAGE AND ADMINISTRATION ]. Examples: Cyclobenzaprine, metaxalone. Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Evaluate patients for signs for diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed. Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Evaluate patients for signs of urinary retention or reduced gastric motility when Oxycodone and Acetaminophen Tablets are used concomitantly with anticholinergic drugs. Alcohol, ethyl Hepatotoxicity has occurred in chronic alcoholics following various dose levels (moderate to excessive) of acetaminophen. Oral Contraceptives Increase in glucuronidation resulting in increased plasma clearance and a decreased half-life of acetaminophen. Charcoal (activated) Reduces acetaminophen absorption when administered as soon as possible after overdose. Beta Blockers (Propranolol) Propranolol appears to inhibit the enzyme systems responsible for the glucuronidation and oxidation of acetaminophen. Therefore, the pharmacologic effects of acetaminophen may be increased. Loop Diuretics The effects of the loop diuretic may be decreased because acetaminophen may decrease renal prostaglandin excretion and decrease plasma renin activity. Lamotrigine Serum lamotrigine concentrations may be reduced, producing a decrease in therapeutic effects. Probenecid Probenecid may increase the therapeutic effectiveness of acetaminophen slightly. Zidovudine The pharmacologic effects of zidovudine may be decreased because of enhanced non-hepatic or renal clearance of zidovudine."
      },
      {
        "code": "34074-5",
        "type": "DRUG & OR LABORATORY TEST INTERACTIONS SECTION",
        "title": "\n                        ",
        "content": "Depending on the sensitivity/specificity and the test methodology, the individual components of Oxycodone and Acetaminophen Tablets may cross-react with assays used in the preliminary detection of cocaine (primary urinary metabolite, benzoylecgonine) or marijuana (cannabinoids) in human urine. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. The preferred confirmatory method is gas chromatography/mass spectrometry (GC/MS). Moreover, clinical considerations and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used. Acetaminophen may interfere with home blood glucose measurement systems; decreases of >20% in mean glucose values may be noted. This effect appears to be drug, concentration and system dependent."
      },
      {
        "code": "34083-6",
        "type": "CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION",
        "title": "\n                        ",
        "content": "Carcinogenesis Long-term studies to evaluate the carcinogenic potential of the combination of Oxycodone Hydrochloride and Acetaminophen have not been conducted. Long-term studies in mice and rats have been completed by the National Toxicology Program to evaluate the carcinogenic potential of acetaminophen. In 2-year feeding studies, F344/N rats and B6C3F1 mice were fed a diet containing acetaminophen up to 6000 ppm. Female rats demonstrated equivocal evidence of carcinogenic activity based on increased incidences of mononuclear cell leukemia at 0.8 times the maximum human daily dose (MHDD) of 4 grams/day, based on a body surface area comparison. In contrast, there was no evidence of carcinogenic activity in male rats that received up to 0.7 times or mice at up to 1.2 to1.4 times the MHDD, based on a body surface area comparison. Mutagenesis The combination of Oxycodone Hydrochloride and Acetaminophen has not been evaluated for mutagenicity. Oxycodone alone was negative in a bacterial reverse mutation assay (Ames), an in vitro chromosome aberration assay with human lymphocytes without metabolic activation and an in vivo mouse micronucleus assay. Oxycodone was clastogenic in the human lymphocyte chromosomal assay in the presence of metabolic activation and in the mouse lymphoma assay with or without metabolic activation. In the published literature, acetaminophen has been reported to be clastogenic when administered at 1500 mg/kg/day to the rat model (3.6-times the MHDD, based on a body surface area comparison). In contrast, no clastogenicity was noted at a dose of 750 mg/kg/day (1.8-times the MHDD, based on a body surface area comparison), suggesting a threshold effect. Impairment of Fertility In studies conducted by the National Toxicology Program, fertility assessments with acetaminophen have been completed in Swiss CD-1 mice via a continuous breeding study. There were no effects on fertility parameters in mice consuming up to 1.7 times the MHDD of acetaminophen, based on a body surface area comparison. Although there was no effect on sperm motility or sperm density in the epididymis, there was a significant increase in the percentage of abnormal sperm in mice consuming 1.78 times the MHDD (based on a body surface comparison) and there was a reduction in the number of mating pairs producing a fifth litter at this dose, suggesting the potential for cumulative toxicity with chronic administration of acetaminophen near the upper limit of daily dosing. Published studies in rodents report that oral acetaminophen treatment of male animals at doses that are 1.2 times the MHDD and greater (based on a body surface comparison) result in decreased testicular weights, reduced spermatogenesis, reduced fertility, and reduced implantation sites in females given the same doses. These effects appear to increase with the duration of treatment. The clinical significance of these findings is not known. Infertility Use of opioids for an extended period of time may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see ADVERSE REACTIONS ]."
      },
      {
        "code": "42228-7",
        "type": "PREGNANCY SECTION",
        "title": "\n                        ",
        "content": "Teratogenic Effects Animal reproductive studies have not been conducted with Oxycodone and Acetaminophen Tablets. It is also not known whether Oxycodone and Acetaminophen Tablets can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Oxycodone and Acetaminophen Tablets should not be given to a pregnant woman unless in the judgment of the physician, the potential benefits outweigh the possible hazards. Nonteratogenic Effects Fetal/Neonatal Adverse Reactions Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see WARNINGS ] ."
      },
      {
        "code": "34079-4",
        "type": "LABOR & DELIVERY SECTION",
        "title": "\n                        ",
        "content": "Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid overdose reversal agent, such as naloxone or nalmefene, must be available for reversal of opioid-induced respiratory depression in the neonate. Oxycodone and Acetaminophen Tablets are not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including Oxycodone and Acetaminophen Tablets, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression."
      },
      {
        "code": "34080-2",
        "type": "NURSING MOTHERS SECTION",
        "title": "\n                        ",
        "content": "Available data from lactation studies indicate that oxycodone is present in breastmilk and that doses of less than 60 mg/day of the immediate-release formulation are unlikely to result in clinically relevant exposures in breastfed infants. A pharmacokinetics study utilizing opportunistic sampling of 76 lactating women receiving oxycodone immediate-release products for postpartum pain management showed that oxycodone concentrates in breastmilk with an average milk to plasma ratio of 3.2. The relative infant dose was low, approximately 1.3% of a weight-adjusted maternal dose ( see Data ). In the same study, among the 70 infants exposed to oxycodone in breastmilk, no adverse events were attributed to oxycodone. However, based on known adverse effects in adults, infants should be monitored for signs of excess sedation and respiratory depression ( see Clinical Considerations ). There are no data on the effects of the oxycodone on milk production. Acetaminophen is also excreted in breast milk in low concentrations. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Oxycodone and Acetaminophen Tablets and any potential adverse effects on the breastfed infant from Oxycodone and Acetaminophen Tablets or from the underlying maternal condition. Infants exposed to Oxycodone and Acetaminophen through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped. Data Oxycodone concentration data from 76 lactating women receiving immediate-release oxycodone products for postpartum pain management, and 28 infants exposed to oxycodone in breastmilk showed that following a median (range) dose of oxycodone in mothers of 9.2 (5 to 10) mg/dose or 33 (5.4 to 59.3) mg/day, oxycodone concentrated in breastmilk with a median (range) milk to plasma ratio of 3.2 (1.2 to 5.3). However, when using maternal breastmilk data to estimate the daily and relative infant dose, the infant dose was 0.006 mg/kg/day, which is 1.3% of a weight-adjusted maternal dose of 10 mg every 6 hours. These estimates based on maternal breastmilk concentrations were corroborated by the observed infant concentrations, of which over 75% (19/25) were below the limit of quantification. Among the 6 infants with quantifiable concentration, the median (range) concentration was 0.2 ng/mL (0.1 to 0.7). These concentrations are 100 to 1000 times lower than concentrations observed in other studies after infants received oxycodone at 0.1 mg/kg/dose (~20 to 200 ng/mL)."
      },
      {
        "code": "34081-0",
        "type": "PEDIATRIC USE SECTION",
        "title": "\n                        ",
        "content": "Safety and effectiveness of Oxycodone and Acetaminophen Tablets in pediatric patients have not been established."
      },
      {
        "code": "34082-8",
        "type": "GERIATRIC USE SECTION",
        "title": "\n                        ",
        "content": "Elderly patients (aged 65 years or older) may have increased sensitivity Oxycodone and Acetaminophen Tablets. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of Oxycodone and Acetaminophen Tablets slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see WARNINGS ]. These drugs are known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "In a pharmacokinetic study of oxycodone in patients with end-stage liver disease, oxycodone plasma clearance decreased and the elimination half-life increased. Because oxycodone is extensively metabolized in the liver, its clearance may decrease in patients with hepatic impairment. Initiate therapy in these patients with a lower than usual dosage of Oxycodone and Acetaminophen Tablets and titrate carefully. Monitor closely for adverse events such as respiratory depression, sedation, and hypotension [see CLINICAL PHARMACOLOGY ]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "\n                        ",
        "content": "In a study of patients with end stage renal impairment, mean elimination half-life was prolonged in uremic patients due to increased volume of distribution and reduced clearance. Oxycodone should be used with caution in patients with renal impairment. Because oxycodone is known to be substantially excreted by the kidney, its clearance may decrease in patients with renal impairment. Initiate therapy with a lower than usual dosage of Oxycodone and Acetaminophen Tablets and titrate carefully. Monitor closely for adverse events such as respiratory depression, sedation, and hypotension [see CLINICAL PHARMACOLOGY ]."
      },
      {
        "code": "34084-4",
        "type": "ADVERSE REACTIONS SECTION",
        "title": "\n                  ",
        "content": "The following adverse reactions have been identified during post approval use of Oxycodone and Acetaminophen Tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Serious adverse reactions that may be associated with oxycodone and acetaminophen use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock [see OVERDOSAGE ]. The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation, and pruritus. Hypersensitivity reactions may include: Skin eruptions, urticarial, erythematous skin reactions. Hematologic reactions may include: thrombocytopenia, neutropenia, pancytopenia, hemolytic anemia. Rare cases of agranulocytosis have likewise been associated with acetaminophen use. In high doses, the most serious adverse effect is a dose-dependent, potentially fatal hepatic necrosis. Renal tubular necrosis and hypoglycemic coma also may occur. Other adverse reactions obtained from postmarketing experiences with oxycodone and acetaminophen are listed by organ system and in decreasing order of severity and/or frequency as follows: Body as a Whole : Anaphylactoid reaction, allergic reaction, malaise, asthenia, fatigue, chest pain, fever, hypothermia, thirst, headache, increased sweating, accidental overdose, non-accidental overdose Cardiovascular : Hypotension, hypertension, tachycardia, orthostatic hypotension, bradycardia, palpitations, dysrhythmias Central and Peripheral Nervous System : Stupor, tremor, paraesthesia, hypoaesthesia, lethargy, seizures, anxiety, mental impairment, agitation, cerebral edema, confusion, dizziness Fluid and Electrolyte : Dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis Gastrointestinal : Dyspepsia, taste disturbances, abdominal pain, abdominal distention, sweating increased, diarrhea, dry mouth, flatulence, gastrointestinal disorder, nausea, vomiting, pancreatitis, intestinal obstruction, ileus Hepatic : Transient elevations of hepatic enzymes, increase in bilirubin, hepatitis, hepatic failure, jaundice, hepatotoxicity, hepatic disorder Hearing and Vestibular : Hearing loss, tinnitus Hematologic : Thrombocytopenia Hypersensitivity : Acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria, anaphylactoid reaction Metabolic and Nutritional : Hypoglycemia, hyperglycemia, acidosis, alkalosis Musculoskeletal : Myalgia, rhabdomyolysis Ocular: Miosis, visual disturbances, red eye Psychiatric : Drug dependence, drug abuse, insomnia, confusion, anxiety, agitation, depressed level of consciousness, nervousness, hallucination, somnolence, depression, suicide Respiratory System : Bronchospasm, dyspnea, hyperpnea, pulmonary edema, tachypnea, aspiration, hypoventilation, laryngeal edema Skin and Appendages: Erythema, urticaria, rash, flushing Urogenital : Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, urinary retention Serotonin syndrome : Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs. Adrenal insufficiency : Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Anaphylaxis : Anaphylaxis has been reported with ingredients contained in Oxycodone and Acetaminophen Tablets. Androgen deficiency : Cases of androgen deficiency have occurred with use of opioids for an extended period of time. Hyperalgesia and Allodynia : Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration [see WARNINGS ]. Hypoglycemia : Cases of hypoglycemia have been reported in patients taking opioids. Most reports were in patients with at least one predisposing risk factor (e.g., diabetes). Postmarketing Experience Opioid-induced esophageal dysfunction (OIED): Cases of OIED have been reported in patients taking opioids, and may occur more frequently in patients taking higher doses of opioids, and/or in patients taking opioids longer term [see WARNINGS ]. Adverse Reactions from Observational Studies A prospective, observational cohort study estimated the risks of addiction, abuse, and misuse in patients initiating long-term use of Schedule II opioid analgesics between 2017 and 2021. Study participants included in one or more analyses had been enrolled in selected insurance plans or health systems for at least one year, were free of at least one outcome at baseline, completed a minimum number of follow-up assessments, and either: 1) filled multiple extended-release/long-acting opioid analgesic prescriptions during a 90 day period (n=978); or 2) filled any Schedule II opioid analgesic prescriptions covering at least 70 of 90 days (n=1,244). Those included also had no dispensing of the qualifying opioids in the previous 6 months. Over 12 months: approximately 1% to 6% of participants across the two cohorts newly met criteria for addiction, as assessed with two validated interview-based measures of moderate-to-severe opioid use disorder based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, and approximately 9% and 22% of participants across the two cohorts newly met criteria for prescription opioid abuse and misuse [defined in DRUG ABUSE AND DEPENDENCE ], respectively, as measured with a validated self-reported instrument. A retrospective, observational cohort study estimated the risk of opioid-involved overdose or opioid overdose-related death in patients with new long-term use of Schedule II opioid analgesics from 2006 through 2016 (n=220,249). Included patients had been enrolled in either one of two commercial insurance programs, one managed care program, or one Medicaid program for at least 9 months. New long-term use was defined as having Schedule II opioid analgesic prescriptions covering at least 70 days\u2019 supply over the 3 months prior to study entry and none during the preceding 6 months. Patients were excluded if they had an opioid-involved overdose in the 9 months prior to study entry. Overdose was measured using a validated medical code-based algorithm with linkage to the National Death Index database. The 5-year cumulative incidence estimates for opioid-involved overdose or opioid overdose-related death ranged from approximately 1.5% to 4% across study sites, counting only the first event during follow-up. Approximately 17% of first opioid overdoses observed over the entire study period (5-11 years, depending on the study site) were fatal. Higher baseline opioid dose was the strongest and most consistent predictor of opioid-involved overdose or opioid overdose-related death. Study exclusion criteria may have selected patients at lower risk of overdose, and substantial loss to follow-up (approximately 80%) also may have biased estimates. The risk estimates from the studies described above may not be generalizable to all patients receiving opioid analgesics, such as those with exposures shorter or longer than the duration evaluated in the studies."
      },
      {
        "code": "42227-9",
        "type": "DRUG ABUSE AND DEPENDENCE SECTION",
        "title": "\n                  ",
        "content": "NA"
      },
      {
        "code": "34085-1",
        "type": "CONTROLLED SUBSTANCE SECTION",
        "title": "\n                        ",
        "content": "Oxycodone and Acetaminophen Tablets contain oxycodone, a Schedule II controlled substance."
      },
      {
        "code": "34086-9",
        "type": "ABUSE SECTION",
        "title": "\n                        ",
        "content": "Oxycodone and Acetaminophen Tablet contains Oxycodone, a substance with high potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction [see WARNINGS ]. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Misuse and abuse of Oxycodone and Acetaminophen Tablets increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. The risk is increased with concurrent abuse of Oxycodone and Acetaminophen Tablets with alcohol and other CNS depressants. Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of addiction. All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Patients at high risk of Oxycodone and Acetaminophen Tablets abuse include those with a history of prolonged use of any opioid, including products containing Oxycodone, those with a history of drug or alcohol abuse, or those who use Oxycodone and Acetaminophen Tablets in combination with other abused drugs. \u201cDrug-seeking\u201d behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated \u201closs\u201d of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). \u201cDoctor shopping\u201d (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with inadequate pain control. Oxycodone and Acetaminophen Tablets, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised. Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. Risks Specific to Abuse of Oxycodone and Acetaminophen Tablets Abuse of Oxycodone and Acetaminophen Tablets poses a risk of overdose and death. The risk is increased with concurrent use of Oxycodone and Acetaminophen Tablets with alcohol and/or other CNS depressants. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV."
      },
      {
        "code": "34087-7",
        "type": "DEPENDENCE SECTION",
        "title": "\n                        ",
        "content": "Both tolerance and physical dependence can develop during use of opioid therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use. Do not rapidly reduce or abruptly discontinue Oxycodone and Acetaminophen Tablets in a patient physically dependent on opioids. Rapid tapering of Oxycodone and Acetaminophen Tablets in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. When discontinuing Oxycodone and Acetaminophen Tablets, gradually taper the dosage using a patient-specific plan that considers the following: the dose of Oxycodone and Acetaminophen Tablets the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see DOSAGE AND ADMINISTRATION , and WARNINGS ]. Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see PREGNANCY ]."
      },
      {
        "code": "34088-5",
        "type": "OVERDOSAGE SECTION",
        "title": "\n                  ",
        "content": "Following an acute overdosage, toxicity may result from the oxycodone or the acetaminophen. Clinical Presentation Oxycodone Acute overdosage with Oxycodone can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [see CLINICAL PHARMACOLOGY ]. Toxic leukoencephalopathy has been reported after opioid overdose and can present hours, days, or weeks after apparent recovery from the initial intoxication. Acetaminophen Dose-dependent potentially fatal hepatic necrosis is the most serious adverse effect of acetaminophen overdosage. Renal tubular necrosis, hypoglycemic coma, and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis, and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. Treatment of Overdose Oxycodone In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support measures. For clinically significant respiratory or circulatory depression secondary to opioid overdose, administer an opioid overdose reversal agent such as naloxone or nalmefene. Because the duration of opioid reversal is expected to be less than the duration of action of oxycodone in Oxycodone and Acetaminophen Tablets, carefully monitor the patient until spontaneous respiration is reliably reestablished. If the response to an opioid overdose reversal agent is suboptimal or only brief in nature, administer additional reversal agent as directed by the product\u2019s prescribing information. In an individual physically dependent on opioids, administration of the recommended usual dosage of the opioid overdose reversal agent will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the reversal agent administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the reversal agent should be initiated with care and by titration with smaller than usual doses of the reversal agent. Acetaminophen Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration. Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "\n                  ",
        "content": "Important Dosage and Administration Instructions Oxycodone and Acetaminophen Tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see WARNINGS ]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of Oxycodone and Acetaminophen Tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available. There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient\u2019s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see WARNINGS ]. Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with Oxycodone and Acetaminophen Tablets. Consider this risk when selecting an initial dose and when making dose adjustments [see WARNINGS ]. Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose. The presence of risk factors for overdose should not prevent the management of pain in any patient [see WARNINGS ; Addiction, Abuse, and Misuse; Life-Threatening Respiratory Depression; Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants]. Discuss the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program). There are important differences among the opioid overdose reversal agents, such as route of administration, product strength, approved patient age range, and pharmacokinetics. Be familiar with these differences, as outlined in the approved labeling for those products, prior to recommending or prescribing such an agent. Initial Dosage Use of Oxycodone and Acetaminophen Tablets as the First Opioid Analgesic Initiate treatment with Oxycodone and Acetaminophen Tablets using Oxycodone and Acetaminophen Tablets 2.5 mg/325 mg tablets in a dosing range of 1 to 2 tablets every 6 hours as needed for pain, at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient\u2019s response to their initial dose of Oxycodone and Acetaminophen Tablets. The total daily dose of acetaminophen should not exceed 4 grams. The usual adult dosage is one tablet every 6 hours as needed for pain. The total daily dose of acetaminophen should not exceed 4 grams. Strength Usual Adult Dosage Maximal Daily Dose Oxycodone and Acetaminophen Tablets USP, 2.5 mg/325 mg 1 or 2 tablets every 6 hours as needed for pain. 12 Tablets Oxycodone and Acetaminophen Tablets USP, 5 mg/325 mg 1 tablet every 6 hours as needed for pain. 12 Tablets Oxycodone and Acetaminophen Tablets USP, 7.5 mg/325 mg 1 tablet every 6 hours as needed for pain. 8 Tablets Oxycodone and Acetaminophen Tablets USP, 10 mg/325 mg 1 tablet every 6 hours as needed for pain. 6 Tablets Conversion from Oxycodone Hydrochloride and Acetaminophen Tablets to Extended-Release Oxycodone The relative bioavailability of Oxycodone and Acetaminophen Tablets compared to extended-release Oxycodone is unknown, so conversion to extended-release Oxycodone may lead to increased risk of excessive sedation and respiratory depression. Titration and Maintenance of Therapy Individually titrate Oxycodone and Acetaminophen Tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving Oxycodone and Acetaminophen Tablets to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as reassessing for the development of addiction, abuse, or misuse [see WARNINGS ]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the Oxycodone and Acetaminophen Tablets dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after dosage increase), consider reducing the dosage [see WARNINGS ]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions. Safe Reduction or Discontinuation of Oxycodone and Acetaminophen Tablets Do not rapidly reduce or abruptly discontinue Oxycodone and Acetaminophen Tablets in patients who may be physically dependent on opioids. Rapid reduction or abrupt discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid reduction or abrupt discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking Oxycodone and Acetaminophen Tablets, there are a variety of factors that should be considered, including the total daily dose of opioid (including Oxycodone and Acetaminophen Tablets) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with co-morbid pain and substance use disorders may benefit from referral to a specialist. There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on Oxycodone and Acetaminophen Tablets who are physically opioid- dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper. It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, evaluate patients for any changes in mood, emergence of suicidal thoughts, or use of other substances. When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [see WARNINGS/ Withdrawal , DRUG ABUSE AND DEPENDENCE ]."
      },
      {
        "code": "34069-5",
        "type": "HOW SUPPLIED SECTION",
        "title": "\n                  ",
        "content": "Oxycodone and Acetaminophen Tablets, USP are supplied as follows: 2.5 mg/325 mg White to off-white, round, radius edged, flat tablets debossed with \u20182.5\u2019 on one side and \u2018667\u2019 on other side. Bottles of 100 NDC 70010-667-01 Bottles of 500 NDC 70010-667-05 5 mg/325 mg White to off-white, round, radius edged, flat tablets debossed with \u20185\u2019 above the score on one side and \u2018668\u2019 on other side. Bottles of 100 NDC 70010-668-01 Bottles of 500 NDC 70010-668-05 7.5 mg/325 mg White to off-white, round, radius edged, flat tablets debossed with \u20187.5\u2019 on one side and \u2018669\u2019 on other side. Bottles of 100 NDC 70010-669-01 Bottles of 500 NDC 70010-669-05 10 mg/325 mg White to off-white, round, radius edged, flat tablets debossed with \u201810\u2019 on one side and \u2018670\u2019 on other side. Bottles of 100 NDC 70010-670-01 Bottles of 500 NDC 70010-670-05 Storage Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]. Dispense in a tight, light-resistant container as defined in the USP. Store Oxycodone and Acetaminophen Tablets, USP securely and dispose of properly [see PRECAUTIONS/Information for patients ]. DEA Order Form Required. Manufactured by: Granules Pharmaceuticals Inc. Chantilly, VA 20151 Rev. 10/2025"
      },
      {
        "code": "42231-1",
        "type": "SPL MEDGUIDE SECTION",
        "title": "\n                  ",
        "content": "Oxycodone (ox\" i koe' done) and Acetaminophen (a seet\" a min' oh fen) Tablets, CII Oxycodone and Acetaminophen Tablets are: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain, severe enough to require an opioid analgesic and for which alternative treatments are inadequate and when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them. An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death. Important information about Oxycodone and Acetaminophen Tablets: Get emergency help or call 911 right away if you take too much Oxycodone and Acetaminophen Tablets (overdose). When you first start taking Oxycodone and Acetaminophen Tablets, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Ask your healthcare provider about medicines like naloxone or nalmefene that can be used in an emergency to reverse an opioid overdose. Taking Oxycodone and Acetaminophen Tablets with other opioid medicines, benzodiazepines, gabapentinoids (gabapentin or pregabalin), alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death. Never give anyone else your Oxycodone and Acetaminophen Tablets. They could die from taking it. Selling or giving away Oxycodone and Acetaminophen Tablets is against the law. Store Oxycodone and Acetaminophen Tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Do not take Oxycodone and Acetaminophen Tablets if you have: Severe asthma, trouble breathing, or other lung problems. A bowel blockage or have narrowing of the stomach or intestines. Known hypersensitivity to oxycodone, acetaminophen, or any ingredient in Oxycodone and Acetaminophen Tablets. Before taking Oxycodone and Acetaminophen Tablets, tell your healthcare provider if you have a history of: Head injury, seizures Liver, kidney, thyroid problems Problems urinating Pancreas or gallbladder problems Abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problems Tell your healthcare provider if you: are pregnant or planning to become pregnant. Use of Oxycodone and Acetaminophen Tablets for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated. noticing your pain getting worse. If your pain gets worse after you take Oxycodone and Acetaminophen Tablets, do not take more of Oxycodone and Acetaminophen Tablets without first talking to your healthcare provider. Talk to your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking Oxycodone and Acetaminophen Tablets. breastfeeding. Oxycodone and Acetaminophen passes into breast milk and may harm your baby. Carefully observe infants for increased sleepiness (more than usual), breathing difficulties, or limpness. Seek immediate medical care if you notice these signs. living in a household where there are small children or someone who has abused street or prescription drugs. taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking Oxycodone and Acetaminophen Tablets with certain other medicines can cause serious side effects that could lead to death. When taking Oxycodone and Acetaminophen Tablets: Do not change your dose. Take Oxycodone and Acetaminophen Tablets exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed. For acute (short-term) pain, you may only need to take Oxycodone and Acetaminophen Tablets for a few days. You may have some Oxycodone and Acetaminophen Tablets left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused Oxycodone and Acetaminophen Tablets. Take your prescribed dose every 6 hours as needed for pain. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time. Call your healthcare provider if the dose you are taking does not control your pain. If you have been taking Oxycodone and Acetaminophen Tablets regularly, do not stop taking Oxycodone and Acetaminophen Tablets without talking to your healthcare provider. Dispose of expired, unwanted, or unused Oxycodone and Acetaminophen Tablets by taking your drug to an authorized DEA-registered collector or drug take-back program. If one is not available, you can dispose of Oxycodone and Acetaminophen Tablets by mixing the product with dirt, cat litter, or coffee grounds; placing the mixture in a sealed plastic bag, and throwing the bag in your trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines. While taking Oxycodone and Acetaminophen Tablets DO NOT: Drive or operate heavy machinery, until you know how Oxycodone and Acetaminophen Tablets affect you. Oxycodone and Acetaminophen Tablets can make you sleepy, dizzy, or lightheaded. Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with Oxycodone and Acetaminophen Tablets may cause you to overdose and die. The possible side effects of Oxycodone and Acetaminophen Tablets: Constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe. Get emergency medical help or call 911 right away if you have: Trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion. These are not all the possible side effects of Oxycodone and Acetaminophen Tablets. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov. For more information call Granules Pharmaceuticals Inc., at 1-877-770-3183. Manufactured by: Granules Pharmaceuticals Inc. Chantilly, VA 20151 This Medication Guide has been approved by the U.S Food and Drug Administration. Rev. 10/2025"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "\n                  ",
        "content": "NDC 70010-667-01         CII Oxycodone and Acetaminophen Tablets, USP 2.5 mg*/325 mg Multiple strengths: Do not dispense unless strength is stated. Dispense the enclosed Medication Guide to each patient. Rx onl y 100 Tablets"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "\n                  ",
        "content": "NDC 70010-668-01 CII Oxycodone and Acetaminophen Tablets, USP 5 mg*/325 mg Multiple strengths: Do not dispense unless strength is stated. Dispense the enclosed Medication Guide to each patient. Rx only 100 Tablets"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "\n                  ",
        "content": "NDC 70010-669-01 CII Oxycodone and Acetaminophen Tablets, USP 7.5 mg*/325 mg Multiple strengths: Do not dispense unless strength is stated. Dispense the enclosed Medication Guide to each patient. Rx only 100 Tablets"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "\n                  ",
        "content": "NDC 70010-670-01        CII Oxycodone and Acetaminophen Tablets, USP 10 mg*/325 mg Multiple strengths: Do not dispense unless strength is stated. Dispense the enclosed Medication Guide to each patient. Rx only 100 Tablets"
      }
    ],
    "category": "Prescription"
  },
  {
    "filename": "prescription_570974d4-0d5b-4df2-b307-37380511835d.xml",
    "document_id": "570974d4-0d5b-4df2-b307-37380511835d",
    "document_type": "Human Prescription Drug Label",
    "title": "These highlights do not include all the information needed to use NAPROXEN ORAL SUSPENSION safely and effectively. See full prescribing information for NAPROXEN ORAL SUSPENSION.",
    "effective_date": "20251007",
    "version": "1",
    "author": {
      "name": "Aurobindo Pharma Limited",
      "id": "650082092"
    },
    "product": {
      "ndc": "59651-528",
      "name": "Naproxen",
      "form": "SUSPENSION",
      "generic_name": "Naproxen",
      "active_ingredients": [
        {
          "name": "NAPROXEN",
          "code": "57Y76R9ATQ",
          "strength": "125 mg",
          "per": "5 mL"
        }
      ],
      "inactive_ingredients": [
        "BENZYL ALCOHOL",
        "FD&C YELLOW NO. 6",
        "FUMARIC ACID",
        "MAGNESIUM ALUMINUM SILICATE TYPE IC",
        "METHYLPARABEN",
        "MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE)",
        "NONCRYSTALLIZING SORBITOL SOLUTION",
        "PROPYLENE GLYCOL",
        "WATER",
        "SODIUM CHLORIDE",
        "SUCROSE",
        "XANTHAN GUM"
      ],
      "packaging": [
        {
          "quantity": "473 mL",
          "ndc": "",
          "container": "BOTTLE"
        },
        {
          "quantity": "1 1",
          "ndc": "59651-528-47",
          "container": "CARTON"
        }
      ],
      "route": "ORAL",
      "marketing_status": "active",
      "marketing_start_date": "20251003",
      "approval_status": "ANDA",
      "color": "ORANGE"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL PRODUCT DATA ELEMENTS SECTION"
      },
      {
        "code": "43683-2",
        "type": "RECENT MAJOR CHANGES SECTION"
      },
      {
        "code": "34066-1",
        "type": "BOXED WARNING SECTION",
        "title": "WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS",
        "content": "Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [ see Warnings and Precautions (5.1) ]. Naproxen oral suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [ see Contraindications (4) , Warnings and Precautions (5.1) ] . Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [ see Warnings and Precautions  (5.2) ]."
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "1 INDICATIONS AND\u00a0USAGE",
        "content": "Naproxen oral suspension is indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis polyarticular juvenile idiopathic arthritis tendonitis bursitis acute gout the management of: pain primary dysmenorrhea"
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "2 DOSAGE\u00a0AND ADMINISTRATION"
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "2.1 General Dosing Instructions",
        "content": "Carefully consider the potential benefits and risks of naproxen oral suspension and other treatment options before deciding to use naproxen oral suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] . After observing the response to initial therapy with naproxen oral suspension, the dose and frequency should be adjusted to suit an individual patient\u2019s needs. Always use a calibrated measuring device when administering naproxen oral suspension to ensure the dose is measured and administered accurately. A household teaspoon or tablespoon is not an adequate measuring device, especially when one-half of a teaspoonful is to be measured. Given the variability of the household spoon measure, it is strongly recommended that caregivers obtain and use a calibrated measuring device. Health care providers should recommend an appropriate measuring device that can measure and deliver the prescribed dose accurately, and instruct caregivers to use extreme caution in measuring the dosage. Naproxen-containing products such as naproxen oral suspension, and other naproxen products should not be used concomitantly since they all circulate in the plasma as the naproxen anion."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "2.2 Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis",
        "content": "The recommended dosage of naproxen oral suspension is shown in Table 1. Table 1: Recommended dosages of naproxen oral suspension Naproxen oral suspension 250 mg (10 mL) or 375 mg (15 mL) or 500 mg (20 mL) twice daily twice daily twice daily Naproxen oral suspension should be shaken gently before use. During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. The morning and evening doses do not have to be equal in size and administration of the drug more frequently than twice daily does not generally make a difference in response. In patients who tolerate lower doses well, the dose may be increased to naproxen 1500 mg/day for limited periods of up to 6 months when a higher level of anti-inflammatory/analgesic activity is required. When treating such patients with naproxen 1500 mg/day, the physician should observe sufficient increased clinical benefits to offset the potential increased risk."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "2.3 Polyarticular Juvenile Idiopathic Arthritis",
        "content": "The use of naproxen oral suspension is recommended for juvenile arthritis in children 2 years or older because it allows for more flexible dose titration based on the child\u2019s weight. In pediatric patients, doses of 5 mg/kg/day produced plasma levels of naproxen similar to those seen in adults taking 500 mg of naproxen [ see Clinical Pharmacology (12.3) ]. The recommended total daily dose of naproxen is approximately 10 mg/kg given in 2 divided doses (i.e., 5 mg/kg given twice a day). A measuring cup marked in 1/2 teaspoon and 2.5 milliliter increments is provided with the naproxen oral suspension. The following table may be used as a guide for dosing of naproxen oral suspension: Patient\u2019s Weight Dose Administered as 13 kg (29 lb) 62.5 mg twice daily 2.5 mL (1/2 tsp) twice daily 25 kg (55 lb) 125 mg twice daily 5 mL (1 tsp) twice daily 38 kg (84 lb) 187.5 mg twice daily 7.5 mL (1 1/2 tsp) twice daily"
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "2.4 Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis",
        "content": "The recommended starting dose of naproxen oral suspension is 500 mg (20 mL), followed by 250 mg (10 mL) every 6 to 8 hours as required. The total daily dose should not exceed 1250 mg (50 mL)."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "2.5 Acute Gout",
        "content": "The recommended starting dose is 750 mg (30 mL) of naproxen oral suspension followed by 250 mg (10 mL) every 8 hours until the attack has subsided."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "2.6 Non-Interchangeability with Other Formulations of Naproxen",
        "content": "Different dose strengths and formulations (e.g., tablets, suspension) of naproxen are not interchangeable. This difference should be taken into consideration when changing strengths or formulations."
      },
      {
        "code": "43678-2",
        "type": "DOSAGE FORMS & STRENGTHS SECTION",
        "title": "3 DOSAGE FORMS AND STRENGTHS",
        "content": "Naproxen oral suspension USP: 125 mg/5 mL (contains 39 mg sodium): Available in 1 pint (473 mL) light-resistant bottles."
      },
      {
        "code": "34070-3",
        "type": "CONTRAINDICATIONS SECTION",
        "title": "4 CONTRAINDICATIONS",
        "content": "Naproxen oral suspension is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see Warnings and Precautions (5.7, 5.9) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [ see Warnings and Precautions (5.7, 5.8) ] In the setting of coronary artery bypass graft (CABG) surgery [ see Warnings and Precautions (5.1) ]"
      },
      {
        "code": "43685-7",
        "type": "WARNINGS AND PRECAUTIONS SECTION",
        "title": "5 WARNINGS AND PRECAUTIONS"
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.1 Cardiovascular Thrombotic Events",
        "content": "Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as naproxen, increases the risk of serious gastrointestinal (GI) events [ see Warnings and Precautions (5.2) ]. Status Post Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [ see Contraindications (4) ]. Post-MI Patients Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up. Avoid the use of naproxen oral suspension in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If naproxen oral suspension is used in patients with a recent MI, monitor patients for signs of cardiac ischemia."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.2 Gastrointestinal Bleeding, Ulceration, and Perforation",
        "content": "NSAIDs, including naproxen, cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDS. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. However, even short-term NSAID therapy is not without risk. Risk Factors for GI Bleeding, Ulceration, and Perforation Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-\u00adfold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding. Strategies to Minimize the GI Risks in NSAID-treated patients: Use the lowest effective dosage for the shortest possible duration. Avoid administration of more than one NSAID at a time. Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs. Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy. If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue naproxen oral suspension until a serious GI adverse event is ruled out. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding [ see Drug Interactions (7) ]."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.3 Hepatotoxicity",
        "content": "Elevations of ALT or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of NSAID-treated patients in clinical trials. In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported. Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs including naproxen. Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and \"flulike\" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue naproxen oral suspension immediately, and perform a clinical evaluation of the patient."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.4 Hypertension",
        "content": "NSAIDs, including naproxen oral suspension, can lead to new onset of hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [ see Drug Interactions (7) ]. Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.5 Heart Failure and Edema",
        "content": "The Coxib and traditional NSAID Trialists\u2019 Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death. Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of naproxen may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [ see Drug Interactions (7) ]. Avoid the use of naproxen oral suspension in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If naproxen oral suspension is used in patients with severe heart failure, monitor patients for signs of worsening heart failure. Each 5 mL of naproxen oral suspension contains 39 mg of sodium. This should be considered in patients whose overall intake of sodium must be severely restricted."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.6 Renal Toxicity and Hyperkalemia",
        "content": "Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy was usually followed by recovery to the pretreatment state. No information is available from controlled clinical studies regarding the use of naproxen oral suspension in patients with advanced renal disease. The renal effects of naproxen oral suspension may hasten the progression of renal dysfunction in patients with preexisting renal disease. Correct volume status in dehydrated or hypovolemic patients prior to initiating naproxen oral suspension. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of naproxen oral suspension [ see Drug Interactions (7) ]. Avoid the use of naproxen oral suspension in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If naproxen oral suspension is used in patients with advanced renal disease, monitor patients for signs of worsening renal function. Hyperkalemia Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.7 Anaphylactic Reactions",
        "content": "Naproxen has been associated with anaphylactic reactions in patients with and without known hypersensitivity to naproxen and in patients with aspirin-sensitive asthma [ see Contraindications (4) and Warnings and Precautions (5.8) ]. Seek emergency help if an anaphylactic reaction occurs."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.8 Exacerbation of Asthma Related to Aspirin Sensitivity",
        "content": "A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, naproxen oral suspension is contraindicated in patients with this form of aspirin sensitivity [ see Contraindications (4) ]. When naproxen oral suspension is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.9 Serious Skin Reactions",
        "content": "NSAIDs, including naproxen can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life threatening. \u00a0These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of naproxen oral suspension at the first appearance of skin rash or any other sign of hypersensitivity. Naproxen oral suspension is contraindicated in patients with previous serious skin reactions to NSAIDs [ see Contraindications (4) ]."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.10 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)",
        "content": "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as naproxen oral suspension. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue naproxen oral suspension and evaluate the patient immediately."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.11 Fetal Toxicity",
        "content": "Premature Closure of Fetal Ductus Arterios us Avoid use of NSAIDs, including naproxen oral suspension, in pregnant women at about 30 weeks of gestation and later. NSAIDs, including naproxen oral suspension, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs, including naproxen oral suspension, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit naproxen oral suspension use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if naproxen oral suspension treatment extends beyond 48 hours. Discontinue naproxen oral suspension if oligohydramnios occurs and follow up according to clinical practice [ see Use in Specific Populations (8.1) ]."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.12 Hematologic Toxicity",
        "content": "Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with naproxen oral suspension has any signs or symptoms of anemia, monitor hemoglobin or hematocrit. NSAIDs, including naproxen oral suspension, may increase the risk of bleeding events. Concomitant use of warfarin and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [ see Drug Interactions (7) ]."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.13 Masking of Inflammation and Fever",
        "content": "The pharmacological activity of naproxen oral suspension in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "5.14 Long-Term Use and Laboratory Monitoring",
        "content": "Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [ see Warnings and Precautions \u00a0(5.2 , 5.3 , 5.6) ] . Patients with initial hemoglobin values of 10 g or less who are to receive long-term therapy should have hemoglobin values determined periodically. Because of adverse eye findings in animal studies with drugs of this class, it is recommended that ophthalmic studies be carried out if any change or disturbance in vision occurs."
      },
      {
        "code": "34084-4",
        "type": "ADVERSE REACTIONS SECTION",
        "title": "6 ADVERSE REACTIONS",
        "content": "The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events [ see Warnings and Precautions\u00a0(5.1) ] GI Bleeding, Ulceration and Perforation [ see Warnings and Precautions (5.2) ] Hepatotoxicity [ see Warnings and Precautions (5.3) ] Hypertension [ see Warnings and Precautions\u00a0(5.4) ] Heart Failure and Edema [ see Warnings and Precautions (5.5) ] Renal Toxicity and Hyperkalemia\u00a0[ see Warnings and Precautions (5.6) ] Anaphylactic Reactions [ see Warnings and Precautions (5.7) ] Serious Skin Reactions [ see Warnings and Precautions (5.9) ] Hematologic Toxicity [ see Warnings and Precautions (5.12) ]"
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "6.1 Clinical Trials Experience",
        "content": "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below. In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea. The most frequent complaints reported related to the gastrointestinal tract. A clinical study found gastrointestinal reactions to be more frequent and more severe in rheumatoid arthritis patients taking daily doses of 1500 mg naproxen compared to those taking 750 mg naproxen. In controlled clinical trials with about 80 pediatric patients and in well-monitored, open-label studies with about 400 pediatric patients with polyarticular juvenile idiopathic arthritis treated with naproxen, the incidence of rash and prolonged bleeding times were greater, the incidence of gastrointestinal and central nervous system reactions were about the same, and the incidence of other reactions were lower in pediatric patients than in adults. In patients taking naproxen in clinical trials, the most frequently reported adverse experiences in approximately 1% to 10% of patients are: Gastrointestinal (GI) Experiences, including: heartburn*, abdominal pain*, nausea*, constipation*, diarrhea, dyspepsia, stomatitis Central Nervous System: headache*, dizziness*, drowsiness*, lightheadedness, vertigo Dermatologic: pruritus (itching)*, skin eruptions*, ecchymoses*, sweating, purpura Special Senses: tinnitus*, visual disturbances, hearing disturbances Cardiovascular: edema*, palpitations General: dyspnea*, thirst *Incidence of reported reaction between 3% and 9%. Those reactions occurring in less than 3% of the patients are unmarked. In patients taking NSAIDs, the following adverse experiences have also been reported in approximately 1% to 10% of patients. Gastrointestinal (GI) Experiences, including: flatulence, gross bleeding/perforation, GI ulcers (gastric/duodenal), vomiting General: abnormal renal function, anemia, elevated liver enzymes, increased bleeding time, rashes"
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "6.2 Postmarketing Experience",
        "content": "The following adverse reactions have been identified during post approval use of naproxen. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following are additional adverse experiences reported in <1% of patients taking naproxen during clinical trials and through postmarketing reports. Those adverse reactions observed through postmarketing reports are italicized. Body as a Whole : anaphylactoid reactions, angioneurotic edema, menstrual disorders, pyrexia (chills and fever) Cardiovascular : congestive heart failure, vasculitis, hypertension, pulmonary edema Gastrointestinal : inflammation, bleeding (sometimes fatal, particularly in the elderly), ulceration, perforation and obstruction of the upper or lower gastrointestinal tract. Esophagitis, stomatitis, hematemesis, pancreatitis, vomiting, colitis, exacerbation of inflammatory bowel disease (ulcerative colitis, Crohn\u2019s disease). Hepatobiliary : jaundice, abnormal liver function tests, hepatitis (some cases have been fatal) Hemic and Lymphatic : eosinophilia, leucopenia, melena, thrombocytopenia, agranulocytosis, granulocytopenia, hemolytic anemia, aplastic anemia Metabolic and Nutritional : hyperglycemia, hypoglycemia Nervous System : inability to concentrate, depression, dream abnormalities, insomnia, malaise, myalgia, muscle weakness, aseptic meningitis, cognitive dysfunction, convulsions Respiratory : eosinophilic pneumonitis, asthma Dermatologic : alopecia, urticaria, skin rashes, toxic epidermal necrolysis, erythema multiforme, erythema nodosum, lichen planus, pustular reaction, systemic lupus erythematoses, bullous reactions, including Stevens-Johnson syndrome, fixed drug eruption, photosensitive dermatitis, photosensitivity reactions, including rare cases resembling porphyria cutanea tarda (pseudoporphyria) or epidermolysis bullosa. If skin fragility, blistering or other symptoms suggestive of pseudoporphyria occur, treatment should be discontinued and the patient monitored. Special Senses : hearing impairment, corneal opacity, papillitis, retrobulbar optic neuritis, papilledema Urogenital : glomerular nephritis, hematuria, hyperkalemia, interstitial nephritis, nephrotic syndrome, renal disease, renal failure, renal papillary necrosis, raised serum creatinine Reproduction (female) : infertility In patients taking NSAIDs, the following adverse experiences have also been reported in <1% of patients. Body as a Whole : fever, infection, sepsis, anaphylactic reactions, appetite changes, death Cardiovascular : hypertension, tachycardia, syncope, arrhythmia, hypotension, myocardial infarction Gastrointestinal : dry mouth, esophagitis, gastric/peptic ulcers, gastritis, glossitis, eructation Hepatobiliary : hepatitis, liver failure Hemic and Lymphatic : rectal bleeding, lymphadenopathy, pancytopenia Metabolic and Nutritional : weight changes Nervous System : anxiety, asthenia, confusion, nervousness, paresthesia, somnolence, tremors, convulsions, coma, hallucinations Respiratory : asthma, respiratory depression, pneumonia Dermatologic : exfoliative dermatitis Special Senses : blurred vision, conjunctivitis Urogenital : cystitis, dysuria, oliguria/polyuria, proteinuria"
      },
      {
        "code": "34073-7",
        "type": "DRUG INTERACTIONS SECTION",
        "title": "7 DRUG INTERACTIONS",
        "content": "See Table 2 for clinically significant drug interactions with naproxen. Table 2: Clinically Significant Drug Interactions with Naproxen. Drugs That Interfere with Hemostasis Clinical Impact: Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of naproxen oral suspension with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and Precautions (5.12) ]. Aspirin Clinical Impact: A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen [ see Clinical Pharmacology (12.2) ]. There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period. Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [ see Warnings and Precautions (5.2) ]. Intervention: Because there may be an increased risk of cardiovascular events following discontinuation of naproxen due to the interference with the antiplatelet effect of aspirin during the washout period, for patients taking low-dose aspirin for cardioprotection who require \u00a0intermittent analgesics, consider use of an NSAID that does not interfere with the antiplatelet effect of aspirin, or non-NSAID analgesics where appropriate. Concomitant use of naproxen oral suspension and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [ see Warnings and Precautions (5.12) ]. Naproxen oral suspension is not a substitute for low dose aspirin for cardiovascular protection. ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Intervention: During concomitant use of naproxen oral suspension and\u00a0 ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. During concomitant use of naproxen oral suspension and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [ see Warnings and Precautions (5.6) ]. When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter. Diuretics Clinical Impact: Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. Intervention: During concomitant use of naproxen oral suspension with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions\u00a0(5.6) ]. Digoxin Clinical Impact: The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin Intervention: During concomitant use of naproxen oral suspension and digoxin, monitor serum digoxin levels. Lithium Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. Intervention: During concomitant use of naproxen oral suspension and lithium, monitor patients for signs of lithium toxicity. Methotrexate Clinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). Intervention: During concomitant use of naproxen oral suspension and methotrexate, monitor patients for methotrexate toxicity. Cyclosporine Clinical Impact: Concomitant use of naproxen oral suspension and cyclosporine may increase cyclosporine\u2019s nephrotoxicity. Intervention: During concomitant use of naproxen oral suspension and cyclosporine, monitor patients for signs of worsening renal function. NSAIDs and Salicylates Clinical Impact: Concomitant use of naproxen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [ see Warnings and Precautions (5.2) ]. Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. Pemetrexed Clinical Impact: Concomitant \u00a0use of naproxen oral suspension and pemetrexed may increase the risk of pemetrexed-associated\u00a0 myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). Intervention: During concomitant use of naproxen oral suspension and\u00a0 pemetrexed,\u00a0 in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min,\u00a0 monitor for myelosuppression,\u00a0 renal and GI toxicity. NSAIDs with short elimination half-lives (e.g., diclofenac,\u00a0 indomethacin) should be avoided for a period of two days before, the day of, and\u00a0 two days following administration of pemetrexed. In the absence of data regarding\u00a0 potential interaction between pemetrexed and NSAIDs with longer half-lives\u00a0 (e.g.,\u00a0 meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration. Antacids and Sucralfate Clinical Impact: Concomitant\u00a0 administration\u00a0of some antacids (magnesium oxide or aluminum hydroxide)\u00a0 and sucralfate can delay the absorption of naproxen. Intervention: Concomitant\u00a0 administration\u00a0of antacids\u00a0 such as magnesium oxide or aluminum hydroxide, and sucralfate with naproxen oral suspension is not recommended. Cholestyramine Clinical Impact: Concomitant\u00a0 administration\u00a0of cholestyramine can delay the absorption of naproxen. Intervention: Concomitant\u00a0 administration\u00a0of cholestyramine with naproxen oral suspension is not recommended. Probenecid Clinical Impact: Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. Intervention: Patients simultaneously receiving naproxen oral suspension and probenecid should be observed for adjustment of dose if required. Other albumin-bound drugs Clinical Impact: Naproxen is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as coumarin-type anticoagulants, sulphonylureas, hydantoins, other NSAIDs, and aspirin [ see Warnings and Precautions (5.2) ]. Intervention: Patients simultaneously receiving naproxen oral suspension and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required. Drug/Laboratory Test Interactions Bleeding times Clinical Impact: Naproxen may decrease platelet aggregation and prolong bleeding time. Intervention: This effect should be kept in\u00a0 mind when bleeding times are determined. Porter-Silber test Clinical Impact: The administration of naproxen\u00a0 may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-di- nitrobenzene used in this assay. Intervention: Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used. Urinary assays of 5-hydroxy\u00a0 indoleacetic acid (5HIAA) Clinical Impact: Naproxen may interfere with\u00a0 some urinary assays of 5-hydroxy indoleacetic\u00a0 acid (5HIAA). Intervention: This \u00a0effect\u00a0should \u00a0be \u00a0kept\u00a0in \u00a0mind\u00a0when \u00a0urinary \u00a05-hydroxy\u00a0indoleacetic\u00a0acid \u00a0is determined."
      },
      {
        "code": "43684-0",
        "type": "USE IN SPECIFIC POPULATIONS SECTION",
        "title": "8 USE IN SPECIFIC POPULATIONS"
      },
      {
        "code": "42228-7",
        "type": "PREGNANCY SECTION",
        "title": "8.1 Pregnancy",
        "content": "Risk Summary Use of NSAIDs, including naproxen oral suspension, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, limit dose and duration of naproxen oral suspension use between about 20 and 30 weeks of gestation, and avoid naproxen oral suspension use at about 30 weeks of gestation and later in pregnancy ( see Clinical Considerations, Data ). Premature Closure of Fetal Ductus Arteriosus Use of NSAIDs, including naproxen oral suspension, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. Data from observational studies regarding other potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. In animal reproduction studies in rats, rabbits, and mice no evidence of teratogenicity or fetal harm when naproxen was administered during the period of organogenesis at doses 0.13, 0.26, and 0.6 times the maximum recommended human daily dose of 1500 mg/day, respectively. Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors such as naproxen, resulted in increased\u00a0pre- and post-implantation loss. Prostaglandins also have been shown to have an important role in fetal kidney development. In published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses. The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy, because NSAIDs, including naproxen oral suspension, can cause premature closure of the fetal ductus arteriosus ( see Data ). Oligohydramnios/Neonatal Renal Impairment: If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit the use to the lowest effective dose and shortest duration possible. If naproxen oral suspension treatment extends beyond 48 hours, consider monitoring with ultrasound for oligohydramnios. If oligohydramnios occurs, discontinue naproxen oral suspension, and follow up according to clinical practice ( see Data ). Labor or Delivery There are no studies on the effects of naproxen oral suspension during labor or delivery. In animal studies, NSAIDS, including naproxen, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth. Data Human Data There is some evidence to suggest that when inhibitors of prostaglandin synthesis are used to delay preterm labor there is an increased risk of neonatal complications such as necrotizing enterocolitis, patent ductus arteriosus and intracranial hemorrhage. Naproxen treatment given in late pregnancy to delay parturition has been associated with persistent pulmonary hypertension, renal dysfunction and abnormal prostaglandin E levels in preterm infants. Because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly starting at 30 weeks of gestation, or third trimester) should be avoided. Premature Closure of Fetal Ductus Arteriosus: Published literature reports that the use of NSAIDs at about 30 weeks of gestation and later in pregnancy may cause premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment: Published studies and postmarketing reports describe maternal NSAID use at about 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. In many cases, but not all, the decrease in amniotic fluid was transient and reversible with cessation of the drug. There have been a limited number of case reports of maternal NSAID use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible. Some cases of neonatal renal dysfunction required treatment with invasive procedures, such as exchange transfusion or dialysis. Methodological limitations of these postmarketing studies and reports include lack of a control group; limited information regarding dose, duration, and timing of drug exposure; and concomitant use of other medications. These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal NSAID use. Because the published safety data on neonatal outcomes involved mostly preterm infants, the generalizability of certain reported risks to the full-term infant exposed to NSAIDs through maternal use is uncertain. Animal Data Reproduction studies have been performed in rats at 20 mg/kg/day (0.13 times the maximum recommended human daily dose of 1500 mg/day based on body surface area comparison), rabbits at 20 mg/kg/day (0.26 times the maximum recommended human daily dose, based on body surface area comparison), and mice at 170 mg/kg/day (0.6 times the maximum recommended human daily dose based on body surface area comparison) with no evidence of impaired fertility or harm to the fetus due to the drug."
      },
      {
        "code": "34079-4",
        "type": "LABOR & DELIVERY SECTION",
        "title": "8.2\u00a0 Lactation",
        "content": "Risk Summary The naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for naproxen oral suspension and any potential adverse effects on the breastfed infant from the naproxen oral suspension or from the underlying maternal condition."
      },
      {
        "code": "34080-2",
        "type": "NURSING MOTHERS SECTION",
        "title": "8.3 Females and Males of Reproductive Potential",
        "content": "Infertility Females Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including naproxen oral suspension, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawal of NSAIDs, including naproxen oral suspension, in women who have difficulties conceiving or who are undergoing investigation of infertility."
      },
      {
        "code": "34081-0",
        "type": "PEDIATRIC USE SECTION",
        "title": "8.4 Pediatric Use",
        "content": "Safety and effectiveness in pediatric patients below the age of 2 years have not been established. Pediatric dosing recommendations for polyarticular juvenile idiopathic arthritis are based on well-controlled studies. There are no adequate effectiveness or dose-response data for other pediatric conditions, but the experience in polyarticular juvenile idiopathic arthritis and other use experience have established that single doses of 2.5 to 5 mg/kg (as naproxen suspension), with total daily dose not exceeding 15 mg/kg/day, are well tolerated in pediatric patients over 2 years of age."
      },
      {
        "code": "34082-8",
        "type": "GERIATRIC USE SECTION",
        "title": "8.5 Geriatric Use",
        "content": "The hepatic and renal tolerability of long-term naproxen administration was studied in two double-blind clinical trials involving 586 patients. Of the patients studied, 98 patients were age 65 and older and 10 of the 98 patients were age 75 and older. Naproxen was administered at doses of 375 mg twice daily or 750 mg twice daily for up to 6 months. Transient abnormalities of laboratory tests assessing hepatic and renal function were noted in some patients, although there were no differences noted in the occurrence of abnormal values among different age groups. Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [ see Warnings and Precautions (5.1 , 5.2 , 5.3 , 5.6 , 5.14) ] . Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. The clinical significance of this finding is unclear, although it is possible that the increase in free naproxen concentration could be associated with an increase in the rate of adverse events per a given dosage in some elderly patients. Caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly, it is prudent to use the lowest effective dose. Experience indicates that geriatric patients may be particularly sensitive to certain adverse effects of nonsteroidal anti-inflammatory drugs. Elderly or debilitated patients seem to tolerate peptic ulceration or bleeding less well when these events do occur. Most spontaneous reports of fatal GI events are in the geriatric population [ see Warnings and Precautions (5.6) ]. Naproxen is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Geriatric patients may be at a greater risk for the development of a form of renal toxicity precipitated by reduced prostaglandin formation during administration of nonsteroidal anti-inflammatory drugs [ see Warnings and Precautions (5.6) ]."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "8.6 Hepatic Impairment",
        "content": "Caution is advised when high doses are required and some adjustment of dosage may be required in these patients. It is prudent to use the lowest effective dose [ see Clinical Pharmacology (12.3) ]."
      },
      {
        "code": "42229-5",
        "type": "Spl Unclassified Section",
        "title": "8.7 Renal Impairment",
        "content": "Naproxen-containing products are not recommended for use in patients with moderate to severe and severe renal impairment (creatinine clearance <30 mL/min) [ see Warnings and Precautions (5.6) , Clinical Pharmacology (12.3) ]."
      },
      {
        "code": "34088-5",
        "type": "OVERDOSAGE SECTION",
        "title": "10 OVERDOSAGE",
        "content": "Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare. A few patients have experienced convulsions, but it is not clear whether or not these were drug-related. It is not known what dose of the drug would be life threatening [ see Warnings and Precautions\u00a0(5.1 , 5.2 ) ]. Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. There are no specific antidotes. Hemodialysis does not decrease the plasma concentration of naproxen because of the high degree of its protein binding. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding. For additional information about overdosage treatment contact a poison control center (1-800-222-1222)."
      },
      {
        "code": "34089-3",
        "type": "DESCRIPTION SECTION",
        "title": "11 DESCRIPTION",
        "content": "Naproxen oral suspension, USP is available as a light orange-colored, pineapple-orange flavored homogenous suspension \u00a0containing 125 mg/5 mL of naproxen USP for oral administration. Naproxen is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs. The chemical name is (S)-6-methoxy-\u03b1-methyl-2-naphthaleneacetic acid. The molecular weight is 230.26. Its molecular formula is C 14 H 14 O 3 , and it has the following chemical structure. Naproxen USP is\u00a0a white to off-white crystalline powder. It is soluble in chloroform, in dehydrated alcohol, and in alcohol, sparingly soluble in ether, practically insoluble in water. The octanol/water partition coefficient of naproxen at pH 7.4 is 1.6 to 1.8. The inactive ingredients in naproxen oral suspension USP include art pineapple\u00a0flavor, benzyl alcohol, FD&C yellow No. 6, fumaric acid, magnesium aluminum silicate, methylparaben, modified food starch\u00a0(corn),\u00a0\u00a0nat orange flavor, noncrystallizing sorbitol solution, propylene glycol, purified water, sodium chloride (39 mg/5 mL, 0.667 mEq), sucrose, and xanthan gum. The pH of the suspension ranges from 2.2 to 3.7."
      },
      {
        "code": "34090-1",
        "type": "CLINICAL PHARMACOLOGY SECTION",
        "title": "12 CLINICAL PHARMACOLOGY"
      },
      {
        "code": "43679-0",
        "type": "MECHANISM OF ACTION SECTION",
        "title": "12.1 Mechanism of Action",
        "content": "Naproxen has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of naproxen, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Naproxen is a potent inhibitor of prostaglandin synthesis in vitro . Naproxen concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because naproxen is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues."
      },
      {
        "code": "43681-6",
        "type": "PHARMACODYNAMICS SECTION",
        "title": "12.2 Pharmacodynamics",
        "content": "In a healthy volunteer study, 10 days of concomitant administration of naproxen 220 mg once-daily with low-dose immediate-release aspirin (81 mg) showed an interaction with the antiplatelet activity of aspirin as measured by % serum thromboxane B2 inhibition at 24 hours following the day 10 dose [98.7% (aspirin alone) vs 93.1% (naproxen and aspirin)]. The interaction was observed even following discontinuation of naproxen on day 11 (while aspirin dose was continued) but normalized by day 13. In the same study, the interaction was greater when naproxen was administered 30 minutes prior to aspirin [98.7% vs 87.7%] and minimal when aspirin was administered 30 minutes prior to naproxen [98.7% vs 95.4%]. Following administration of naproxen 220 mg twice-daily with low-dose immediate release aspirin (first naproxen dose given 30 minutes prior to aspirin), the interaction was minimal at 24 h following day 10 dose [98.7% vs 95.7%]. However, the interaction was more prominent after discontinuation of naproxen (washout) on day 11 [98.7% vs 84.3%] and did not normalize completely by day 13 [98.5% vs 90.7%]. [see Drug Interactions (7) ] ."
      },
      {
        "code": "43682-4",
        "type": "PHARMACOKINETICS SECTION",
        "title": "12.3 Pharmacokinetics",
        "content": "Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%. The elimination half-life of naproxen ranges from 12 to 17 hours. Steady-state levels of naproxen are reached in 4 to 5 days, and the degree of naproxen accumulation is consistent with this half-life. Absorption Peak plasma levels of naproxen given as naproxen oral suspension are attained in 1 to 4 hours. When naproxen oral suspension and immediate release naproxen tablets were given to fasted subjects (n=12) in a single-dose, crossover study, there were comparable pharmacokinetic parameters between the two formulations. Naproxen Oral Suspension Naproxen Tablets 500 mg C max (mcg/mL) 64.3 71.1 T max (hours) 2.6 2.3 T 1/2 (hours) 16.8 16.3 AUC 0\u2013t (mcg\u00b7hr/mL) 1249 1218 Distribution Naproxen has a volume of distribution of 0.16 L/kg. At therapeutic levels naproxen is greater than 99% albumin-bound. At doses of naproxen greater than 500 mg/day there is less than proportional increase in plasma levels due to an increase in clearance caused by saturation of plasma protein binding at higher doses (average trough Css 36.5, 49.2 and 56.4 mg/L with 500, 1000 and 1500 mg daily doses of naproxen, respectively). The naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma [ see Use in Specific Populations (8.2) ] . Elimination Metabolism Naproxen is extensively metabolized in the liver to 6-0-desmethyl naproxen, and both parent and metabolites do not induce metabolizing enzymes. Both naproxen and 6-0-desmethyl naproxen are further metabolized to their respective acylglucuronide conjugated metabolites. Excretion The clearance of naproxen is 0.13 mL/min/kg. Approximately 95% of the naproxen from any dose is excreted in the urine, primarily as naproxen (<1%), 6-0-desmethyl naproxen (<1%) or their conjugates (66% to 92%). The plasma half-life of the naproxen anion in humans ranges from 12 to 17 hours. The corresponding half-lives of both naproxen\u2019s metabolites and conjugates are shorter than 12 hours, and their rates of excretion have been found to coincide closely with the rate of naproxen clearance from the plasma. Small amounts, 3% or less of the administered dose, are excreted in the feces. In patients with renal failure metabolites may accumulate [ see Warnings and Precautions (5.6) ]. Specific Populations Pediatric In pediatric patients aged 5 to 16 years with arthritis, plasma naproxen levels following a 5 mg/kg single dose of naproxen suspension [see Dosage and Administration (2) ] were found to be similar to those found in normal adults following a 500 mg dose. The terminal half-life appears to be similar in pediatric and adult patients. Pharmacokinetic studies of naproxen were not performed in pediatric patients younger than 5 years of age. Pharmacokinetic parameters appear to be similar following administration of naproxen oral suspension or tablets in pediatric patients. Geriatric Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly, although the unbound fraction is <1% of the total naproxen concentration. Unbound trough naproxen concentrations in elderly subjects have been reported to range from 0.12% to 0.19% of total naproxen concentration, compared with 0.05% to 0.075% in younger subjects. Hepatic Impairment Naproxen pharmacokinetics has not been determined in subjects with hepatic insufficiency. Chronic alcoholic liver disease and probably other diseases with decreased or abnormal plasma proteins (albumin) reduce the total plasma concentration of naproxen, but the plasma concentration of unbound naproxen is increased. Renal Impairment Naproxen pharmacokinetics has not been determined in subjects with renal insufficiency. Given that naproxen, its metabolites and conjugates are primarily excreted by the kidney, the potential exists for naproxen metabolites to accumulate in the presence of renal insufficiency. Elimination of naproxen is decreased in patients with severe renal impairment. Drug Interaction Studies Aspirin When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. The clinical significance of this interaction is not known. See Table 2 for clinically significant drug interactions of NSAIDs with aspirin [ see Drug Interactions (7) ] ."
      },
      {
        "code": "43680-8",
        "type": "NONCLINICAL TOXICOLOGY SECTION",
        "title": "13 NONCLINICAL TOXICOLOGY"
      },
      {
        "code": "34083-6",
        "type": "CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION",
        "title": "13.1 Carcinogenesis, Mutagenesis,\u00a0Impairment of Fertility",
        "content": "Carcinogenesis A 2-year study was performed in rats to evaluate the carcinogenic potential of naproxen at rat doses of 8, 16, and 24 mg/kg/day (0.05, 0.1, and 0.16 times the maximum recommended human daily dose of 1500 mg/day based on a body surface area comparison). No evidence of tumorigenicity was found. Mutagenesis Naproxen tested positive in the in vivo sister chromatid exchange assay for but was not mutagenic in the in vitro bacterial reverse mutation assay (Ames test). Impairment of Fertility Male rats were treated with 2, 5, 10, and 20 mg/kg naproxen by oral gavage for 60 days prior to mating and female rats were treated with the same doses for 14 days prior to mating and for the first 7 days of pregnancy. There were no adverse effects on fertility noted (up to 0.13 times the MRDH based on body surface area)."
      },
      {
        "code": "34092-7",
        "type": "CLINICAL STUDIES SECTION",
        "title": "14 CLINICAL STUDIES",
        "content": "Naproxen has been studied in patients with rheumatoid arthritis, osteoarthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, tendonitis and bursitis, and acute gout. Improvement in patients treated for rheumatoid arthritis was demonstrated by a reduction in joint swelling, a reduction in duration of morning stiffness, a reduction in disease activity as assessed by both the investigator and patient, and by increased mobility as demonstrated by a reduction in walking time. Generally, response to naproxen has not been found to be dependent on age, sex, severity or duration of rheumatoid arthritis. In patients with osteoarthritis, the therapeutic action of naproxen has been shown by a reduction in joint pain or tenderness, an increase in range of motion in knee joints, increased mobility as demonstrated by a reduction in walking time, and improvement in capacity to perform activities of daily living impaired by the disease. In a clinical trial comparing standard formulations of naproxen 375 mg twice a day (750 mg a day) vs 750 mg twice a day (1500 mg/day), 9 patients in the 750 mg group terminated prematurely because of adverse events. Nineteen patients in the 1500 mg group terminated prematurely because of adverse events. Most of these adverse events were gastrointestinal events. In clinical studies in patients with rheumatoid arthritis, osteoarthritis, and polyarticular juvenile idiopathic arthritis, naproxen has been shown to be comparable to aspirin and indomethacin in controlling the aforementioned measures of disease activity, but the frequency and severity of the milder gastrointestinal adverse effects (nausea, dyspepsia, heartburn) and nervous system adverse effects (tinnitus, dizziness, lightheadedness) were less in naproxen-treated patients than in those treated with aspirin or indomethacin. In patients with ankylosing spondylitis, naproxen has been shown to decrease night pain, morning stiffness and pain at rest. In double-blind studies the drug was shown to be as effective as aspirin, but with fewer side effects. In patients with acute gout, a favorable response to naproxen was shown by significant clearing of inflammatory changes (e.g., decrease in swelling, heat) within 24 to 48 hours, as well as by relief of pain and tenderness. Naproxen has been studied in patients with mild to moderate pain secondary to postoperative, orthopedic, postpartum episiotomy and uterine contraction pain and dysmenorrhea. Onset of pain relief can begin within 1 hour in patients taking naproxen. Analgesic effect was shown by such measures as reduction of pain intensity scores, increase in pain relief scores, decrease in numbers of patients requiring additional analgesic medication, and delay in time to remedication. The analgesic effect has been found to last for up to 12 hours. Naproxen may be used safely in combination with gold salts and/or corticosteroids; however, in controlled clinical trials, when added to the regimen of patients receiving corticosteroids, it did not appear to cause greater improvement over that seen with corticosteroids alone. Whether naproxen has a \u201csteroid-sparing\u201d effect has not been adequately studied. When added to the regimen of patients receiving gold salts, naproxen did result in greater improvement. Its use in combination with salicylates is not recommended because there is evidence that aspirin increases the rate of excretion of naproxen and data are inadequate to demonstrate that naproxen and aspirin produce greater improvement over that achieved with aspirin alone. In addition, as with other NSAIDs, the combination may result in higher frequency of adverse events than demonstrated for either product alone. In 51 Cr blood loss and gastroscopy studies with normal volunteers, daily administration of 1000 mg of naproxen has been demonstrated to cause statistically significantly less gastric bleeding and erosion than 3250 mg of aspirin."
      },
      {
        "code": "34069-5",
        "type": "HOW SUPPLIED SECTION",
        "title": "16 HOW SUPPLIED/STORAGE AND HANDLING",
        "content": "Naproxen Oral Suspension USP: 125 mg/5 mL (contains 39 mg sodium) is available as light orange-colored, pineapple-orange flavored homogenous suspension in 1 pint (473 mL) light-resistant bottles. It is supplied as follows: Bottle of 473 mL\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-528-47 Storage Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP\u00a0Controlled Room Temperature]. Avoid excessive heat above 40\u00b0C (104\u00b0F). Dispense in light-resistant containers. Shake gently before use."
      },
      {
        "code": "34076-0",
        "type": "INFORMATION FOR PATIENTS SECTION",
        "title": "17 PATIENT COUNSELING INFORMATION",
        "content": "Advise the patient and caregiver to read the FDA-approved patient labeling ( Medication Guide ) that accompanies each prescription dispensed. Inform patients, families, or their caregivers should be informed of the following information before initiating therapy with naproxen oral suspension and periodically during the course of ongoing therapy. Cardiovascular Thrombotic Events Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their health care provider immediately [ see Warnings and Precautions (5.1) ]. Gastrointestinal Bleeding, Ulceration, and Perforation Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their health care provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for and the signs and symptoms of GI bleeding [ see Warnings and Precautions (5.2) ]. Hepatotoxicity Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, diarrhea, jaundice, right upper quadrant tenderness, and \u201cflu-like\u201d symptoms). If these occur, instruct patients to stop naproxen oral suspension and seek immediate medical therapy [ see Warnings and Precautions\u00a0(5.3) ]. Heart Failure and Edema Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [ see Warnings and Precautions\u00a0(5.5) ]. Anaphylactic Reactions Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [ see Contraindications (4) and Warnings and Precautions (5.7) ]. Serious Skin Reactions, including DRESS Advise patients to stop taking naproxen oral suspension immediately if they develop any type of rash or fever and to contact their healthcare provider as soon as possible [ see Warnings and Precautions (5.9 , 5.10) ]. Female Fertility Advise females of reproductive potential who desire pregnancy that NSAIDs, including naproxen oral suspension, may be associated with a reversible delay in ovulation [ see Use in Specific Populations (8.3) ]. Fetal Toxicity Inform pregnant women to avoid use of naproxen oral suspension and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus. If treatment with naproxen oral suspension is needed for a pregnant woman between about 20 to 30 weeks gestation, advise her that she may need to be monitored for oligohydramnios, if treatment continues for longer than 48 hours [ see Warnings and Precautions (5.11) and Use in Specific Populations (8.1) ]. Avoid Concomitant Use of NSAIDs Inform patients that the concomitant use of naproxen oral suspension with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [see Warnings and Precautions (5.2) and Drug Interactions (7) ]. Alert patients that NSAIDs may be present in \u201cover the counter\u201d medications for treatment of colds, fever, or insomnia. Use of NSAIDS and Low-Dose Aspirin Inform patients not to use low-dose aspirin concomitantly with naproxen oral suspension until they talk to their healthcare provider [see Drug Interactions (7) ]. Dosing Instructions Instruct patients on how to measure and take the correct dose of naproxen oral suspension and to always use a calibrated measuring device when administering naproxen oral suspension to ensure the dose is measured and administered accurately [ see Dosage and Administration (2.1) ]. If the prescribed concentration is changed, instruct patients on how to correctly measure the new dose to avoid errors. Dispense with Medication Guide available at: www.aurobindousa.com/medication-guides Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Issued: January 2025 Dispense with Medication Guide available at: www.aurobindousa.com/medication-guides"
      },
      {
        "code": "42231-1",
        "type": "SPL MEDGUIDE SECTION",
        "content": "Medication Guide for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)? NSAIDs can cause serious side effects, including: Increased risk of a heart attack or stroke that can lead to death. This risk may happen\u00a0early in treatment and may increase: o\u00a0\u00a0 with increasing doses of NSAIDs o\u00a0\u00a0 with longer use of NSAIDs Do not take NSAIDs right before or after a heart surgery called a \u201ccoronary artery bypass graft (CABG).\" Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines: o\u00a0\u00a0 anytime during use o\u00a0\u00a0 without warning symptoms o\u00a0\u00a0 that may cause death The risk of getting an ulcer or bleeding increases with: o\u00a0\u00a0\u00a0\u00a0\u00a0 past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs o\u00a0\u00a0\u00a0\u00a0\u00a0 taking medicines called \u201ccorticosteroids\u201d, \u201canticoagulants\u201d, \u201cSSRIs\u201d, or \u201cSNRIs\u201d o\u00a0\u00a0\u00a0\u00a0\u00a0 increasing doses of NSAIDs o\u00a0\u00a0\u00a0\u00a0\u00a0 older age o\u00a0\u00a0\u00a0\u00a0\u00a0 longer use of NSAIDs o\u00a0\u00a0\u00a0\u00a0\u00a0 poor health o\u00a0\u00a0\u00a0\u00a0 \u00a0smoking o\u00a0\u00a0\u00a0\u00a0\u00a0 advanced liver disease o\u00a0\u00a0\u00a0\u00a0\u00a0 drinking alcohol o\u00a0\u00a0\u00a0\u00a0\u00a0 bleeding problems NSAIDs should only be used: exactly as prescribed at the lowest dose possible for your treatment for the shortest time needed What are NSAIDs? NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain. Who should not take NSAIDs? Do not take NSAIDs: if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs. right before or after heart bypass surgery. How should I take naproxen oral suspension? Use ONLY a calibrated measuring device to measure your dose of naproxen oral suspension. DO NOT use a household teaspoon or tablespoon. Your pharmacist can provide you with the proper device to correctly measure your dose. Before taking NSAIDS, tell your healthcare provider about all of your medical conditions, including if you: have liver or kidney problems have high blood pressure have asthma are pregnant or plan to become pregnant. Taking NSAIDs at about 20 weeks of pregnancy or later may harm your unborn baby. If you need to take NSAIDs for more than 2 days when you are between 20 and 30 weeks of pregnancy, your healthcare provider may need to monitor the amount of fluid in your womb around your baby. You should not take NSAIDs after about 30 weeks of pregnancy. are breastfeeding or plan to breast feed. Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. NSAIDs and some other medicines can interact with each other and cause serious side effects. Do not start taking any new medicine without talking to your healthcare provider first. What are the possible side effects of NSAIDs? NSAIDs can cause serious side effects, including: See \u201cWhat is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)? new or worse high blood pressure heart failure liver problems including liver failure kidney problems including kidney failure low red blood cells \u00a0(anemia) life-threatening skin reactions life-threatening allergic reactions Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness. Get emergency help right away if you get any of the following symptoms: shortness of breath or trouble breathing slurred speech chest pain swelling of the face or throat weakness in one part or side of your body Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms: nausea more tired or weaker than usual diarrhea itching your skin or eyes look yellow indigestion or stomach pain flu-like symptoms vomit blood there is blood in your bowel movement or it is black and sticky like tar unusual weight gain skin rash or blisters with fever swelling of the arms, legs, hands and feet If you take too much of your NSAID, call your healthcare provider or get medical help right away. These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Other information about NSAIDs Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines. Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days. General information about the safe and effective use of NSAIDs Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals. Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India For more information, call Aurobindo Pharma USA, Inc. 1-866-850-2876. This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: January 2025"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 125 mg/5 mL (473 mL Container Label)",
        "content": "NDC 59651-528-47 Rx only Naproxen Oral Suspension, USP 125 mg/5 mL FOR ORAL ADMINSTRATION ONLY. SHAKE WELL BEFORE USING. PHARMACIST: Dispense the Medication Guide provided separately to each patient. AUROBINDO\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 473 mL"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 125 mg/5 mL (473 mL Container Carton Label)",
        "content": "NDC 59651-528-47 Rx only Naproxen Oral Suspension, USP 125 mg/5 mL FOR ORAL ADMINSTRATION ONLY. SHAKE WELL BEFORE USING. PHARMACIST: Dispense the Medication Guide provided separately to each patient. 473 mL AUROBINDO"
      }
    ],
    "category": "Prescription"
  },
  {
    "filename": "prescription_da424329-9a63-4df3-bced-4157d2086e20.xml",
    "document_id": "da424329-9a63-4df3-bced-4157d2086e20",
    "document_type": "HUMAN PRESCRIPTION DRUG LABEL",
    "title": "\n      ",
    "effective_date": "20250825",
    "version": "5",
    "author": {
      "name": "Hikma Specialty USA Inc.",
      "id": "078883518"
    },
    "product": {
      "ndc": "59467-679",
      "name": "KLOXXADO",
      "form": "SPRAY",
      "generic_name": "Naloxone HCL",
      "active_ingredients": [
        {
          "name": "NALOXONE HYDROCHLORIDE",
          "code": "F850569PQR",
          "strength": "8 mg",
          "per": "0.1 mL"
        }
      ],
      "inactive_ingredients": [
        "EDETATE DISODIUM",
        "PROPYLENE GLYCOL",
        "WATER",
        "SODIUM HYDROXIDE",
        "HYDROCHLORIC ACID",
        "ALCOHOL"
      ],
      "packaging": [
        {
          "quantity": "0.1 mL",
          "ndc": "59467-679-01",
          "container": "VIAL, SINGLE-DOSE"
        }
      ],
      "route": "NASAL",
      "marketing_status": "active",
      "marketing_start_date": "20210803",
      "approval_status": "NDA"
    },
    "sections": [
      {
        "code": "48780-1",
        "type": "SPL product data elements section"
      },
      {
        "code": "43683-2",
        "type": "RECENT MAJOR CHANGES SECTION"
      },
      {
        "code": "34067-9",
        "type": "INDICATIONS & USAGE SECTION",
        "title": "1 INDICATIONS AND USAGE ",
        "content": "KLOXXADO is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. KLOXXADO is intended for immediate administration as emergency therapy in settings where opioids may be present. KLOXXADO is not a substitute for emergency medical care."
      },
      {
        "code": "34068-7",
        "type": "DOSAGE & ADMINISTRATION SECTION",
        "title": "2 DOSAGE AND ADMINISTRATION "
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "2.1 Important Dosage and Administration Instructions ",
        "content": "\u2022 KLOXXADO is for intranasal use only. \u2022 One spray delivers the entire contents of the drug product. \u2022 All approved naloxone hydrochloride products achieve plasma concentrations that have been shown to be efficacious in reversing the effects of opioid overdose. Comparing different products on a nominal mg-for-mg basis may be misleading [see Clinical Pharmacology ( 12.3 )] . \u2022 The device is ready to use. Do not prime or test prior to administration. \u2022 Do not attempt to reuse KLOXXADO. Each KLOXXADO contains a single dose of naloxone and cannot be reused. \u2022 Because suspected opioid overdose is usually managed by someone other than the patient, instruct the prescription recipient to inform those around them about the presence of KLOXXADO and the Instructions for Use . Instruct the patient or caregiver to read the Instructions for Use at the time they receive a prescription for KLOXXADO. Emphasize the following instructions to the patient or caregiver. \u2022 Administer KLOXXADO as quickly as possible because prolonged respiratory depression may result in damage to the central nervous system or death. \u2022 Always seek immediate emergency medical assistance after the first dose of KLOXXADO has been administered in the event of a suspected, potentially life-threatening opioid emergency because the duration of action of most opioids exceeds that of naloxone hydrochloride. Keep the patient under continued surveillance and administer repeated doses of KLOXXADO, as necessary, until emergency personnel arrive [see Warnings and Precautions ( 5.1 )]. \u2022 Administer KLOXXADO according to the printed instructions on the carton and the Instructions for Use . \u2022 Place the patient in the supine position. Prior to administration, be sure the device nozzle is inserted in either nostril of the patient and provide support to the back of the neck to allow the head to tilt back. Do not prime or test the device prior to administration. \u2022 To administer the dose, press firmly on the device plunger and remove the device nozzle from the nostril after use. Place the patient in recovery position by turning him/her onto their side as shown in the Instructions for Use and call for emergency medical assistance immediately after the first dose of KLOXXADO. \u2022 Administer additional doses of KLOXXADO, using a new nasal spray, every 2 to 3 minutes as needed if the patient does not respond or responds and then relapses into respiratory depression. Administer KLOXXADO in alternate nostrils with each dose [see Dosing and Administration (2.2)]."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "2.2 Dosing in Adult and Pediatric Patients ",
        "content": "Initial Dosing KLOXXADO nasal spray, 8 mg The recommended initial dose of KLOXXADO in adult and pediatric patients is one spray delivered by intranasal administration into one nostril, which delivers 8 mg of naloxone hydrochloride to adult or pediatric patients. Repeat Dosing Seek emergency medical assistance as soon as possible, after administering the first dose of KLOXXADO. If the desired response is not obtained after 2 or 3 minutes, administer an additional dose using a new KLOXXADO in alternate nostril. If there is still no response and additional doses are available, administer additional doses of KLOXXADO every 2 to 3 minutes, alternating nostrils and using a new KLOXXADO, until emergency medical assistance arrives. The requirement for repeat doses of KLOXXADO depends upon the amount, type, and route of administration of the opioid being antagonized. If the patient responds to KLOXXADO and subsequently relapses back into respiratory depression before emergency assistance arrives, administer an additional dose using a new KLOXXADO, in the opposite nostril, and continue surveillance of the patient. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance. Reversal of respiratory depression by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete and require repeated administration of KLOXXADO using a new nasal spray [see Warnings and Precautions ( 5.2 )]."
      },
      {
        "code": "43678-2",
        "type": "DOSAGE FORMS & STRENGTHS SECTION",
        "title": "3 DOSAGE FORMS AND STRENGTHS ",
        "content": "Nasal spray: a clear, colorless to yellow solution filled into a clear glass vial, stoppered, and fitted with a unit-dose nasal spray device containing 8 mg of naloxone hydrochloride (equivalent to 7.2 mg naloxone) in 0.1 mL of spray."
      },
      {
        "code": "34070-3",
        "type": "CONTRAINDICATIONS SECTION",
        "title": "4 CONTRAINDICATIONS ",
        "content": "KLOXXADO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients in KLOXXADO."
      },
      {
        "code": "43685-7",
        "type": "WARNINGS AND PRECAUTIONS SECTION",
        "title": "5 WARNINGS AND PRECAUTIONS "
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.1 Risk of Recurrent Respiratory and Central Nervous System Depression  ",
        "content": "The duration of action of most opioids may exceed that of KLOXXADO resulting in a return of respiratory and/or central nervous system depression after an initial improvement in symptoms. Therefore, it is necessary to seek emergency assistance immediately after administration of the first dose of KLOXXADO and to keep the patient under continued surveillance. Administer additional doses of KLOXXADO if the patient is not adequately responding or responds and then relapses back into respiratory depression, as necessary [see Dosage and Administration ( 2.2 )] . Additional supportive and/or resuscitative measure may be helpful while awaiting emergency medical assistance."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.2 Risk of Limited Efficacy with Partial Agonists or Mixed Agonist/Antagonists ",
        "content": "Reversal of respiratory depression by partial agonists or mixed/antagonists such as buprenorphine and pentazocine may be incomplete. Larger or repeat doses of naloxone hydrochloride may be required to antagonize buprenorphine because the latter has a long duration of action due to its slow rate of binding and subsequent slow dissociation from the opioid receptor [see Dosage and Administration ( 2.2 )] . Buprenorphine antagonism is characterized by a gradual onset of the reversal effects and a decreased duration of action of the normally prolonged respiratory depression."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "5.3 Precipitation of Severe Opioid Withdrawal ",
        "content": "The use of KLOXXADO in patients who are opioid-dependent may precipitate opioid withdrawal; the risk and severity of withdrawal increases as naloxone exposure increases. Opioid withdrawal is characterized by the following signs and symptoms: body aches, diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may include the following signs and symptoms: convulsion, excessive crying, and hyperactive reflexes. Monitor the patient for the development of the signs and symptoms of opioid withdrawal. Abrupt postoperative reversal of opioid depression after using naloxone hydrochloride may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor patients with pre-existing cardiac disease or patients who have received medications with potential adverse cardiovascular effects for hypotension, ventricular tachycardia or fibrillation, and pulmonary edema in an appropriate healthcare setting. It has been suggested that the pathogenesis of pulmonary edema associated with the use of naloxone hydrochloride is similar to neurogenic pulmonary edema, i.e., a centrally mediated massive catecholamine response leading to a dramatic shift of blood volume into the pulmonary vascular bed resulting in increased hydrostatic pressures. There may be clinical settings, particularly the postpartum period in neonates with known or suspected exposure to maternal opioid use, where it is preferable to avoid the abrupt precipitation of opioid withdrawal symptoms. In these settings, consider use of an alternative, naloxone-containing product that can be titrated to effect and, where applicable, dosed according to weight [see Use in Specific Population ( 8.4 )]."
      },
      {
        "code": "34084-4",
        "type": "ADVERSE REACTIONS SECTION",
        "title": "6 ADVERSE REACTIONS ",
        "content": "The following serious adverse reactions are discussed elsewhere in the labeling: \u2022 Recurrent Respiratory and Central Nervous System Depression [see Warnings and Precautions ( 5.1 )] \u2022 Precipitation of Severe Opioid Withdrawal [see Warnings and Precautions ( 5.3 )]"
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "6.1 Clinical Trials Experience ",
        "content": "Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice. KLOXXADO nasal spray, 4 mg No adverse events were reported in a pharmacokinetic study of 72 healthy adult volunteers exposed to one spray of 4 mg KLOXXADO nasal spray in one nostril. KLOXXADO nasal spray, 8 mg In two pharmacokinetic studies a total of 47 healthy adult volunteers were exposed to a single dose of KLOXXADO nasal spray 8 mg, one spray in one nostril.  The following adverse reactions were reported in two subjects each: abdominal pain, asthenia, dizziness, headache, nasal discomfort, and presyncope. On local tissue assessments for nasal irritation, signs of nasal inflammation and nasal congestion were observed."
      },
      {
        "code": "42229-5",
        "type": "SPL UNCLASSIFIED SECTION",
        "title": "6.2 Postmarketing Experience  ",
        "content": "The following adverse events have been identified during the post-approval use of naloxone hydrochloride injection in the postoperative setting. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. Excessive doses of naloxone hydrochloride in postoperative patients have resulted in significant reversal of analgesia and have caused agitation. Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated an acute withdrawal syndrome. Signs and symptoms have included: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, tachycardia. In some patients, there was aggressive behavior upon abrupt reversal of an opioid overdose. In the neonate, opioid withdrawal has included: convulsions, excessive crying, hyperactive reflexes [see Warnings and Precautions ( 5.3 )] . The following most frequently reported events (in decreasing frequency) have been identified primarily during post-approval use of naloxone hydrochloride (all routes of administration): withdrawal syndrome, vomiting, nonresponsiveness to stimuli, drug ineffective, agitation, somnolence, and loss of consciousness."
      },
      {
        "code": "43684-0",
        "type": "USE IN SPECIFIC POPULATIONS SECTION",
        "title": "8 USE IN SPECIFIC POPULATIONS  "
      },
      {
        "code": "42228-7",
        "type": "PREGNANCY SECTION",
        "title": "8.1 Pregnancy ",
        "content": "Risk Summary Available data from retrospective cohort studies on naloxone use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Naloxone may precipitate opioid withdrawal in the pregnant woman and fetus [see Warnings and Precautions ( 5.3 ) and Clinical Considerations ] . In animal reproduction studies, no embryotoxic or teratogenic effects were observed in mice and rats treated with naloxone hydrochloride during the period of organogenesis at doses equivalent to 3-times and 6-times, respectively, a human dose of 16 mg (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Maternal and Fetal/Neonatal Adverse Reactions Naloxone hydrochloride crosses the placenta, and may precipitate withdrawal in the fetus, as well as in the opioid-dependent mother [see Warnings and Precautions ( 5.3 )] . The fetus should be evaluated for signs of distress after KLOXXADO is used. Careful monitoring is needed until the fetus and mother are stabilized. Data Animal Data Naloxone hydrochloride was administered during organogenesis to mice and rats at doses 3-times and 6-times, respectively, a human dose of 16 mg based on body surface area comparison. These studies demonstrated no embryotoxic or teratogenic effects due to naloxone hydrochloride."
      },
      {
        "code": "77290-5",
        "type": "LACTATION SECTION",
        "title": "8.2 Lactation ",
        "content": "Risk Summary There is no information regarding the presence of naloxone in human milk, the effects of naloxone on the breastfed infant or on milk production. Studies in nursing mothers have shown that naloxone does not affect prolactin or oxytocin hormone levels. Naloxone is minimally orally available and is unlikely to affect the breastfed infant."
      },
      {
        "code": "34081-0",
        "type": "PEDIATRIC USE SECTION",
        "title": "8.4 Pediatric Use ",
        "content": "The safety and effectiveness of KLOXXADO have been established in pediatric patients of all ages for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Use of naloxone hydrochloride in pediatric patients is supported by evidence from adult bioavailability studies with additional evidence from the reported safe and effective use of other naloxone hydrochloride products. No pediatric studies were conducted for KLOXXADO. Absorption of naloxone hydrochloride following intranasal administration in pediatric patients may be erratic or delayed. Even when the opiate-intoxicated pediatric patient responds appropriately to naloxone hydrochloride, he/she must be carefully monitored for at least 24 hours, as a relapse may occur as naloxone hydrochloride is metabolized. In opioid-dependent pediatric patients, (including neonates), administration of naloxone hydrochloride may result in an abrupt and complete reversal of opioid effects, precipitating an acute opioid withdrawal syndrome. There may be clinical settings, particularly the postpartum period in neonates with known or suspected exposure to maternal opioid use, where it is preferable to avoid the abrupt precipitation of opioid withdrawal symptoms. Unlike acute opioid withdrawal in adults, acute opioid withdrawal in neonates manifesting as seizures may be life-threatening if not recognized and properly treated. Other signs and symptoms in neonates may include excessive crying and hyperactive reflexes. In these settings where it may be preferable to avoid the abrupt precipitation of acute opioid withdrawal symptoms, consider use of an alternative, naloxone hydrochloride product that can be dosed according to weight and titrated to effect [see Warnings and Precautions ( 5.3 )]. Also, in situations where the primary concern is for infants at risk for opioid overdose, consider whether the availability of alternate naloxone-containing products may be better suited than KLOXXADO. Juvenile Animal Study In a juvenile animal study, male and female juvenile rats were administered a single intranasal dose of saline, vehicle consisting of 20% alcohol and 5% propylene glycol, or naloxone (123 mg/kg, 185 mg/kg, and 246 mg/kg) on postnatal day 7 (PND 7). There were no test article-related findings on sexual maturation, neuroapoptosis, or on a limited number of neurocognitive endpoints which included social interactions as well as learning and memory. The no-effect dose level for neurodevelopmental toxicity was the high dose tested, which is 2.7-times a neonate dose based on body surface area comparison and a neonate weight of 2.5 kg."
      },
      {
        "code": "34082-8",
        "type": "GERIATRIC USE SECTION",
        "title": "8.5 Geriatric Use ",
        "content": "Clinical studies of KLOXXADO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."
      },
      {
        "code": "34089-3",
        "type": "DESCRIPTION SECTION",
        "title": "11 DESCRIPTION ",
        "content": "KLOXXADO (naloxone hydrochloride) nasal spray contains the active moiety naloxone, an opioid antagonist, in the form of hydrochloride salt.  The chemical name of Naloxone hydrochloride dihydrate is 17-Allyl-4,5\u03b1-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride dihydrate. It has the molecular weight of 399.87 g/mol. Naloxone hydrochloride dihydrate molecular formula is C 19 H 21 NO 4\u00b7 HCl \u00b7 2H 2 O, and it has the following chemical structure, as shown below. Naloxone hydrochloride occurs as a white to slightly off-white powder, and is soluble in water, in dilute acids, and in strong alkali; slightly soluble in alcohol; practically insoluble in ether and in chloroform. KLOXXADO (naloxone hydrochloride) nasal spray is supplied in a pre-filled, single-dose intranasal spray.  Each spray or 0.1 mL of KLOXXADO (naloxone hydrochloride) nasal spray contains 8 mg of naloxone hydrochloride (equivalent to 8.79 mg of naloxone hydrochloride dihydrate, USP or 7.2 mg naloxone). Inactive ingredients are dehydrated alcohol (8 mg strength: 20% (w/w)), edetate disodium dihydrate, USP, propylene glycol, USP, and sodium hydroxide, NF and hydrochloric acid, NF as pH adjusters, in purified water, USP. The pH range for KLOXXADO (naloxone hydrochloride) nasal spray is from 4.0 to 5.5."
      },
      {
        "code": "34090-1",
        "type": "CLINICAL PHARMACOLOGY SECTION",
        "title": "12 CLINICAL PHARMACOLOGY "
      },
      {
        "code": "43679-0",
        "type": "MECHANISM OF ACTION SECTION",
        "title": "12.1 Mechanism of Action ",
        "content": "Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Administration of naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine."
      },
      {
        "code": "43681-6",
        "type": "PHARMACODYNAMICS SECTION",
        "title": "12.2 Pharmacodynamics ",
        "content": "When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The time to onset of action is shorter for intravenous compared to subcutaneous or intramuscular routes of administration. The duration of action is dependent upon the dose and route of administration of naloxone hydrochloride."
      },
      {
        "code": "43682-4",
        "type": "PHARMACOKINETICS SECTION",
        "title": "12.3 Pharmacokinetics ",
        "content": "In a pharmacokinetic study in up to 72 healthy adult volunteers under fasting conditions, the bioavailability (BA) of a single 4 mg dose (one spray) of KLOXXADO was compared to a single 8 mg nasal dose of KLOXXADO and a single 4 mg nasal dose of a previously approved naloxone nasal spray. Naloxone plasma concentration versus time profiles are shown in Figure 1. The pharmacokinetic parameters of naloxone are summarized in Table 1. Figure 1.  Mean \u00b1 SD Plasma Concentration Time Profiles of Naloxone Following a Single Dose of Kloxxado nasal spray 4 mg versus Kloxxado 8 mg nasal spray, and a Previously Approved naloxone nasal spray 4 mg in Healthy Subjects  (A: 0-4h and B: 0-30 min) Kloxxado nasal spray 4 mg, Kloxxado nasal spray 8 mg, and a Previously Approved Naloxone Nasal Spray 4 mg Administration in Healthy Subjects Kloxxado nasal spray 4 mg, Kloxxado nasal spray 8 mg, and a Previously Approved Naloxone Nasal Spray 4 mg Administration in Healthy Subjects Parameter Kloxxado Nasal Spray 4 mg Previously Approved Naloxone Nasal Spray 4 mg Kloxxado Nasal Spray 8 mg N 71 N=71 due to withdrawal. 70 N=70 due to withdrawal. 70 T max (h) T max reported as median (minimum \u2013 maximum). 0.17 (0.07-0.50) 0.25 (0.13-1.00) 0.25 (0.07-1.00) C max (ng/mL) 11.11 (41.74) 6.56 (35.87) 14.41 (47.17) AUC last (ngh/mL) 12.31 (31.61) 10.14 (35.44) 19.57 (35.39) AUC 0inf (ngh/mL) 12.57 (30.63) 10.41 (33.82) 19.81 (34.73) T 1/2 (h) 1.27 (26.32) 1.30 (26.22) 1.56 (126.82) In two pharmacokinetic studies in up to 24 healthy adult volunteers for each study, the bioavailability (BA) of a single 8 mg dose (one spray) of KLOXXADO was compared to a single 0.4 mg intramuscular dose and a single 2 mg intravenous dose of naloxone. Naloxone plasma concentration versus time profiles are shown in Figure 2. The pharmacokinetic parameters of naloxone are summarized in Table 2. Figure 2.  Mean \u00b1 SD Plasma Concentration-Time Profiles of Naloxone Following A Single Dose of Intranasal versus Intramuscular/Intravenous Administration in Healthy Subjects. (A: 0-4 h and B: 0-30 min.) Table 2.  Mean (CV%) Plasma Pharmacokinetic Parameters of Naloxone Following a Single Dose of Intranasal and Intramuscular/Intravenous Administration in Healthy Subjects Parameter KLOXXADO 8 mg Intramuscular Injection 0.4 mg Intravenous Injection 2 mg Study Study I Study II Study I Study II Study II N 24 23 N=23 due to one subject withdrawal. 24 23 24 T max (h) T max reported as median (minimum \u2013 maximum). 0.25 (0.10 \u2013 1.00) 0.25 (0.10 \u2013 1.00) 0.25 (0.13 \u2013 1.00) 0.25 (0.10 \u2013 1.00) NA C max (ng/mL) 12.3 (55.4) 12.8 (37.0) 0.876 (36.7) 0.910 (36.8) 26.2 (82.4) C max of Intravenous Injection 2 mg was observed value from the first sampling time of 2 minutes post-dose. AUC last (ng\u2022h/mL) 18.0 (29.6) 18.4 (33.4) 1.82 (24.0) 1.87 (24.7) 12.7 (27.6) AUC 0-inf (ng\u2022h/mL) 16.7 (31.9) N=15 19.0 (32.7) N=19 1.94 (20.9) N=22 for AUC 0-inf and t 1/2 1.95 (21.9) 12.8 (27.5) t 1/2 (h) 2.69 (69.9) 1.76 (39.7) 1.41 (20.0) 1.40 (38.9) 1.22 (16.4) Dose normalized Relative BA (%) vs IM Injection 41.6 47.4 100 100 NA Dose normalized Absolute BA (%) vs IV Injection NA 36.6 NA 77.2 100 NA= Not applicable Absorption The median T max for naloxone following administration of a single dose of 4 mg Kloxxado nasal spray, a previously approved naloxone nasal spray 4 mg, and Kloxxado nasal spray 8 mg were 0.17 hour, 0.25 hour, and 0.25 hour, respectively. The median T max (15 min) for naloxone following administration of a single dose of 8 mg KLOXXADO nasal spray was the same as following administration of a single intramuscular dose of 0.4 mg naloxone hydrochloride. The relative bioavailability of naloxone following administration of a single dose 4 mg Kloxxado nasal spray was 122% as compared to following administration of a single intranasal dose of a previously approved naloxone nasal spray 4 mg.  The relative bioavailability of naloxone following administration of a single dose of 4 mg Kloxxado nasal spray was 65% as compared to following administration of a single intranasal dose of 8 mg Kloxxado.  The dose normalized relative bioavailability of naloxone following administration of a single dose of 8 mg KLOXXADO was 42 to 47% as compared to following administration of a single intramuscular dose of 0.4 mg naloxone hydrochloride. The absolute bioavailability of naloxone following administration of a single dose of 8 mg KLOXXADO nasal spray was 37% as compared to following administration of a single intravenous dose of 2 mg naloxone hydrochloride. Distribution Following parenteral administration, naloxone is distributed in the body and readily crosses the placenta. Plasma protein binding occurs but is relatively weak. Plasma albumin is the major binding constitute, but significant binding of naloxone also occurs to plasma constituents other than albumin. It is not known whether naloxone is excreted into human milk. Elimination Following a single intranasal administration of Kloxxado nasal spray 4 mg, the mean half-life (t 1/2 ) of naloxone in plasma was approximately 1.27 (26.32% CV) hours. The mean t 1/2 was 1.30 (26.22% CV) hours for a 4 mg intranasal administration of a previously approved naloxone nasal spray and 1.56 (126.82% CV) hours for an 8 mg Kloxxado intranasal administration. Following a single intranasal administration of 8 mg KLOXXADO, the mean half-life (t 1/2 ) of naloxone in plasma was 1.8 (39.7% CV) to 2.7 (69.6% CV) hours. The mean t 1/2 was 1.4 (38.9% CV) to 1.4 (20.0% CV) hours for a 0.4 mg naloxone hydrochloride intramuscular injection and 1.2 (16.4% CV) hours for a 2 mg naloxone hydrochloride intravenous injection. In a neonatal study of naloxone hydrochloride the mean (\u00b1SD) plasma half-life was observed to be 3.1 \u00b1 0.5 hours. Metabolism Naloxone hydrochloride is metabolized in the liver, primarily by glucuronide conjugation, with naloxone-3-glucoronide as the major metabolite. Excretion After an oral or intravenous dose, about 25 to 40% of naloxone is excreted as metabolites in urine within 6 hours, about 50% in 24 hours, and 60 to 70% in 72 hours."
      },
      {
        "code": "43680-8",
        "type": "NONCLINICAL TOXICOLOGY SECTION",
        "title": "13 NONCLINICAL TOXICOLOGY "
      },
      {
        "code": "34083-6",
        "type": "CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION",
        "title": "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility ",
        "content": "Carcinogenesis Studies in animals to assess the carcinogenic potential of naloxone have not been conducted. Mutagenesis Naloxone was weakly positive in the Ames mutagenicity and in the in vitro human lymphocyte chromosome aberration test but was negative in the in vitro Chinese hamster V79 cell HGPRT mutagenicity assay and in the in vivo rat bone marrow chromosome aberration study. Impairment of Fertility Reproduction studies conducted in mice and rats at doses 3-times and 6-times, respectively, a human dose of 16 mg based on body surface area comparison, demonstrated no adverse effects on fertility of naloxone hydrochloride."
      },
      {
        "code": "34069-5",
        "type": "HOW SUPPLIED SECTION",
        "title": "16 HOW SUPPLIED/STORAGE AND HANDLING ",
        "content": "KLOXXADO (naloxone hydrochloride) nasal spray is a clear, colorless to yellow solution supplied in a single-dose spray device that consists of a stoppered glass vial encased in a container holder fitted with a spray actuator, cannula, and spray pin.  It delivers a single dose of 8 mg of naloxone hydrochloride (equivalent to 7.2 mg naloxone) in 0.1 mL. Each KLOXXADO carton contains two individual blisters sealed with a paper backing with a \u201cpeel off\u201d feature. The carton contains abbreviated instructions-for-use printed on the back. In addition, a quick instructions leaflet is attached to the bottom of each individual blister. KLOXXADO nasal spray, 8 mg 1 Carton containing two nasal spray devices:  NDC# 59467-679-01 Not made with natural rubber latex. Storage and Handling Store KLOXXADO in the blister and cartons provided. Store at 20\u00baC to 25\u00baC (68\u00baF to 77\u00baF), with excursions permitted to 40\u00b0C (104\u00b0F) and to 5\u00b0C (41\u00b0F). Do not store at or above 40\u00b0C (104\u00b0F). Do not freeze. Protect from light. KLOXXADO freezes at temperatures below -15\u00b0C (5\u00b0F). If this happens, the device will not spray. If KLOXXADO is frozen and is needed in an emergency, do NOT wait for KLOXXADO to thaw. Get emergency medical help right away. However, KLOXXADO may be thawed by allowing it to sit at room temperature for 15 minutes, and it may still be used if it has been thawed after being previously frozen."
      },
      {
        "code": "34076-0",
        "type": "INFORMATION FOR PATIENTS SECTION",
        "title": "17 PATIENT COUNSELING INFORMATION ",
        "content": "Advise the patient and family members or caregivers to read the FDA-approved patient labeling ( Patient Information and Instructions for Use ). Recognition of Opioid Overdose Inform patients and their family members or caregivers about how to recognize the signs and symptoms of an opioid overdose such as the following: \u2022 Extreme somnolence \u2013 inability to awaken a patient verbally or upon a firm sternal rub. \u2022 Respiratory depression \u2013 this can range from slow or shallow respiration to no respiration in a patient who is unarousable. \u2022 Other signs and symptoms that may accompany somnolence and respiratory depression include the following: \u2022 Miosis \u2022 Bradycardia and/or hypotension Risk of Recurrent Respiratory and Central Nervous System Depression Instruct patients and their family members or caregivers that, because the duration of action of most opioids may exceed that of KLOXXADO, they must seek immediate emergency medical assistance after the first dose of KLOXXADO and keep the patient under continued surveillance [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.3 )]. Limited Efficacy for/with Partial Agonists or Mixed Agonist/Antagonists Instruct patients and their family members or caregivers that the reversal of respiratory depression caused by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete and may require higher doses of naloxone hydrochloride or repeated administration of KLOXXADO, using a new nasal spray each time [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.2 )]. Precipitation of Severe Opioid Withdrawal Instruct patients and their family members or caregivers that the use of KLOXXADO in patients who are opioid dependent may precipitate opioid withdrawal [see Warnings and Precautions ( 5.3 ), Adverse Reactions ( 6 )]. Administration Instructions Instruct patients and their family members or caregivers to: \u2022 Ensure KLOXXADO is present and readily available in locations where a person may be intentionally or accidentally exposed to an opioid overdose (i.e., opioid emergencies). \u2022 Administer KLOXXADO as quickly as possible if a patient is unresponsive and an opioid overdose is suspected, even when in doubt, because prolonged respiratory depression may result in damage to the central nervous system or death. KLOXXADO is not a substitute for emergency medical care [see Dosage and Administration ( 2.1 )]. \u2022 Lay the patient on their back and administer KLOXXADO into one nostril while providing support to the back of the neck to allow the head to tilt back [see Dosage and Administration ( 2.1 )]. \u2022 Use each nasal spray only one time, DO NOT test or prime prior to use [see Dosage and Administration ( 2.1 )]. \u2022 Place patient in a recovery position by turning him/her to their side as shown in the Instructions for Use and call for emergency medical assistance immediately after administration of the first dose of KLOXXADO. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance [see Dosage and Administration ( 2.1 )]. \u2022 Monitor patients and administer additional dose of KLOXXADO using a new KLOXXADO every 2 to 3 minutes, if the patient is not responding or responds and then relapses back into respiratory depression. Administer KLOXXADO in alternate nostrils with each dose [see Dosage and Administration ( 2.1 )]. \u2022 Replace KLOXXADO before its expiration date. Distributed by: Hikma Specialty USA Inc. Columbus, OH  43228 C50001066/03 Revised September 2025 KLOXXADO \u00ae is a registered trademark of Hikma Pharmaceuticals USA Inc."
      },
      {
        "code": "42230-3",
        "type": "SPL PATIENT PACKAGE INSERT SECTION",
        "content": "PATIENT INFORMATION KLOXXADO \u00ae (Kloks-AH-doh) (naloxone hydrochloride) nasal spray You and your family members or caregivers should read this Patient Information leaflet before an opioid emergency happens. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. What is the most important information I should know about KLOXXADO nasal spray? KLOXXADO nasal spray is used to temporarily reverse the effects of opioid medicines. The medicine in KLOXXADO nasal spray has no effect in people who are not taking opioid medicines. Always carry KLOXXADO nasal spray with you in case of an opioid emergency. \u2022 Use KLOXXADO nasal spray right away if you or your caregiver think signs or symptoms of an opioid emergency are present, even if you are not sure, because an opioid emergency can cause severe injury or death. Signs and symptoms of an opioid emergency may include: o unusual sleepiness and you are not able to awaken the person with a loud voice or by rubbing firmly on the middle of their chest (sternum) o breathing problems including slow or shallow breathing in someone difficult to awaken or who looks like they are not breathing o the black circle in the center of the colored part of the eye (pupil) is very small, sometimes called \u201cpinpoint pupils\u201d, in someone difficult to awaken \u2022 Family members, caregivers, or other people who may have to use KLOXXADO nasal spray in an opioid emergency should know where KLOXXADO nasal spray is stored and how to give KLOXXADO nasal spray before an opioid emergency happens. \u2022 Get emergency medical help right away after giving the first dose of KLOXXADO nasal spray. Rescue breathing or CPR (cardiopulmonary resuscitation) may be given while waiting for emergency medical help. \u2022 The signs and symptoms of an opioid emergency can return after KLOXXADO nasal spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO nasal spray and watch the person closely until emergency help is received. What is KLOXXADO nasal spray? \u2022 KLOXXADO nasal spray is a prescription medicine used in adults and children for the treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness or not being able to respond. \u2022 KLOXXADO nasal spray is to be given right away and does not take the place of emergency medical care. \u2022 Get emergency medical help right away after giving the first dose of KLOXXADO nasal spray, even if the person wakes up. \u2022 KLOXXADO nasal spray is safe and effective in children for known or suspected opioid overdose. Do not use KLOXXADO nasal spray if you are allergic to naloxone hydrochloride or any of the ingredients in KLOXXADO nasal spray. See the end of this leaflet for a complete list of ingredients in KLOXXADO nasal spray. Before using KLOXXADO nasal spray, tell your healthcare provider about all of your medical conditions, including if you: \u2022 have heart problems \u2022 are pregnant or plan to become pregnant. Use of KLOXXADO nasal spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use KLOXXADO nasal spray. \u2022 are breastfeeding or plan to breastfeed. It is not known if KLOXXADO nasal spray passes into your breast milk. Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should I use KLOXXADO nasal spray? Read the \u201cInstructions for Use\u201d at the end of this Patient Information leaflet for detailed information about the right way to use KLOXXADO nasal spray. \u2022 Use KLOXXADO nasal spray exactly as prescribed by your healthcare provider. \u2022 Each KLOXXADO nasal spray contains only 1 dose of medicine and cannot be reused. \u2022 Lay the person on their back. Support their neck with your hand and allow the head to tilt back before giving KLOXXADO nasal spray. \u2022 KLOXXADO nasal spray should be given into one nostril. \u2022 If additional doses are needed, give KLOXXADO nasal spray in the other nostril. What are the possible side effects of KLOXXADO nasal spray? KLOXXADO nasal spray may cause serious side effects, including: \u2022 Sudden opioid withdrawal symptoms. In someone who has been using opioids regularly, opioid withdrawal symptoms can happen suddenly after receiving KLOXXADO nasal spray and may include: o body aches o diarrhea o increased heart rate o fever o runny nose o sneezing o goose bumps o sweating o yawning o nausea or vomiting o nervousness o restlessness or irritability o shivering or trembling o stomach cramping o weakness o increased blood pressure In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include: seizures, crying more than usual, and increased reflexes. The most common side effects of KLOXXADO in adults include: stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort and a feeling like you are going to faint. These are not all of the possible side effects of KLOXXADO nasal spray. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store KLOXXADO nasal spray? \u2022 Store KLOXXADO nasal spray at room temperature between 68\u00baF to 77\u00baF (20\u00b0C to 25\u00b0C). \u2022 Do not freeze. Do not expose to temperatures below 41\u00b0F (5\u00b0C) or above 104\u00b0F (40\u00b0C). \u2022 Keep KLOXXADO nasal spray in its box until ready to use. Protect from light. \u2022 Replace KLOXXADO nasal spray before the expiration date on the box. Keep KLOXXADO nasal spray and all medicines out of the reach of children. General information about the safe and effective use of KLOXXADO nasal spray. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KLOXXADO nasal spray for a condition for which it was not prescribed. You can ask your pharmacist or healthcare provider for information about KLOXXADO nasal spray that is written for health professionals. What are the ingredients in KLOXXADO nasal spray? Active ingredient: naloxone hydrochloride Inactive ingredients: dehydrated alcohol (8 mg strength: 20% (w/w)), edetate disodium dihydrate, propylene glycol, and sodium hydroxide and hydrochloric acid as pH adjusters in purified water. KLOXXADO nasal spray is not made with natural rubber latex. Distributed by: Hikma Specialty USA Inc . Columbus, OH 43228 C50001066/03 KLOXXADO \u00ae nasal spray is a registered trademark of Hikma Pharmaceuticals USA Inc. For more information, visit www.Hikma.com or call Hikma Specialty USA Inc. at 1-800-962-8364. This Patient Information has been approved by the U.S. Food and Drug Administration.           Revised:  September 2025"
      },
      {
        "code": "59845-8",
        "type": "INSTRUCTIONS FOR USE SECTION",
        "content": "INSTRUCTIONS FOR USE KLOXXADO \u00ae (Kloks-AH-doh) (naloxone hydrochloride) nasal spray You and your family members or caregivers should read the Instructions for Use that comes with KLOXXADO nasal spray before using it. Talk to your healthcare provider if you and your family members or caregivers have any questions about the use of KLOXXADO nasal spray. Use KLOXXADO nasal spray for known or suspected opioid overdose in adults and children. Important:  For use in the nose only. \u2022 Do not remove or test the KLOXXADO nasal spray until ready to use. \u2022 Each KLOXXADO nasal spray has 1 dose and cannot be reused. \u2022 You do not need to prime KLOXXADO nasal spray. How to use KLOXXADO nasal spray: Step 1 .\tLay the person on their back to receive a dose of KLOXXADO nasal spray. Step 2. Remove KLOXXADO nasal spray from the box. Peel back the tab with the black triangle (\u25b2) to open the KLOXXADO nasal spray blister. Note: KLOXXADO freezes at temperatures below 5\u00b0F (-15\u00b0C). If this happens, the device will not spray. Get emergency medical help right away if this happens. Do not wait for KLOXXADO to thaw. KLOXXADO may still be used if it has been thawed after being previously frozen. Step 3 .\tHold the KLOXXADO nasal spray with your thumb on the bottom of the plunger and your first and middle fingers on either side of the nozzle. \u2022 Do not apply any pressure until you are ready to give the dose. Step 4. Tilt the person\u2019s head back and provide support under the neck with your hand. Gently insert the tip of the nozzle into one nostril until your fingers on either side of the nozzle are against the bottom of the person\u2019s nose. Step 5. Press the plunger firmly to give the dose of KLOXXADO nasal spray. Step 6. Remove the KLOXXADO nasal spray from the nostril after giving the dose. What to do after KLOXXADO nasal spray has been used: Step 7.\tGet emergency help right away. \u2022 Move the person on their side (recovery position) after giving KLOXXADO nasal spray. \u2022 Watch the person closely for 2 to 3 minutes. \u2022 If the person does not respond by waking up, to voice or touch, or start breathing normally, another dose may be given. \u2022 Repeat Steps 2 through 6 using a new KLOXXADO nasal spray to give another dose in the other nostril. If additional KLOXXADO nasal sprays are available, Steps 2 through 6 may be repeated every 2 to 3 minutes, alternating nostrils, until the person responds or emergency medical help is received. Step 8. Put the used KLOXXADO nasal spray back into its box. Step 9. Throw away (dispose of) the used KLOXXADO nasal spray in a place that is away from children. How should I store KLOXXADO nasal spray? \u2022 Store KLOXXADO nasal spray at room temperature between 68\u00baF to 77\u00baF (20\u00b0C to 25\u00b0C). \u2022 Do not freeze. Do not expose to temperatures below 41\u00b0F (5\u00b0C) or above 104\u00b0F (40\u00b0C). \u2022 Keep KLOXXADO nasal spray in its box until ready to use. Protect from light. \u2022 Replace KLOXXADO nasal spray before the expiration date on the box. Keep KLOXXADO nasal spray and all medicines out of the reach of children . Distributed by: Hikma Specialty USA Inc. Columbus, OH 43228 C50001066/03 KLOXXADO \u00ae is a registered trademark of Hikma Pharmaceuticals USA Inc. For more information, visit www.Hikma.com or call Hikma Specialty USA Inc. at 1-800-962-8364. This Instructions for Use has been approved by the U.S. Food and Drug Administration.         Revised:  September 2025"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL ",
        "content": "KLOXXADO \u00ae (naloxone HCl) nasal spray, 8 mg - Folding Carton NDC # 59467-679-01"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL ",
        "content": "KLOXXADO \u00ae (naloxone HCl) nasal spray, 8 mg \u2013 Foil Peel Backing NDC # 59467-679-01"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL ",
        "content": "KLOXXADO \u00ae (naloxone HCl) nasal spray, 8 mg \u2013 Device Label - Front NDC # 59467-679-01"
      },
      {
        "code": "51945-4",
        "type": "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL",
        "title": "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL ",
        "content": "KLOXXADO \u00ae (naloxone HCl) nasal spray, 8 mg \u2013 Device Label \u2013 Back NDC # 59467-679-01"
      }
    ],
    "category": "Prescription"
  }
]